false
--12-31
Q3
0001382574
0001382574
2023-01-01
2023-09-30
0001382574
2024-01-16
0001382574
2023-09-30
0001382574
2022-12-31
0001382574
us-gaap:NonrelatedPartyMember
2023-09-30
0001382574
us-gaap:NonrelatedPartyMember
2022-12-31
0001382574
us-gaap:RelatedPartyMember
2023-09-30
0001382574
us-gaap:RelatedPartyMember
2022-12-31
0001382574
us-gaap:SeriesAPreferredStockMember
2023-09-30
0001382574
us-gaap:SeriesAPreferredStockMember
2022-12-31
0001382574
us-gaap:SeriesBPreferredStockMember
2023-09-30
0001382574
us-gaap:SeriesBPreferredStockMember
2022-12-31
0001382574
2023-07-01
2023-09-30
0001382574
2022-07-01
2022-09-30
0001382574
2022-01-01
2022-09-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2022-12-31
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2022-12-31
0001382574
us-gaap:CommonStockMember
2022-12-31
0001382574
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001382574
us-gaap:RetainedEarningsMember
2022-12-31
0001382574
us-gaap:NoncontrollingInterestMember
2022-12-31
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2023-03-31
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2023-03-31
0001382574
us-gaap:CommonStockMember
2023-03-31
0001382574
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001382574
us-gaap:RetainedEarningsMember
2023-03-31
0001382574
us-gaap:NoncontrollingInterestMember
2023-03-31
0001382574
2023-03-31
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2023-06-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2023-06-30
0001382574
us-gaap:CommonStockMember
2023-06-30
0001382574
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001382574
us-gaap:RetainedEarningsMember
2023-06-30
0001382574
us-gaap:NoncontrollingInterestMember
2023-06-30
0001382574
2023-06-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2021-12-31
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2021-12-31
0001382574
us-gaap:CommonStockMember
2021-12-31
0001382574
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001382574
us-gaap:RetainedEarningsMember
2021-12-31
0001382574
us-gaap:NoncontrollingInterestMember
2021-12-31
0001382574
2021-12-31
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2022-03-31
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2022-03-31
0001382574
us-gaap:CommonStockMember
2022-03-31
0001382574
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0001382574
us-gaap:RetainedEarningsMember
2022-03-31
0001382574
us-gaap:NoncontrollingInterestMember
2022-03-31
0001382574
2022-03-31
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2022-06-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2022-06-30
0001382574
us-gaap:CommonStockMember
2022-06-30
0001382574
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001382574
us-gaap:RetainedEarningsMember
2022-06-30
0001382574
us-gaap:NoncontrollingInterestMember
2022-06-30
0001382574
2022-06-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2023-01-01
2023-03-31
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2023-01-01
2023-03-31
0001382574
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001382574
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0001382574
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0001382574
us-gaap:NoncontrollingInterestMember
2023-01-01
2023-03-31
0001382574
2023-01-01
2023-03-31
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2023-04-01
2023-06-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2023-04-01
2023-06-30
0001382574
us-gaap:CommonStockMember
2023-04-01
2023-06-30
0001382574
us-gaap:AdditionalPaidInCapitalMember
2023-04-01
2023-06-30
0001382574
us-gaap:RetainedEarningsMember
2023-04-01
2023-06-30
0001382574
us-gaap:NoncontrollingInterestMember
2023-04-01
2023-06-30
0001382574
2023-04-01
2023-06-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2023-07-01
2023-09-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2023-07-01
2023-09-30
0001382574
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001382574
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0001382574
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0001382574
us-gaap:NoncontrollingInterestMember
2023-07-01
2023-09-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2022-01-01
2022-03-31
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2022-01-01
2022-03-31
0001382574
us-gaap:CommonStockMember
2022-01-01
2022-03-31
0001382574
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-03-31
0001382574
us-gaap:RetainedEarningsMember
2022-01-01
2022-03-31
0001382574
us-gaap:NoncontrollingInterestMember
2022-01-01
2022-03-31
0001382574
2022-01-01
2022-03-31
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2022-04-01
2022-06-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2022-04-01
2022-06-30
0001382574
us-gaap:CommonStockMember
2022-04-01
2022-06-30
0001382574
us-gaap:AdditionalPaidInCapitalMember
2022-04-01
2022-06-30
0001382574
us-gaap:RetainedEarningsMember
2022-04-01
2022-06-30
0001382574
us-gaap:NoncontrollingInterestMember
2022-04-01
2022-06-30
0001382574
2022-04-01
2022-06-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2022-07-01
2022-09-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2022-07-01
2022-09-30
0001382574
us-gaap:CommonStockMember
2022-07-01
2022-09-30
0001382574
us-gaap:AdditionalPaidInCapitalMember
2022-07-01
2022-09-30
0001382574
us-gaap:RetainedEarningsMember
2022-07-01
2022-09-30
0001382574
us-gaap:NoncontrollingInterestMember
2022-07-01
2022-09-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2023-09-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2023-09-30
0001382574
us-gaap:CommonStockMember
2023-09-30
0001382574
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001382574
us-gaap:RetainedEarningsMember
2023-09-30
0001382574
us-gaap:NoncontrollingInterestMember
2023-09-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2022-09-30
0001382574
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2022-09-30
0001382574
us-gaap:CommonStockMember
2022-09-30
0001382574
us-gaap:AdditionalPaidInCapitalMember
2022-09-30
0001382574
us-gaap:RetainedEarningsMember
2022-09-30
0001382574
us-gaap:NoncontrollingInterestMember
2022-09-30
0001382574
2022-09-30
0001382574
MEDS:TrxadeIncMember
2023-09-30
0001382574
MEDS:MembershipInterestPurchaseAgreementsMember
MEDS:AlliancePharmaSolutionsLLCAndCommunitySpecialtyPharmacyLLCMember
2023-01-20
2023-01-20
0001382574
MEDS:AlliancePharmaSolutionsLLCMember
MEDS:MembershipInterestPurchaseAgreementsMember
2023-01-20
2023-01-20
0001382574
MEDS:MasterServiceAgreementMember
2023-01-20
2023-01-20
0001382574
MEDS:SosRxLLCMember
2022-02-15
0001382574
MEDS:ExchangeHealthLLCMember
2022-02-15
0001382574
MEDS:SosRxLLCMember
2022-02-15
0001382574
us-gaap:SeriesBPreferredStockMember
MEDS:MergerAgreementMember
2023-07-30
2023-07-31
0001382574
MEDS:MergerAgreementMember
us-gaap:SeriesBPreferredStockMember
2023-07-31
0001382574
MEDS:MergerAgreementMember
us-gaap:CommonStockMember
2023-07-31
0001382574
MEDS:MergerAgreementMember
MEDS:SuranAijarapuMember
2023-06-27
2023-06-28
0001382574
MEDS:MergerAgreementMember
MEDS:PrashantPatelMember
2023-06-27
2023-06-28
0001382574
MEDS:AmendedMegerAgreementMember
us-gaap:CommonStockMember
us-gaap:SubsequentEventMember
2024-01-08
0001382574
MEDS:AmendedMegerAgreementMember
us-gaap:CommonStockMember
us-gaap:SubsequentEventMember
2024-01-08
2024-01-08
0001382574
MEDS:AmendedMegerAgreementMember
us-gaap:SeriesBPreferredStockMember
us-gaap:SubsequentEventMember
2024-01-08
0001382574
2023-06-20
2023-06-21
0001382574
2023-06-21
0001382574
MEDS:SingleCustomerMember
MEDS:GSGPPELLCMember
2023-09-30
0001382574
MEDS:GSGPPELLCMember
2023-01-01
2023-09-30
0001382574
MEDS:GSGPPELLCMember
2022-01-01
2022-09-30
0001382574
us-gaap:WarrantMember
2023-01-01
2023-09-30
0001382574
us-gaap:WarrantMember
2023-01-04
0001382574
MEDS:NumeratorMember
2023-07-01
2023-09-30
0001382574
MEDS:NumeratorMember
2022-07-01
2022-09-30
0001382574
MEDS:NumeratorMember
2023-01-01
2023-09-30
0001382574
MEDS:NumeratorMember
2022-01-01
2022-09-30
0001382574
MEDS:DenominatorMember
2023-07-01
2023-09-30
0001382574
MEDS:DenominatorMember
2022-07-01
2022-09-30
0001382574
MEDS:DenominatorMember
2023-01-01
2023-09-30
0001382574
MEDS:DenominatorMember
2022-01-01
2022-09-30
0001382574
us-gaap:SeriesBPreferredStockMember
MEDS:MergerAgreementMember
MEDS:SuperlatusIncMember
2023-07-31
0001382574
us-gaap:SeriesBPreferredStockMember
MEDS:MergerAgreementMember
MEDS:SuperlatusIncMember
2023-07-30
2023-07-31
0001382574
us-gaap:SeriesBPreferredStockMember
MEDS:MergerAgreementMember
2024-01-07
2024-01-08
0001382574
us-gaap:SeriesBPreferredStockMember
MEDS:MergerAgreementMember
MEDS:SuperlatusIncMember
2024-01-07
2024-01-08
0001382574
us-gaap:SeriesBPreferredStockMember
2023-07-31
2023-07-31
0001382574
MEDS:AssetPurchaseAgreementMember
2023-09-26
2023-09-27
0001382574
MEDS:SosRxLLCMember
2023-02-04
0001382574
MEDS:AlliancePharmaSolutionsLLCMember
2023-08-22
0001382574
MEDS:PromissoryNoteMember
2023-08-22
0001382574
MEDS:SuperlatusIncMember
2023-07-30
2023-07-31
0001382574
MEDS:SuperlatusIncMember
2023-07-31
0001382574
MEDS:TheUrgentCompanyMember
2023-01-01
2023-09-30
0001382574
MEDS:TheUrgentCompanyMember
2023-09-30
0001382574
MEDS:SosRxLLCMember
2023-09-30
0001382574
MEDS:SosRxLLCMember
2022-12-31
0001382574
MEDS:AlliancePharmaSolutionsLLCMember
2023-08-22
0001382574
MEDS:SOSRxMember
2023-07-01
2023-09-30
0001382574
MEDS:SOSRxMember
2022-07-01
2022-09-30
0001382574
MEDS:AlliancePharmaSolutionMember
2023-07-01
2023-09-30
0001382574
MEDS:AlliancePharmaSolutionMember
2022-07-01
2022-09-30
0001382574
MEDS:SOSRxMember
2023-01-01
2023-09-30
0001382574
MEDS:SOSRxMember
2022-01-01
2022-09-30
0001382574
MEDS:AlliancePharmaSolutionMember
2023-01-01
2023-09-30
0001382574
MEDS:AlliancePharmaSolutionMember
2022-01-01
2022-09-30
0001382574
MEDS:ScietechLLCMember
2023-09-30
0001382574
MEDS:SOSRxMember
2022-02-15
0001382574
MEDS:SosRxLLCMember
2022-02-14
2022-02-15
0001382574
MEDS:SOSRxMember
2022-02-14
2022-02-15
0001382574
MEDS:ExchangeHealthLLCMember
MEDS:SoftwareAndContractsMember
2022-02-14
2022-02-15
0001382574
us-gaap:RelatedPartyMember
2023-01-01
2023-09-30
0001382574
MEDS:ProductRevenueMember
2023-07-01
2023-09-30
0001382574
MEDS:ProductRevenueMember
2022-07-01
2022-09-30
0001382574
MEDS:ProductRevenueMember
2023-01-01
2023-09-30
0001382574
MEDS:ProductRevenueMember
2022-01-01
2022-09-30
0001382574
MEDS:ServiceRevenueMember
2023-07-01
2023-09-30
0001382574
MEDS:ServiceRevenueMember
2022-07-01
2022-09-30
0001382574
MEDS:ServiceRevenueMember
2023-01-01
2023-09-30
0001382574
MEDS:ServiceRevenueMember
2022-01-01
2022-09-30
0001382574
MEDS:PromissoryNoteAgreementMember
2023-08-22
0001382574
MEDS:PromissoryNoteAgreementMember
2023-09-30
0001382574
us-gaap:DevelopedTechnologyRightsMember
2023-01-01
2023-09-30
0001382574
us-gaap:DevelopedTechnologyRightsMember
2023-09-30
0001382574
MEDS:ReceivablesAgreementMember
2023-06-27
0001382574
MEDS:ReceivablesAgreementMember
2023-03-14
0001382574
MEDS:ReceivablesAgreementMember
2022-09-14
0001382574
MEDS:ReceivablesAgreementMember
2022-06-27
0001382574
MEDS:ReceivablesAgreementMember
2023-09-30
0001382574
MEDS:ReceivablesAgreementMember
2022-12-31
0001382574
MEDS:PerfectDayNoteMember
2023-09-27
0001382574
MEDS:DanamNoteMember
2023-09-14
0001382574
MEDS:DanamNoteMember
2023-10-13
0001382574
MEDS:DanamNoteMember
2023-09-30
0001382574
MEDS:DanamNoteMember
us-gaap:SubsequentEventMember
2023-10-01
2023-10-31
0001382574
MEDS:DanamNoteMember
srt:ScenarioForecastMember
2024-01-16
0001382574
MEDS:EatWellJuneTwentyTwentyThreeNoteMember
2023-06-16
2023-06-16
0001382574
MEDS:EatWellJuneTwentyTwentyThreeNoteMember
2023-06-16
0001382574
MEDS:EatWellJuneTwentyTwentyThreeNoteMember
2023-09-30
0001382574
MEDS:EatWellFebruaryTwentyTwentyThreeNoteMember
MEDS:LoanAgreementMember
2023-02-08
0001382574
MEDS:EatWellFebruaryTwentyTwentyThreeNoteMember
MEDS:LoanAgreementMember
2023-02-08
2023-02-08
0001382574
MEDS:EatWellFebruaryTwentyTwentyThreeNoteMember
MEDS:LoanAgreementMember
2023-09-30
0001382574
MEDS:EatWellSeptemberTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2022-09-14
0001382574
MEDS:EatWellSeptemberTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2022-09-14
2022-09-14
0001382574
MEDS:EatWellSeptemberTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2023-09-30
0001382574
MEDS:EatWellJulyTwentySixTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2022-07-26
0001382574
MEDS:EatWellJulyTwentySixTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2022-07-26
2022-07-26
0001382574
MEDS:EatWellJulyTwentySixTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2023-09-30
0001382574
MEDS:EatWellJulyTwelveTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2022-07-12
0001382574
MEDS:EatWellJulyTwelveTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2022-07-12
2022-07-12
0001382574
MEDS:EatWellJulyTwelveTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2023-09-30
0001382574
MEDS:EatWellMarchTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2022-03-15
0001382574
MEDS:EatWellMarchTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2022-03-15
2022-03-15
0001382574
MEDS:EatWellMarchTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2023-09-30
0001382574
MEDS:EatWellFebruaryTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2022-02-01
0001382574
MEDS:EatWellFebruaryTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2022-02-01
2022-02-01
0001382574
MEDS:EatWellFebruaryTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2023-09-30
0001382574
MEDS:EatWellJanuaryTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2022-01-20
0001382574
MEDS:EatWellJanuaryTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2022-01-20
2022-01-20
0001382574
MEDS:EatWellJanuaryTwentyTwentyTwoNoteMember
MEDS:LoanAgreementMember
2023-09-30
0001382574
MEDS:EatWellDecemberTwentyTwentyOneNoteMember
MEDS:LoanAgreementMember
2021-12-24
0001382574
MEDS:EatWellDecemberTwentyTwentyOneNoteMember
MEDS:LoanAgreementMember
2021-12-24
2021-12-24
0001382574
MEDS:EatWellDecemberTwentyTwentyOneNoteMember
MEDS:LoanAgreementMember
2023-09-30
0001382574
MEDS:EatWellNovemberTwentyTwentyOneNoteMember
MEDS:LoanAgreementMember
2021-11-10
0001382574
MEDS:EatWellNovemberTwentyTwentyOneNoteMember
MEDS:LoanAgreementMember
2021-11-10
2021-11-10
0001382574
MEDS:EatWellNovemberTwentyTwentyOneNoteMember
MEDS:LoanAgreementMember
2023-09-30
0001382574
MEDS:EatWellAugustTwentyTwentyOneNoteMember
MEDS:LoanAgreementMember
2021-08-18
0001382574
MEDS:EatWellAugustTwentyTwentyOneNoteMember
MEDS:LoanAgreementMember
2021-08-18
2021-08-18
0001382574
MEDS:EatWellAugustTwentyTwentyOneNoteMember
MEDS:LoanAgreementMember
2023-09-30
0001382574
MEDS:PerfectDayNoteMember
2023-09-30
0001382574
MEDS:EatWellJuneTwentyTwentyTwentyThreeNoteMember
2023-09-30
0001382574
MEDS:EatWellFebruaryTwentyTwentyThreeNoteMember
2023-09-30
0001382574
MEDS:EatWellSeptemberTwentyTwentyTwoNoteMember
2023-09-30
0001382574
MEDS:EatWellJulyTwentySixTwentyTwentyTwoNoteMember
2023-09-30
0001382574
MEDS:EatWellJulyTwelveTwentyTwentyTwoNoteMember
2023-09-30
0001382574
MEDS:EatWellMarchTwentyTwentyTwoNoteMember
2023-09-30
0001382574
MEDS:EatWellFebruaryTwentyTwentyTwoNoteMember
2023-09-30
0001382574
MEDS:EatWellJanuaryTwentyTwentyTwoNoteMember
2023-09-30
0001382574
MEDS:EatWellDecemberTwentyTwentyOneNoteMember
2023-09-30
0001382574
MEDS:EatWellNovemberTwentyTwentyOneNoteMember
2023-09-30
0001382574
MEDS:EatWellAugustTwentyTwentyOneNoteMember
2023-09-30
0001382574
us-gaap:SeriesBPreferredStockMember
2023-06-26
0001382574
MEDS:OfficersMember
2022-08-30
2022-08-31
0001382574
us-gaap:CommonStockMember
MEDS:EmployeesMember
2023-01-01
2023-09-30
0001382574
srt:BoardOfDirectorsChairmanMember
2022-08-30
2022-08-31
0001382574
MEDS:PreFundedWarrantsMember
2022-10-04
0001382574
MEDS:PreFundedWarrantsMember
2022-10-04
2022-10-04
0001382574
MEDS:PreFundedWarrantsMember
2023-01-04
0001382574
MEDS:PrivatePlacementWarrantsMember
2023-01-01
2023-09-30
0001382574
MEDS:PreFundedWarrantsMember
2023-09-30
0001382574
us-gaap:WarrantMember
2022-01-01
2022-09-30
0001382574
MEDS:StockOptionPlanMember
2023-01-01
2023-09-30
0001382574
MEDS:SecondAmendedAndRestatedTwoThousandAndNineteenEquityIncentivePlanMember
2023-01-01
2023-09-30
0001382574
MEDS:SecondAmendedAndRestatedTwoThousandAndNineteenEquityIncentivePlanMember
2023-09-30
0001382574
us-gaap:StockCompensationPlanMember
2023-01-01
2023-09-30
0001382574
MEDS:StockOptionsMember
2022-12-31
0001382574
MEDS:StockOptionsMember
2023-01-01
2023-09-30
0001382574
MEDS:StockOptionsMember
2023-09-30
0001382574
MEDS:IPSMember
MEDS:StudebakerDefenseGroupLLCMember
2020-07-01
2020-07-31
0001382574
MEDS:StudebakerDefenseGroupLLCMember
MEDS:IntegraMember
2020-08-13
2020-08-14
0001382574
MEDS:StudebakerDefenseGroupLLCMember
MEDS:IPSMember
2021-01-01
2021-06-30
0001382574
2023-04-12
2023-04-13
0001382574
MEDS:IPSMember
MEDS:SandwaveGroupDsnBhdMember
2020-08-01
2020-08-31
0001382574
MEDS:CrecomBurjGroupSdnBhdMember
MEDS:IPSMember
2020-08-01
2020-08-31
0001382574
MEDS:IPSMember
MEDS:SandwaveGroupDsnBhdMember
2021-01-01
2021-06-30
0001382574
2021-09-30
0001382574
MEDS:WaxmanMember
2023-09-30
0001382574
2021-09-28
2021-09-30
0001382574
2022-06-01
2022-06-30
0001382574
MEDS:TrxadeIncMember
2023-01-01
2023-09-30
0001382574
MEDS:IPSMember
2023-01-01
2023-09-30
0001382574
MEDS:SuperlatusMember
2023-01-01
2023-09-30
0001382574
us-gaap:AllOtherSegmentsMember
2023-01-01
2023-09-30
0001382574
MEDS:TrxadeIncMember
2023-09-30
0001382574
MEDS:IPSMember
2023-09-30
0001382574
MEDS:SuperlatusMember
2023-09-30
0001382574
us-gaap:AllOtherSegmentsMember
2023-09-30
0001382574
MEDS:TrxadeIncMember
2022-01-01
2022-09-30
0001382574
MEDS:IPSMember
2022-01-01
2022-09-30
0001382574
MEDS:SuperlatusMember
2022-01-01
2022-09-30
0001382574
us-gaap:AllOtherSegmentsMember
2022-01-01
2022-09-30
0001382574
MEDS:TrxadeIncMember
2022-09-30
0001382574
MEDS:IPSMember
2022-09-30
0001382574
MEDS:SuperlatusMember
2022-09-30
0001382574
us-gaap:AllOtherSegmentsMember
2022-09-30
0001382574
MEDS:SperoFoodsIncMember
MEDS:PurchaseAgreementMember
us-gaap:SubsequentEventMember
2023-10-04
2023-10-04
0001382574
MEDS:HudsonGlobalVenturesLLCMember
MEDS:SeriesCConvertiblePreferredStockMember
MEDS:SecuritiesPurchaseAgreementMember
us-gaap:SubsequentEventMember
2023-10-04
2023-10-04
0001382574
MEDS:HudsonGlobalVenturesLLCMember
MEDS:SeriesCConvertiblePreferredStockMember
MEDS:SecuritiesPurchaseAgreementMember
us-gaap:SubsequentEventMember
2023-10-04
0001382574
MEDS:HudsonGlobalVenturesLLCMember
us-gaap:CommonStockMember
MEDS:SecuritiesPurchaseAgreementMember
us-gaap:SubsequentEventMember
2023-10-04
0001382574
MEDS:HudsonGlobalVenturesLLCMember
MEDS:SecuritiesPurchaseAgreementMember
us-gaap:SubsequentEventMember
us-gaap:WarrantMember
2023-10-04
0001382574
MEDS:HudsonGlobalVenturesLLCMember
MEDS:PurchaseAgreementMember
us-gaap:SubsequentEventMember
us-gaap:CommonStockMember
2023-10-04
2023-10-04
0001382574
MEDS:ReceivablesAgreementMember
us-gaap:SubsequentEventMember
2023-10-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
MEDS:Integer
xbrli:pure
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
10-Q
(Mark
One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the Quarterly Period Ended September 30, 2023
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission
File Number: 001-39199
![](https://www.sec.gov/Archives/edgar/data/1382574/000149315224002429/form10-q_001.jpg)
TRxADE
HEALTH, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
46-3673928 |
(State
or other jurisdiction of |
|
(I.R.S.
Employer |
incorporation
or organization) |
|
Identification
No.) |
|
|
|
2420
Brunello Trace |
|
|
Lutz,
Florida |
|
33558 |
(Address
of principal executive offices) |
|
(Zip
code) |
(800)
261-0281
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.00001 Par Value Per Share |
|
MEDS |
|
The
NASDAQ Stock Market LLC
(The
NASDAQ Capital Market) |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes ☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
|
|
|
|
Non-accelerated
filer |
☒ |
Smaller
reporting company |
☒ |
|
|
|
|
Emerging
growth company |
☒ |
|
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
There
were 1,205,008 shares of the registrant’s common stock outstanding on January 16, 2024 and 307,145 shares of preferred stock
outstanding.
TRxADE
HEALTH, INC.
FORM
10-Q
For
the Quarter Ended September 30, 2023
TABLE
OF CONTENTS
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
Quarterly Report on Form 10-Q (“Report”), including without limitation, “Management’s Discussion and
Analysis of Financial Condition and Results of Operations,” contains forward-looking statements, within the meaning of the
federal securities laws, including the Private Securities Litigation Reform Act of 1995, regarding future events and the future results
of the Company that are based on current expectations, estimates, forecasts, and projections about the industry in which the Company
operates and the beliefs and assumptions of the management of the Company. Words such as “expects,” “anticipates,”
“targets,” “goals,” “projects,” “intends,” “plans,”
“believes,” “seeks,” “estimates,” variations of such words, and similar expressions
are intended to identify such forward-looking statements. These forward-looking statements are only predictions and are subject to risks,
uncertainties and assumptions that are difficult to predict. These factors include, but are not limited to:
|
● |
Our limited amount of cash; |
|
● |
The negative effect on our business and our ability
to raise capital that is created by the fact that there is a substantial doubt about our ability to continue as a going concern; |
|
● |
Risks of our operations not being profitable; |
|
● |
Claims relating to alleged violations of intellectual
property rights of others; |
|
● |
Technical problems with our websites; |
|
● |
Risks relating to implementing our acquisition strategies; |
|
● |
Negative effects on our operations associated with
the opioid pain medication health crisis; |
|
● |
Regulatory and licensing requirement risks; |
|
● |
Risks related to changes in the U.S. healthcare environment; |
|
● |
The status of our information systems, facilities and
distribution networks; |
|
● |
Risks associated with the operations of our more established
competitors; |
|
● |
Regulatory changes; |
|
● |
Healthcare fraud; |
|
● |
The potential impact of some future pandemic; |
|
● |
Inflation, rising interest rates, governmental responses
thereto and possible recessions caused thereby. |
|
● |
Changes in laws or regulations relating to our operations; |
|
● |
Privacy laws; |
|
● |
System errors; |
|
● |
Dependence on current management; |
|
● |
Our growth strategy; |
|
● |
Risks related to the disruption of management’s
attention from ongoing business operations due to pursuit of requirements related to being a listed company; and |
|
● |
Other factors discussed in this Quarterly Report on
Form 10-Q and in Part I, Item 1A. “Risk Factors” in Part I, Item 1A. “Risk Factors” and Part II, Item 7.
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Form 10-K. |
While
forward-looking statements reflect our good faith beliefs, assumptions and expectations, they are not guarantees of future performance.
The forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Furthermore, we disclaim any obligation
to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information,
data or methods, future events or other changes. Moreover, because we operate in a very competitive and rapidly changing environment,
new risk factors are likely to emerge from time to time. We caution investors not to place undue reliance on these forward-looking statements
and urge you to carefully review the disclosures we make concerning risks in this Quarterly Report and in Part I, Item 1A. “Risk
Factors” and Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
in our Annual Report on Form 10-K and Part II, Item 1A. “Risk Factors” in the Quarterly Report for the period ending June
30, 2023, filed with the Securities and Exchange Commission (SEC) on August 18, 2023. Readers of this Quarterly Report on Form 10-Q should
also read our other periodic filings made with the SEC and other publicly filed documents for further discussion regarding such factors.
PART
I: FINANCIAL INFORMATION
ITEM
1. FINANCIAL STATEMENTS
TRxADE
HEALTH, INC.
Consolidated
Balance Sheets
September
30, 2023 and December 31, 2022
(Unaudited)
| |
September 30, | | |
December 31, | |
| |
| 2023 | | |
| 2022 | |
Assets | |
| | | |
| | |
Current Assets | |
| | | |
| | |
Cash | |
$ | 34,031 | | |
$ | 1,094,891 | |
Accounts receivable, net | |
| 850,103 | | |
| 649,263 | |
Inventory | |
| 3,026,918 | | |
| 68,448 | |
Prepaid assets | |
| 246,093 | | |
| 104,462 | |
Notes receivable | |
| 1,275,000 | | |
| - | |
Other receivables | |
| 115,684 | | |
| - | |
Current assets of discontinued operations | |
| - | | |
| 176,057 | |
Total Current Assets | |
| 5,547,829 | | |
| 2,093,121 | |
| |
| | | |
| | |
Property plant and equipment, net | |
| 287,920 | | |
| 65,214 | |
Deposits | |
| 49,031 | | |
| 49,031 | |
Intangible assets, net | |
| 9,451,562 | | |
| - | |
Goodwill | |
| 5,129,116 | | |
| - | |
Other assets | |
| - | | |
| - | |
Operating lease right-of-use assets | |
| 1,188,385 | | |
| 1,051,815 | |
Noncurrent assets of discontinued operations | |
| - | | |
| 450,845 | |
Total Assets | |
$ | 21,653,843 | | |
$ | 3,710,026 | |
| |
| | | |
| | |
Liabilities and Shareholders’ Equity | |
| | | |
| | |
Current Liabilities | |
| | | |
| | |
Accounts payable | |
| 1,328,599 | | |
| 527,984 | |
Accrued liabilities | |
| 386,024 | | |
| 271,230 | |
Other current liabilities | |
| 412,390 | | |
| 67,517 | |
Contingent funding liabilities | |
| 452,348 | | |
| 108,036 | |
Current portion of operating lease liabilities | |
| 251,087 | | |
| 196,872 | |
Notes payable, current portion | |
| 5,230,000 | | |
| - | |
Notes payable— related party, current portion | |
| - | | |
| 166,667 | |
Warrant liability | |
| 1,031,841 | | |
| 588,533 | |
Current liabilities of discontinued operations | |
| - | | |
| 219,952 | |
Total Current Liabilities | |
| 9,092,289 | | |
| 2,146,791 | |
| |
| | | |
| | |
Long Term Liabilities | |
| | | |
| | |
Operating lease liabilities, net of current portion | |
| 976,869 | | |
| 887,035 | |
Notes payable, net of current portion | |
| 25,000 | | |
| - | |
Notes payable- related party, net of current portion | |
| - | | |
| 333,333 | |
| |
| | | |
| | |
Total Liabilities | |
| 10,094,158 | | |
| 3,367,159 | |
| |
| | | |
| | |
Stockholders’ Equity | |
| | | |
| | |
| |
| | | |
| | |
Series A preferred stock, $0.00001 par value; 9,212,246 shares authorized; none issued and outstanding, as of September 30, 2023 and December 31, 2022. | |
| - | | |
| - | |
Series B preferred stock, $0.00001 par value; 787,754 shares authorized; 306,855 issued and outstanding, as of September 30, 2023 and December 31, 2022. | |
| - | | |
| - | |
Preferred
stock, value | |
| - | | |
| - | |
Common stock, $0.00001 par value; 6,666,667 shares authorized; 818,961 and 626,247 shares issued and outstanding, as of September 30, 2023 and December 31, 2022, respectively | |
| 8 | | |
| 6 | |
Additional paid-in capital | |
| 33,089,652 | | |
| 20,482,666 | |
Retained deficit | |
| (21,529,975 | ) | |
| (19,719,536 | ) |
Total TRxADE Health Inc. Stockholders’ Equity | |
| 11,559,685 | | |
| 763,136 | |
Non-controlling interest in subsidiary | |
| - | | |
| (420,269 | ) |
Total Stockholders’ Equity | |
| 11,559,685 | | |
| 342,867 | |
| |
| | | |
| | |
Total Liabilities and Stockholders’ Equity | |
$ | 21,653,843 | | |
$ | 3,710,026 | |
The
accompanying notes are an integral part of the unaudited consolidated financial statements.
TRxADE
HEALTH, INC.
Consolidated
Statements of Operations
For
the Three and Nine Months Ended September 30, 2023 and 2022
(Unaudited)
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
Three Months Ended
September 30, | | |
Nine Months Ended
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
| | | |
| | | |
| | | |
| | |
Revenues | |
$ | 2,058,028 | | |
$ | 2,055,803 | | |
$ | 5,919,786 | | |
$ | 7,993,805 | |
| |
| | | |
| | | |
| | | |
| | |
Cost of sales | |
| 353,450 | | |
| 683,375 | | |
| 1,072,934 | | |
| 3,991,234 | |
Gross profit | |
| 1,704,578 | | |
| 1,372,428 | | |
| 4,846,852 | | |
| 4,002,571 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Wage and salary expense | |
| 698,030 | | |
| 849,371 | | |
| 2,077,362 | | |
| 2,949,386 | |
Professional fees | |
| 418,294 | | |
| 82,710 | | |
| 782,286 | | |
| 256,807 | |
Accounting and legal expense | |
| 408,957 | | |
| 191,007 | | |
| 782,495 | | |
| 567,086 | |
Technology expense | |
| 410,612 | | |
| 238,577 | | |
| 1,010,374 | | |
| 690,875 | |
General and administrative expense | |
| 613,834 | | |
| 229,526 | | |
| 1,264,902 | | |
| 1,392,130 | |
Total operating expenses | |
| 2,549,727 | | |
| 1,591,191 | | |
| 5,917,419 | | |
| 5,856,284 | |
| |
| | | |
| | | |
| | | |
| | |
Operating loss | |
| (845,149 | ) | |
| (218,763 | ) | |
| (1,070,567 | ) | |
| (1,853,713 | ) |
| |
| | | |
| | | |
| | | |
| | |
Nonoperating income (expense) | |
| | | |
| | | |
| | | |
| | |
Change in fair value of warrant liability | |
| 925,320 | | |
| - | | |
| (443,308 | ) | |
| - | |
Interest income | |
| - | | |
| 8,396 | | |
| 4,198 | | |
| 8,396 | |
Gain (loss) on disposal of assets | |
| - | | |
| - | | |
| - | | |
| 2,200 | |
Interest expense | |
| (251,778 | ) | |
| (130,107 | ) | |
| (494,904 | ) | |
| (140,626 | ) |
Total nonoperating income (expense) | |
| 673,542 | | |
| (121,711 | ) | |
| (934,014 | ) | |
| (130,030 | ) |
Net loss from continuing operations | |
| (171,607 | ) | |
| (340,474 | ) | |
| (2,004,581 | ) | |
| (1,983,743 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss on discontinued operations | |
| (3,353,507 | ) | |
| (188,268 | ) | |
| (4,123,028 | ) | |
| (623,096 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss | |
$ | (3,525,114 | ) | |
$ | (528,742 | ) | |
$ | (6,127,609 | ) | |
$ | (2,606,839 | ) |
Net loss attributable to TRxADE Health, Inc. | |
$ | (3,525,114 | ) | |
$ | (503,003 | ) | |
$ | (6,127,609 | ) | |
$ | (2,546,913 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss attributable to non-controlling interests | |
| - | | |
| (25,739 | ) | |
| - | | |
| (59,926 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss per common share from continuing operations | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (0.22 | ) | |
$ | (0.57 | ) | |
$ | (2.83 | ) | |
$ | (3.52 | ) |
Diluted | |
$ | (0.07 | ) | |
$ | (0.57 | ) | |
$ | (0.87 | ) | |
$ | (3.51 | ) |
Net loss per common share from discontinued
operations | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (4.35 | ) | |
$ | (0.34 | ) | |
$ | (5.82 | ) | |
$ | (1.14 | ) |
Diluted | |
$ | (1.42 | ) | |
$ | (0.34 | ) | |
$ | (1.79 | ) | |
$ | (1.14 | ) |
Net loss attributable to common stockholders | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (4.57 | ) | |
$ | (0.91 | ) | |
$ | (8.65 | ) | |
$ | (4.66 | ) |
Diluted | |
$ | (1.49 | ) | |
$ | (0.91 | ) | |
$ | (2.66 | ) | |
$ | (4.64 | ) |
Weighted average common shares outstanding | |
| | | |
| | | |
| | | |
| | |
Basic | |
| 771,192 | | |
| 549,977 | | |
| 708,116 | | |
| 546,879 | |
Diluted | |
| 2,363,233 | | |
| 551,724 | | |
| 2,300,157 | | |
| 548,626 | |
The
accompanying notes are an integral part of the unaudited consolidated financial statements.
TRxADE
HEALTH, INC.
Consolidated
Statements of Changes in Stockholders’ Equity
For
the Three and Nine Months Ended September 30, 2023, and 2022
(Unaudited)
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Series B | | |
Series A | | |
| | |
| | |
Additional | | |
| | |
Noncontrolling | | |
Total | |
| |
Preferred Stock | | |
Preferred Stock | | |
Common Stock | | |
Paid-In | | |
Accumulated | | |
Interests in | | |
Stockholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Subsidiaries | | |
Equity | |
Balance at December 31, 2022 | |
| - | | |
$ | - | | |
| - | | |
$ | - | | |
| 626,247 | | |
$ | 6 | | |
$ | 20,482,666 | | |
$ | (19,719,536 | ) | |
$ | (420,269 | ) | |
$ | 342,867 | |
Common stock issued for services | |
| - | | |
| - | | |
| - | | |
| - | | |
| 14,362 | | |
| - | | |
| 63,486 | | |
| - | | |
| - | | |
| 63,486 | |
Warrants exercised for cash | |
| - | | |
| - | | |
| - | | |
| - | | |
| 40,116 | | |
| 1 | | |
| 6 | | |
| - | | |
| - | | |
| 7 | |
Disposition of assets, related party | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 492,030 | | |
| 420,269 | | |
| 912,299 | |
Options expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 14,434 | | |
| - | | |
| - | | |
| 14,434 | |
Net Loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | (677,953 | ) | |
| - | | |
| (677,953 | ) |
Balance at March 31, 2023 | |
| - | | |
$ | - | | |
| - | | |
$ | - | | |
| 680,725 | | |
$ | 7 | | |
| 20,560,592 | | |
$ | (19,905,459 | ) | |
$ | - | | |
$ | 655,140 | |
Common stock issued for services | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 15,813 | | |
| - | | |
| - | | |
| 15,813 | |
Warrants exercised for cash | |
| - | | |
| - | | |
| - | | |
| - | | |
| 1,795 | | |
| - | | |
| 1,615 | | |
| - | | |
| - | | |
| 1,615 | |
Options expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 7,783 | | |
| - | | |
| - | | |
| 7,783 | |
Net Loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (1,974,878 | ) | |
| - | | |
| (1,974,878 | ) |
Balance at June 30, 2023 | |
| - | | |
$ | - | | |
| - | | |
$ | - | | |
| 682,520 | | |
$ | 7 | | |
$ | 20,585,803 | | |
$ | (21,880,337 | ) | |
$ | - | | |
$ | (1,294,527 | ) |
Options expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 3,761 | | |
| - | | |
| - | | |
| 3,761 | |
Disposition of assets | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 3,875,476 | | |
| - | | |
| 3,875,476 | |
Shares issued pursuant to merger agreement | |
| - | | |
| - | | |
| 15,759 | | |
| - | | |
| 136,441 | | |
| 1 | | |
| 12,500,088 | | |
| - | | |
| - | | |
| 12,500,089 | |
Net Loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (3,525,114 | ) | |
| - | | |
$ | (3,525,114 | ) |
Balance at September 30, 2023 | |
| - | | |
$ | - | | |
| 15,759 | | |
$ | - | | |
| 818,961 | | |
$ | 8 | | |
| 33,089,652 | | |
$ | (21,529,975 | ) | |
$ | - | | |
$ | 11,559,685 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance at December 31, 2021 | |
| - | | |
| - | | |
| - | | |
| - | | |
| 544,430 | | |
| 5 | | |
| 20,017,605 | | |
| (16,247,437 | ) | |
| - | | |
| 3,770,173 | |
Capital contributions | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 792,500 | | |
| 792,500 | |
Common stock issued for services | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 32,083 | | |
| - | | |
| - | | |
| 32,083 | |
Capital distributions | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (775,000 | ) | |
$ | (775,000 | ) |
Warrants exercised for cash | |
| - | | |
| - | | |
| - | | |
| - | | |
| 972 | | |
| - | | |
| 875 | | |
| - | | |
| - | | |
| 875 | |
Options expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 32,783 | | |
| - | | |
| - | | |
| 32,783 | |
Net Loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | (960,147 | ) | |
$ | (5,689 | ) | |
$ | (965,836 | ) |
Balance at March 31, 2022 | |
| - | | |
$ | - | | |
| - | | |
$ | - | | |
| 545,402 | | |
$ | 5 | | |
$ | 20,083,346 | | |
$ | (17,207,584 | ) | |
$ | 11,811 | | |
$ | 2,887,578 | |
Common stock issued for services | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 12,222 | | |
| - | | |
| - | | |
| 12,222 | |
Options expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 16,994 | | |
| - | | |
| - | | |
| 16,994 | |
Net Loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | (1,083,763 | ) | |
| (28,498 | ) | |
$ | (1,112,261 | ) |
Balance at June 30, 2022 | |
| - | | |
$ | - | | |
| - | | |
$ | - | | |
| 545,402 | | |
$ | 5 | | |
$ | 20,112,562 | | |
$ | (18,291,347 | ) | |
$ | (16,687 | ) | |
$ | 1,804,533 | |
Balance | |
| - | | |
| - | | |
| - | | |
| - | | |
| 545,402 | | |
| 5 | | |
| 20,112,562 | | |
$ | (18,291,347 | ) | |
| (16,687 | ) | |
| 1,804,533 | |
Common stock issued for services | |
| - | | |
| - | | |
| - | | |
| - | | |
| 14,511 | | |
| 1 | | |
| 63,125 | | |
| - | | |
| - | | |
| 63,126 | |
Warrants exercised for cash | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Options expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 17,661 | | |
| - | | |
| - | | |
| 17,661 | |
Net Loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | (503,003 | ) | |
$ | (25,739 | ) | |
$ | (528,742 | ) |
Balance at September 30, 2022 | |
| - | | |
$ | - | | |
| - | | |
$ | - | | |
| 559,913 | | |
$ | 6 | | |
$ | 20,193,348 | | |
$ | (18,794,350 | ) | |
$ | (42,426 | ) | |
$ | 1,356,578 | |
Balance | |
| - | | |
| - | | |
| - | | |
| - | | |
| 559,913 | | |
| 6 | | |
| 20,193,348 | | |
$ | (18,794,350 | ) | |
$ | (42,426 | ) | |
| 1,356,578 | |
The
accompanying notes are an integral part of the unaudited consolidated financial statements
TRxADE
HEALTH, INC.
Consolidated
Statements of Cash Flows
For
The Nine Months Ended September 30, 2023 and 2022
(Unaudited)
| |
| 2023 | | |
| 2022 | |
| |
Nine months Ended September 30, | |
| |
| 2023 | | |
| 2022 | |
Cash flows from operating activities: | |
| | | |
| | |
Net loss from continuing operations | |
$ | (2,004,581 | ) | |
$ | (1,983,743 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation expense | |
| 8,464 | | |
| 11,815 | |
Options expense | |
| 25,978 | | |
| 67,439 | |
Common stock issued for services | |
| 79,299 | | |
| 107,430 | |
Bad debt recovery | |
| - | | |
| (98,841 | ) |
Gain on disposal of asset | |
| - | | |
| (4,100 | ) |
Amortization of intangible assets | |
| 325,916 | | |
| 29,400 | |
| |
| | | |
| | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable, net | |
| (212,292 | ) | |
| 227,508 | |
Prepaid assets and deposits | |
| (138,450 | ) | |
| 198,088 | |
Inventory | |
| (39,013 | ) | |
| (19,671 | ) |
Other receivables | |
| - | | |
| (875,250 | ) |
Operating lease right-of-use assets | |
| 152,121 | | |
| 132,847 | |
Other assets | |
| - | | |
| - | |
Operating lease liabilities | |
| (145,707 | ) | |
| (120,401 | ) |
Accounts payable | |
| 854,171 | | |
| 267,384 | |
Accrued liabilities | |
| 43,729 | | |
| (178,714 | ) |
Inventory deposits | |
| - | | |
| - | |
Current liabilities | |
| (5,127 | ) | |
| 105,926 | |
Warrant liability | |
| 443,308 | | |
| - | |
| |
| | | |
| | |
Net cash used in operating activities from continuing operations | |
| (612,184 | ) | |
| (2,132,883 | ) |
Net cash used in operating activities from discontinued operations | |
| (593,893 | ) | |
| (623,096 | ) |
Net cash used in operating activities | |
| (1,206,077 | ) | |
| (2,755,979 | ) |
| |
| | | |
| | |
Cash flows from investing activities: | |
| | | |
| | |
Proceeds from sale of fixed assets | |
| - | | |
| 23,000 | |
Cash received in acquisitions | |
| 5,546 | | |
| - | |
Investment in capitalized software | |
| - | | |
| (335,902 | ) |
Net cash provided by (used in) investing activities from continuing operations | |
| 5,546 | | |
| (312,902 | ) |
Net cash provided by investing activities from discontinued operations | |
| 68,737 | | |
| - | |
Net cash provided by (used in) investing activities | |
| 74,283 | | |
| (312,902 | ) |
| |
| | | |
| | |
Cash flows from financing activities: | |
| | | |
| | |
Proceeds from the issuance of debt | |
| 200,000 | | |
| - | |
Proceeds from repayment of notes receivable | |
| 25,000 | | |
| - | |
Repayment of contingent liability | |
| (1,755,688 | ) | |
| (282,857 | ) |
Proceeds from sale of future revenue | |
| 2,100,000 | | |
| 825,000 | |
Distributions to non-controlling interest | |
| - | | |
| (275,000 | ) |
Proceeds from exercise of warrants | |
| 1,622 | | |
| 875 | |
Net cash provided by financing activities from continuing operations | |
| 570,934 | | |
| 268,018 | |
Net cash used in financing activities from
discontinued operations | |
| (500,000 | ) | |
| - | |
Net cash provided by financing activities | |
| 70,934 | | |
| 268,018 | |
| |
| | | |
| | |
Net change in cash | |
| (1,060,860 | ) | |
| (2,800,863 | ) |
Cash at beginning of the year | |
| 1,094,891 | | |
| 3,122,578 | |
Cash at end of the period | |
$ | 34,031 | | |
$ | 321,715 | |
| |
| | | |
| | |
Supplemental disclosure of cash flow information | |
| | | |
| | |
Cash paid for interest | |
$ | 494,408 | | |
$ | 3,328 | |
Cash paid for income taxes | |
$ | - | | |
$ | - | |
Non-cash Transactions | |
| | | |
| | |
Insurance premium financed | |
$ | 306,152 | | |
$ | 220,354 | |
Note cancelled from SOSRx agreement termination | |
$ | 500,000 | | |
$ | - | |
Note issued as SOSRx contribution | |
$ | - | | |
$ | 500,000 | |
Intangible asset contribution from non-controlling interest | |
$ | - | | |
$ | 792,500 | |
Disposition of assets, related party | |
$ | 492,030 | | |
$ | - | |
Issuance of notes receivable | |
$ | 1,300,000 | | |
$ | - | |
The
accompanying notes are an integral part of the unaudited consolidated financial statements.
NOTE
1 – ORGANIZATION AND BASIS OF PRESENTATION
Overview
TRxADE
HEALTH, INC. (“we”, “our”, “Trxade”, and the “Company”)
owns 100%
of Trxade, Inc., Integra Pharma Solutions, LLC, Community Specialty Pharmacy, LLC, Alliance Pharma Solutions, LLC, Bonum Health,
LLC, Superlatus, Inc. and its wholly-owned subsidiary, Sapientia Technologies, LLC (“Sapientia”), and The Urgent
Company, Inc. On July 31, 2023, the Company merged with
Superlatus, Inc. (see “Merger”, below). On September 27, 2023, the Company acquired The Urgent Company, Inc. (see Note
3).
Trxade,
Inc., operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories
and services.
Integra
Pharma Solutions, LLC (“IPS”, d.b.a. Trxade Prime), is a licensed pharmaceutical wholesaler and sells brand, generic
and non-drug products to customers. IPS customers include all healthcare markets including government organizations,
hospitals, clinics and independent pharmacies nationwide.
Community Specialty Pharmacy, LLC, (“CSP”) is an accredited independent retail pharmacy with a focus
on a community-based model offering home delivery services to patients.
Alliance
Pharma Solutions, LLC (“APS”, d.b.a. DelivMeds) is currently being rebranded and the consumer-based app is
still being developed. To date, we have not generated any revenue from this product.
On
January 20, 2023, the Company entered into Membership Interest Purchase Agreements to sell 100%
of the outstanding membership interests of the Company’s subsidiaries, CSP and APS. The Company will receive consideration in
the amount of $125,000
for APS and $
for CSP. The Company also agreed to enter into a Master Service Agreement to operate the businesses prior to closing. Additional
amounts owed to the Company as a result of this Master Service Agreement totaled $1,075,000
as of the closing date of August 22, 2023 (see Note 3 and Note 6).
Bonum
Health, LLC (“Bonum Health”), was formed to hold certain telehealth assets acquired in October 2019. The “Bonum Health
Hub” was launched in February 2020; however, due to the COVID-19 pandemic, the Company does not anticipate installations moving
forward. The Bonum Health mobile application is available on a subscription basis, primarily as a stand-alone telehealth software application
that can be licensed on a business-to-business (B2B) model to clients as an employment health benefit for the clients’ employees.
SOSRx,
LLC (“SOSRx”) was formed on February 15, 2022. The Company entered into a relationship with Exchange Health, LLC (“Exchange
Health”), a technology company providing an online platform for manufacturers and suppliers to sell and purchase pharmaceuticals.
SOSRx, a Delaware limited liability company, was formed, which was owned 51%
by the Company and 49%
by Exchange Health. SOSRx did not generate material revenue and in February of 2023, the Company voluntarily withdrew from the joint
venture agreement. As part of the voluntary withdrawal the Company has recorded a loss of $352,244 from disposal of assets, which is
included in net loss on discontinued operations in the unaudited consolidated statement of operations in the amount of for the nine-month
period ended September 30, 2023.
Merger
On
July 14, 2023, the Company entered into an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”) with
Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities (“Superlatus”) and Foods Merger
Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”).
Superlatus
is a diversified food technology company with distribution capabilities and systems to optimize food security and population health
via innovative Consumer Packaged Goods (“CPG”) products, agritech, foodtech, plant-based proteins and alt-protein and
includes wholly-owned subsidiary, Sapientia,
Inc. (“Sapientia”), a food tech business.
On
July 31, 2023 (the “Closing Date”), the Company completed its acquisition of Superlatus in accordance with the terms and
conditions of the Merger Agreement (the “Merger”), pursuant to which the Company acquired Superlatus by way of a merger of
the Merger Sub with and into Superlatus, with Superlatus being a wholly owned subsidiary of the Company and the surviving entity in the
Merger.
Under
the terms of the Merger Agreement, at the closing of the Merger (the “Closing”), shareholders of Superlatus received in aggregate
136,441 shares of common stock of the Company, representing 19.99% of the total issued and outstanding common stock of the Company after
the consummation of the Merger and 306,855 shares of Company’s Series B Preferred Stock, par value $0.00001 per share (the “Series
B Preferred Stock”), with a conversion ratio of 100 shares of Series B Preferred Stock to one share of common stock. At Closing,
the value of the common stock was $7.30 per share, resulting in a total value of $225,000,169. Upon consummation of the Merger, the Company
continued to trade under the current ticker symbol “MEDS.”
As
a condition and inducement to Superlatus’ willingness to enter into the Merger Agreement, on June 28, 2023, Suren Ajjarapu and
Prashant Patel (the “Principal Stockholders”) entered into an agreement with TRxADE (the “Stock Swap Agreement”),
pursuant to which, TRxADE will transfer all of the shares or membership interest of the operating subsidiaries currently owned
by TRxADE to Principal Stockholders, in exchange for Suran Ajjarapu to surrender 85,000 share of common stock of TRxADE and Prashant
Patel to surrender 81,666 shares of the common stock of TRxADE (the “Stock Swap Transaction”). The closing of the Stock Swap
Transaction shall take place simultaneously with the approval of TRxADE stockholders of the conversion of the Series B preferred stock
into common stock. The closing of the Stock Swap Transaction is subject to the simultaneous condition that the Merger. As of the date of this filing, TRxADE stockholders have not approved the conversion. The Company is in the process of preparing
a proxy merger, which is expected to occur in 2024. This will complete all contingencies of Merger Agreement and Stock Swap Agreement
and result in a reverse capitalization.
In
connection with the Merger, on July 31, 2023, certain Superlatus shareholders as of immediately prior to the Merger, and certain directors
and officers of MEDS as of immediately prior to the Merger, entered into lock-up agreements with the Company, pursuant to which each
such stockholder will be subject to a 360 day lockup on the sale or transfer of shares of common stock or securities convertible into
or exercisable for or exchangeable for common stock held by each such stockholder at the closing of the Merger (the “Lock-up Agreements”).
In
connection with the Merger, effective one (1) business day immediately prior to the Closing Date (the “MEDS Rights Record Date”),
the Company issued to the shareholders of the Company as of the MEDS Rights Record Date, including the independent directors who are
entitled to certain amount of common stock of the Company in connection with their 2023 annual compensation and regardless of whether
the common stock has been issued or vest before the MEDS Rights Records Date (collectively, the “MEDS Rights Shareholders”)
a non-transferrable right to receive one share of common stock of the Company at no cost (the “MEDS Rights”), with seven
(7) MEDS Rights issued per share of common stock of the Company held as of the MEDS Rights Record Date, conditioned upon their execution
of a Registration Rights Agreement. Such issuances will be made in reliance on the exemption from registration pursuant to Section 3(a)(9)
or Section 4(a)(2) of the Securities Act, Regulation D under the Securities Act promulgated thereunder, and corresponding provisions
of state securities or “blue sky” laws. The MEDS Rights are not actionable or transferable until registration; provided they
become transferable one year after the date of the Merger if no registration has occurred. As of the date of this filing, no MEDS Rights
shares have been issued.
Not
all of the closing conditions of the Merger Agreement were met. As a result, the Company entered into Amendment No. 1 to the Amended
and Restated Agreement and Plan of Merger (the “Amendment”) on January 8, 2024.Under the terms of the Amendment, the
merger consideration to the shareholders of Superlatus was adjusted to the aggregate of 136,441
shares of common stock of the Company, representing 19.99%
of the total issued and outstanding common stock of the Company after the consummation of the Merger and 15,759
shares of Company’s Series B Preferred Stock, par value $0.00001
per share (the “Series B Preferred Stock”), with a conversion ratio of 100
shares of Series B Preferred Stock to one share of common stock. At Closing, the value of the common stock was $7.30
per share, resulting in a total value of $12,500,089.
Additionally, the shareholders of Superlatus agreed to surrender back to the Company 289,731 shares of the Company’s Series B
Preferred Stock. Upon consummation of the Amended Merger Agreement, the Company continues to trade under the current ticker symbol
“MEDS.”
Basis
of Presentation and Principles of Consolidation
The
accompanying unaudited interim consolidated financial statements of TRxADE HEALTH, Inc. have been prepared in accordance with
accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the SEC and
should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report
on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 27, 2023.
In
the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of
financial position and the results of operations for the interim periods presented have been reflected herein. All significant
intercompany balances and transactions have been eliminated in consolidation. The results of operations for the interim periods are
not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would
substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2022, as
reported in the Company’s Annual Report on Form 10-K have been omitted.
Use of Estimates
The preparation of condensed consolidated financial
statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The
Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable
under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities
and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company
may differ materially and adversely from its estimates. To the extent there are material differences between estimates and the actual
results, future results of operations will be affected. Significant estimates for the nine months ended September 30, 2023 and 2022 include
the valuation of intangible assets, including goodwill.
Fair value of financial instruments
The carrying amounts for cash, accounts
receivable, accounts payable, accrued liabilities, and other current liabilities approximate their fair value because of their short-term
maturity.
Stock
Split
Effective
June 21, 2023, the Company executed a 1:15 reverse stock split for stockholders of record on that date. This was executed to comply with
the Nasdaq Listing Rule 5550(a)(2) to have the price of the stock above $1.
Recently
Issued Accounting Pronouncements
In
June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”
(“ASU 2016-13”). ASU 2016-13 requires companies to measure credit losses utilizing a methodology that reflects expected
credit losses and requires a consideration of a broader range of reasonable and supportable information to inform credit loss
estimates. ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those
fiscal years. The Company adopted ASU 2016-13 effective January 1, 2023. The Company determined that the update applied to trade
receivables, but that there was no material impact to the consolidated financial statements from the adoption of ASU
2016-13.
In August 2020, the FASB issued ASU 2020-06, “Debt - Debt with Conversion and Other Options (Subtopic 470-20)
and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting
models for convertible debt instruments and convertible preferred stock and amends the guidance for the derivatives scope exception for
contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and
amends the related earnings per share guidance. This standard is effective for us on January 1, 2022, including interim periods within
those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. The adoption of
ASU 2020-06 did not have a material impact on our financial statements.
Accounts
Receivable, net
On January 1, 2023, the Company adopted ASU 2016-13 “Financial
Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” and
its related amendments using the prospective method. The new standard requires the use of a current expected credit loss impairment
model to develop and recognize credit losses for financial instruments at amortized cost when the asset is first originated or acquired,
and each subsequent reporting period.
The
Company’s receivables are from customers and are typically collected within 90 days. The Company determines the allowance based
on known troubled accounts, historical experience, and other currently available evidence.
The
Company had an account receivable with a single customer, GSG PPE, LLC (“GSG”), for the amount of $630,000,
which was past due. The Company
had obtained a Note Receivable which was due on September 30, 2021 and remained unpaid. The Company did not believe the amount to be
collectible without legal actions, and therefore, recorded bad debt expense reflected on the consolidated statement of operations during
the year ended December 31, 2021. The note was not paid pursuant to its terms and the Company had filed a suit to collect on the note
and the personal guaranty securing the note. The Company settled the lawsuit in June of 2022. During the nine months ended September 30, 2023, and 2022, there was a bad debt recovery from the GSG lawsuit of
$32,074 and $98,841 respectively.
Other
Receivables, net
The
Company’s other receivables balance is from one vendor. On May 20, 2022, effective as of May 18, 2022, Community Specialty
Pharmacy, LLC (“CSP”) entered into an agreement to acquire COVID-19 testing kits from a third-party vendor for an
aggregate of $,
of which $
was paid on May 23, 2022. The Company received the COVID-19 testing kits in July 2022. On August 18, 2022 the Company was informed
by the vendor that the vendor had received a letter from the U.S. Food and Drug Administration (“FDA”) that the COVID-19
test kits were misbranded under Section 502(o) of the Federal Food, Drug, and Cosmetic Act (“FDC Act”) (21 USC 352(o))
and adulterated under Section 501(f) of the FDC Act (21 USC 351(f)). Furthermore, the vendor informed the Company that the letter
from the FDA also stated that because of the FDA’s prohibition on the distribution of adulterated and/or misbranded devices
applies to all parties along the distribution chain, the FDA was advising the vendor against furthering the distribution of the
COVID-19 test kits in interstate commerce. The company wrote the amount off as a loss of inventory as of December 31, 2022. As of September 30, 2023 and December 31, 2022, the balance of this receivable was $0.
On
August 22, 2023, the Company completed the sale of CSP and APS (see Note 3). The net balance due to the Company from these entities,
in excess of the Note Receivable (see Note 6), was $115,684 as of September 30, 2023.
Acquisitions
The
Company accounts for acquisitions and investments in businesses as business combinations if the target meets the definition of a
business and (a) the target is a variable interest entity (“VIE”) and the Company is the target’s primary
beneficiary, and therefore the Company must consolidate its financial statements, or (b) the Company acquires more than 50% of the
voting interest of the target and it was not previously consolidated. The Company records business combinations using the
acquisition method of accounting, which requires all the assets acquired and liabilities assumed to be recorded at fair value as of
the acquisition date. The excess of the purchase price over the estimated fair values of the net tangible and intangible assets
acquired is recorded as goodwill.
The
application of the acquisition method of accounting for business combinations requires management to make significant estimates and assumptions
in the determination of the fair value of assets acquired and liabilities assumed in order to properly allocate purchase price consideration
between assets that are depreciated and amortized from goodwill. The fair value assigned to tangible and intangible assets acquired and
liabilities assumed are based on management’s estimates and assumptions, as well as other information compiled by management, including
valuations that utilize customary valuation procedures and techniques. Significant assumptions and estimates include, but are not limited
to, the cash flows that an asset is expected to generate in the future, the appropriate weighted-average cost of capital, and the cost
savings expected to be derived from acquiring an asset, if applicable.
If
the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the Company’s financial
statements may be exposed to potential impairment of the intangible assets and goodwill.
If
the Company’s investment involves the acquisition of an asset or group of assets that does not meet the definition of a business,
the transaction is accounted for as an asset acquisition. An asset acquisition is recorded at cost, which includes capitalizing transaction
costs, and does not result in the recognition of goodwill.
Intangible Assets and Goodwill
The Company
tests indefinite-lived intangible assets for impairment on an annual basis or whenever events or changes occur that would more-likely-than
not reduce the fair value of the indefinite-lived intangible asset below its carrying value between annual impairment tests. Any indefinite-lived
intangible asset assessment is performed at the Company level.
The Company did not record an indefinite-lived intangible asset impairment charge for the three and nine months ended
September 30, 2023 and 2022.
Income
(loss) Per Common Share
Basic
net income per common share is computed by dividing net income available to common stockholders by the weighted average number of common
shares outstanding. Diluted net income per common share is computed similar to basic net income per common share except that the denominator
is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been
issued and if the additional common shares were dilutive. The dilutive effect of the Company’s options and warrants is computed
using the treasury stock method. As of September 30, 2023, we had 177,536 outstanding warrants to purchase shares of common stock and
17,852 options to purchase shares of common stock. As part of the termination of the White Lion deal, White Lion was issued 50,000 shares
of stock per the agreement on March 1, 2023. Armistice Capital executed its pre-funded warrants on January 4, 2023, and purchased 601,740
shares of stock with a purchase price of $6.02.
The
following table sets forth the computation of basic and diluted loss per share:
SCHEDULE
OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
For the Three Months Ended
September 30, | | |
For the Nine Months Ended
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Numerator: | |
| | | |
| | | |
| | | |
| | |
Net loss from continuing operations | |
$ | (171,607 | ) | |
$ | (314,735 | ) | |
$ | (2,004,581 | ) | |
$ | (1,923,817 | ) |
Net loss from discontinued operations | |
$ | (3,353,507 | ) | |
$ | (188,268 | ) | |
| (4,123,028 | ) | |
$ | (623,096 | ) |
Numerator for basic and diluted EPS - income available to common stockholders | |
| (3,525,114 | ) | |
$ | (503,003 | ) | |
| (6,127,609 | ) | |
$ | (2,546,913 | ) |
Denominator: | |
| | | |
| | | |
| | | |
| | |
Denominator for EPS – weighted average shares | |
| | | |
| | | |
| | | |
| | |
Basic | |
| 771,192 | | |
| 549,977 | | |
| 708,116 | | |
| 546,879 | |
Diluted | |
| 2,363,233 | | |
| 551,724 | | |
| 2,300,157 | | |
| 548,626 | |
Net loss per common share attributable to common stockholders | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (4.57 | ) | |
$ | (0.91 | ) | |
$ | (8.65 | ) | |
$ | (4.66 | ) |
Diluted | |
$ | (1.49 | ) | |
$ | (0.91 | ) | |
$ | (2.66 | ) | |
$ | (4.64 | ) |
Net loss per common share from continuing operations | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (0.22 | ) | |
$ | (0.57 | ) | |
$ | (2.83 | ) | |
$ | (3.52 | ) |
Diluted | |
$ | (0.07 | ) | |
$ | (0.57 | ) | |
$ | (0.87 | ) | |
$ | (3.51 | ) |
Net loss per common share from discontinued operations | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (4.35 | ) | |
$ | (0.34 | ) | |
$ | (5.82 | ) | |
$ | (1.14 | ) |
Diluted | |
$ | (1.42 | ) | |
$ | (0.34 | ) | |
$ | (1.79 | ) | |
$ | (1.14 | ) |
Income taxes
The Company’s provision for income taxes was $0 for the three and nine months ended September 30, 2023, and
$0 for the three and nine months ended September 30, 2022, respectively. The income tax provisions for these three and nine month periods
are based upon estimates of annual income (loss), annual permanent differences and statutory tax rates in the various jurisdictions in
which the Company operates. For all periods presented, the Company utilized net operating loss carryforwards to offset the impact of any
taxable income. The Company’s tax rate differs from the applicable statutory rates due primarily to establishment of a valuation
allowance, utilization of deferred and the effect of permanent differences and adjustments.
NOTE
2 – GOING CONCERN
The
accompanying interim consolidated financial statements have been prepared assuming that the Company will continue as a going concern,
which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the
date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting
Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether
there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern
within one year after the date that the financial statements are issued.
As
of September 30, 2023, the Company had a retained deficit of $21,529,975.
The Company has limited financial resources. As of September 30, 2023, the Company had a working capital deficit of $3,544,460 and
a cash balance of $34,031. The
Company will need to raise additional capital or secure debt funding to support on-going operations. The sources of this capital are
expected to be the sale of equity and debt, which may not be available on favorable terms, if at all, and may, if sold, cause
significant dilution to existing stockholders. If the Company is unable to access additional capital moving forward, it may hurt the
Company’s ability to grow and to generate future revenues, financial position, and liquidity. These factors raise substantial
doubt about the ability of the Company to continue as a going concern. Unless Management is able to obtain additional financing, it
is unlikely that the Company will be able to meet its funding requirements during the next 12 months. The financial statements do
not include any adjustments that might result from the outcome of this uncertainty.
NOTE
3 – ACQUISITIONS AND DISPOSITIONS
Acquisitions
- Provisional
Superlatus,
Inc.
On
July 31, 2023, the Company entered into the Merger Agreement (see Note 1) with Superlatus (“Seller”) whereby the Company
acquired 100%
of the stock of the Seller (the “Acquisition”). Superlatus includes a wholly-owned subsidiary, Sapientia. Consideration
for the Acquisition consisted of (i) 136,441
shares of the Company’s common stock at a fair value of $7.30
per share, representing 19.99%
of the total issued and outstanding share of the Company’s common stock at Closing, and (ii) 306,855
shares of the Company’s Series B Preferred Stock, a new class of the Company’s non-voting convertible preferred stock
with a conversion ratio of 100 to one. The total fair value of the common stock and Series B Preferred Stock on the Closing Date was
$225,000,169
(“Purchase Price”). On January 8, 2024, the Company entered into Amendment No. 1 to the Agreement and Plan of Merger
(the “Amendment”). Under the terms of the Amendment, the merger consideration to the shareholders of Superlatus was
adjusted to an aggregate of 136,441
shares of common stock of the Company, representing 19.99%
of the total issued and outstanding common stock of the Company after the consummation of the Merger and 15,759
shares of Company’s Series B Preferred Stock, par value $0.00001
per share, with a conversion ratio of 100
shares of Series B Preferred Stock to one share of common stock. The total fair value of the common stock and Series B Preferred
Stock on the Closing Date was adjusted to $12,500,089
(“Amended Purchase Price”). Additionally, the shareholders of Superlatus agreed to surrender back to the Company 289,731 shares of the Company’s
Series B Preferred Stock previously received before the amendment.
The
acquisition of Superlatus was accounted for as a business combination using the acquisition method pursuant to FASB ASC Topic 805. As
the acquirer for accounting purposes, the Company had estimated the Purchase Price, assets acquired and liabilities assumed as of the
acquisition date, with the excess of the Purchase Price over the fair value of net assets acquired recognized as goodwill. An independent
valuation expert assisted the Company in determining these fair values.
Accounting
guidance provides that an acquirer must recognize adjustments to provisional amounts that are identified during the measurement period,
which runs through July 31, 2024, in the measurement period in which the adjustment amounts are determined. The acquirer must record
in the financial statements, the effect on earnings of changes in depreciation, amortization or other income effects, if any, as a result
of the changes to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. Items that could
be subject to adjustment include credit fair value adjustments on loans, core deposit intangible and the deferred income tax assets resulting
from the acquisition.
The
provisional Amended Purchase Price allocation as of the acquisition date is presented as follows:
SCHEDULE
OF PURCHASE PRICE ALLOCATION
| |
July 31, 2023 | |
Purchase consideration: | |
| | |
Common Stock, at fair value | |
$ | 996,019 | |
Series B Preferred Stock, at fair value | |
| 11,504,070 | |
Total purchase consideration | |
$ | 12,500,089 | |
| |
| | |
Purchase price allocation: | |
| | |
Cash | |
$ | 5,546 | |
Prepaid expenses | |
| 3,705 | |
Inventory | |
| 122,792 | |
Intangible assets, net | |
| 9,777,478 | |
Goodwill | |
| 5,129,116 | |
Assets acquired | |
| 15,038,637 | |
Accounts payable and other current liabilities | |
| (633,548 | ) |
Notes payable | |
| (1,905,000 | ) |
Liabilities assumed | |
| (2,538,548 | ) |
Net assets acquired | |
$ | 12,500,089 | |
The
Urgent Company, Inc.
On
September 27, 2023, the Company entered into an Asset Purchase Agreement (“APA”) with The Urgent Company, Inc.
(“TUC”) and its wholly owned subsidiaries, pursuant to which, the Company was assigned certain inventory and property
and equipment and assumed certain operating leases for consideration of a $3,150,000
promissory note (“Purchase Price”, see Note 11). This acquisition is expected to enhance the
Company’s production of sustainable food products and enable the expansion of market share.
The
transaction was accounted for as an asset acquisition pursuant to FASB ASC Topic 805. As the acquirer
for accounting purposes, the Company allocated the cost of the asset acquisition to the assets acquired and liabilities assumed as of the acquisition
date based on their respective relative fair value as of the date of the transaction.
The
following summarizes the provisional relative fair values of the assets acquired as of the acquisition date based on the allocation
of the cost of the asset acquisition:
SCHEDULE
OF FAIR VALUES OF ASSETS ACQUIRED
| |
September 27, 2023 | |
Purchase consideration: | |
| | |
Promissory note | |
$ | 3,150,000 | |
Total purchase consideration | |
$ | 3,150,000 | |
| |
| | |
Allocation of cost of assets acquired: | |
| | |
Inventory | |
$ | 2,960,235 | |
Property and equipment | |
| 231,170 | |
Operating right-of-use assets | |
| 383,218 | |
Assets acquired | |
| 3,574,623 | |
Liabilities assumed | |
| (424,623 | ) |
Net assets acquired | |
$ | 3,150,000 | |
Dispositions
and Divestitures
SOSRx, LLC
On
and effective on, February 1, 2023, the Company, Exchange Health and SOSRx, entered into a Voluntary Withdrawal and Release Agreement,
which was replaced in its entirety, corrected, and became effective on February 4, 2023 (as replaced and corrected, the “Release
Agreement”).
As
part of the Release Agreement, a note payable to Exchange Health was forgiven in the amount of $500,000 and $15,000 in accounts payable
was waived. Effective February 4, 2023, the operations of SOSRx were discontinued and operations were shut down. As a result of this,
the assets and liabilities of SOSRx have been reflected as assets and liabilities of discontinued operations in the Company’s consolidated
balance sheets. As of September 30, 2023 and December 31, 2022 as follows:
SCHEDULE OF FINANCIAL STATEMENTS OF DISCONTINUED OPERATIONS
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Cash | |
$ | - | | |
$ | 22,474 | |
Accounts receivable | |
| - | | |
| 363 | |
Total assets of discontinued operations | |
$ | - | | |
$ | 22,837 | |
| |
| | | |
| | |
Accounts payable | |
$ | - | | |
$ | 46,500 | |
Total liabilities of discontinued operations | |
$ | - | | |
$ | 46,500 | |
The
terms of the Release Agreement qualifies the transaction as a discontinued operation in accordance with U.S. GAAP. As a result,
operating results and cash flows related to the SOSRx operations have been reflected as discontinued operations in the
Company’s consolidated statements of operations, consolidated statements of cash flows and consolidated statements of
shareholders’ equity.
Alliance Pharma Solutions, LLC and Community Specialty
Pharmacy, LLC
On August 22, 2023, the Company
and Wood Sage, LCC (“Wood Sage”) entered into a Membership Interest Purchase Agreement, pursuant to which the Company sold
100% of the membership interest in Alliance Pharma Solutions, LLC (“ASP MIPA”) for consideration of a $125,000 promissory
note (“ASP Sale Price”) and a Membership Interest Purchase Agreement, pursuant to which the Company sold 100% of the membership
interest in Community Specialty Pharmacy, LLC (“CSP MIPA”) in exchange for a $ promissory note (“CSP Sale Price”).
The divestiture
of APS and CSP represents an intentional strategic shift in the Company’s operations and will allow the Company to become focused
on food technology As a result, the results of APS and CSP were classified as discontinued operations in our condensed statements of operations
and excluded from both continuing operations and segment results for the three and nine months ended September 30, 2022.
As part
of recognizing the business as held for sale in accordance with U.S. GAAP, the Company was required to measure APS and CSP at the lower
of its carrying amount or fair value less cost to sell. As a result of this analysis, during the three and nine months ended September
30, 2023, the Company recognized a non-cash, pre-tax loss on disposal of $3,209,776. The loss is included in “Net loss from discontinued
operations” in the consolidated statements of operations. The loss was determined by comparing the fair value of the consideration
received for the sale of a 100% interest in APS and CSP with the net assets of APS and CSP, respectively, immediately prior to the transaction.
As a result of the transactions, the following assets and liabilities of APS and CSP were transferred to Wood Sage
as of August 22, 2023:
SCHEDULE
OF ASSETS AND LIABILITIES
| |
Alliance Pharma Solutions, LLC | | |
Community Specialty Pharmacy, LLC | |
Cash | |
$ | 1,050 | | |
$ | 61,988 | |
Accounts receivable, net | |
| - | | |
| 11,452 | |
Inventory | |
| - | | |
| 123,230 | |
Prepaid assets | |
| - | | |
| 525 | |
Intangible assets and capitalized software, net | |
| 739,337 | | |
| - | |
Accounts payable | |
| (23,982 | ) | |
| (231,876 | ) |
Accrued liabilities | |
| - | | |
| (10,182 | ) |
Net assets sold | |
$ | 716,405 | | |
$ | (44,863 | ) |
Discontinued Operations
The results of operations from discontinued operations for the three and nine months ended September 30, 2023 and
2022, have been reflected as discontinued operations in the consolidated statements of operations and consist of the following:
SCHEDULE
OF DISCONTINUED OPERATIONS
| |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
| |
| |
2023 | | |
2022 | |
| |
SOSRx | | |
APS | | |
CSP | | |
Total | |
| |
Three Months Ended September 30, | | |
Three Months Ended September 30, | | |
Three Months Ended September 30, | | |
Three Months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue | |
$ | - | | |
$ | 3,368 | | |
$ | - | | |
$ | - | | |
$ | 124,238 | | |
$ | 341,140 | | |
$ | 124,238 | | |
$ | 344,508 | |
Cost of sales | |
| - | | |
| - | | |
| - | | |
| - | | |
| 127,671 | | |
| 314,945 | | |
| 127,671 | | |
| 314,945 | |
Gross profit | |
| - | | |
| 3,368 | | |
| - | | |
| - | | |
| (3,433 | ) | |
| 26,195 | | |
| (3,433 | ) | |
| 29,563 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Operating expenses | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Wage and salary expense | |
| - | | |
| 17,689 | | |
| - | | |
| - | | |
| 108,772 | | |
| 70,002 | | |
| 108,772 | | |
| 87,691 | |
Professional fees | |
| - | | |
| - | | |
| - | | |
| 10,471 | | |
| 18,079 | | |
| 2,094 | | |
| 18,079 | | |
| 12,565 | |
Accounting and legal expense | |
| - | | |
| - | | |
| 1,948 | | |
| 104 | | |
| 700 | | |
| 500 | | |
| 2,648 | | |
| 604 | |
Technology expense | |
| - | | |
| 23,000 | | |
| 4,177 | | |
| 31,564 | | |
| 2,231 | | |
| 5,445 | | |
| 6,408 | | |
| 60,009 | |
General and administrative | |
| - | | |
| 29,907 | | |
| 134 | | |
| 3,527 | | |
| 4,257 | | |
| 25,428 | | |
| 4,391 | | |
| 58,862 | |
Total operating expense | |
| - | | |
| 70,596 | | |
| 6,259 | | |
| 45,666 | | |
| 134,039 | | |
| 103,469 | | |
| 140,298 | | |
| 219,731 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Operating loss from discontinued operations | |
| - | | |
| (67,228 | ) | |
| (6,259 | ) | |
| (45,666 | ) | |
| (137,472 | ) | |
| (77,274 | ) | |
| (143,731 | ) | |
| (190,168 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Other income (expense) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Gain (loss) on disposal of assets | |
| - | | |
| - | | |
| (1,783,209 | ) | |
| 1,900 | | |
| (1,426,567 | ) | |
| - | | |
| (3,209,776 | ) | |
| 1,900 | |
Total other income (expense) | |
| - | | |
| - | | |
| (1,783,209 | ) | |
| 1,900 | | |
| (1,426,567 | ) | |
| - | | |
| (3,209,776 | ) | |
| 1,900 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Loss from discontinued operations | |
$ | - | | |
$ | (67,228 | ) | |
$ | (1,789,468 | ) | |
$ | (43,766 | ) | |
$ | (1,564,039 | ) | |
$ | (77,274 | ) | |
$ | (3,353,507 | ) | |
$ | (188,268 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Loss per common share from discontinued operations | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | - | | |
$ | (0.12 | ) | |
$ | (2.32 | ) | |
$ | (0.08 | ) | |
$ | (2.03 | ) | |
$ | (0.14 | ) | |
$ | (4.35 | ) | |
$ | (0.34 | ) |
Diluted | |
$ | - | | |
$ | (0.12 | ) | |
$ | (0.76 | ) | |
$ | (0.08 | ) | |
$ | (0.66 | ) | |
$ | (0.14 | ) | |
$ | (1.42 | ) | |
$ | (0.34 | ) |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
| |
| |
2023 | | |
2022 | |
| |
SOSRx | | |
ASP | | |
CSP | | |
Total | |
| |
Nine months ended September 30, | | |
Nine months ended September 30, | | |
Nine months ended September 30, | | |
Nine months ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue | |
$ | - | | |
$ | 20,424 | | |
$ | - | | |
$ | - | | |
$ | 761,306 | | |
$ | 905,083 | | |
$ | 761,306 | | |
$ | 925,507 | |
Cost of sales | |
| - | | |
| - | | |
| - | | |
| - | | |
| 705,206 | | |
| 1,019,470 | | |
| 705,206 | | |
| 1,019,470 | |
Gross profit | |
| - | | |
| 20,424 | | |
| - | | |
| - | | |
| 56,100 | | |
| (114,387 | ) | |
| 56,100 | | |
| (93,963 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Operating expenses | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Wage and salary expense | |
| - | | |
| 54,939 | | |
| - | | |
| - | | |
| 456,297 | | |
| 180,819 | | |
| 456,297 | | |
| 235,758 | |
Professional fees | |
| - | | |
| - | | |
| 3,125 | | |
| 44,962 | | |
| 20,246 | | |
| 5,572 | | |
| 23,371 | | |
| 50,534 | |
Accounting and legal expense | |
| - | | |
| - | | |
| 7,773 | | |
| 104 | | |
| 63,000 | | |
| 500 | | |
| 70,773 | | |
| 604 | |
Technology expense | |
| - | | |
| 53,910 | | |
| 20,611 | | |
| 83,659 | | |
| 9,464 | | |
| 13,989 | | |
| 30,075 | | |
| 151,558 | |
General and administrative | |
| - | | |
| 33,873 | | |
| 3,762 | | |
| 10,761 | | |
| 32,830 | | |
| 47,945 | | |
| 36,592 | | |
| 92,579 | |
Total operating expense | |
| - | | |
| 142,722 | | |
| 35,271 | | |
| 139,486 | | |
| 581,837 | | |
| 248,825 | | |
| 617,108 | | |
| 531,033 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Operating loss from discontinued operations | |
| - | | |
| (122,298 | ) | |
| (35,271 | ) | |
| (139,486 | ) | |
| (525,737 | ) | |
| (363,212 | ) | |
| (561,008 | ) | |
| (624,996 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Other income (expense) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Gain (loss) on disposal of assets | |
| (352,244 | ) | |
| - | | |
| (1,783,209 | ) | |
| 1,900 | | |
| (1,426,567 | ) | |
| - | | |
| (3,562,020 | ) | |
| 1,900 | |
Total other income (expense) | |
| (352,244 | ) | |
| - | | |
| (1,783,209 | ) | |
| 1,900 | | |
| (1,426,567 | ) | |
| - | | |
| (3,562,020 | ) | |
| 1,900 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Loss from discontinued operations | |
$ | (352,244 | ) | |
$ | (122,298 | ) | |
$ | (1,818,480 | ) | |
$ | (137,586 | ) | |
$ | (1,952,304 | ) | |
$ | (363,212 | ) | |
$ | (4,123,028 | ) | |
$ | (623,096 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Loss per common share from discontinued operations | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (0.50 | ) | |
$ | (0.22 | ) | |
$ | (2.57 | ) | |
$ | (0.25 | ) | |
$ | (2.76 | ) | |
$ | (0.66 | ) | |
$ | (5.82 | ) | |
$ | (1.14 | ) |
Diluted | |
$ | (0.15 | ) | |
$ | (0.22 | ) | |
$ | (0.79 | ) | |
$ | (0.25 | ) | |
$ | (0.85 | ) | |
$ | (0.66 | ) | |
$ | (1.79 | ) | |
$ | (1.14 | ) |
NOTE
4- RELATED PARTY TRANSACTIONS
On
April 1, 2023 and July 1, 2023 the Company entered into a relationship with Scietech, LLC (“Scietech”) in an independent
contractor agreement to consult on increasing sales on the IPS and Trxade Inc. platforms. The agreement was for an annual fee of
$400,000 to be split
equally between IPS and Trxade Inc. A 31%
investor in Scietech is the spouse of the interim CFO, Prashant Patel, which qualifies as a related party. The company was chosen
because they were the most qualified to perform the desired qualifications.
On
February 15, 2022, the Company entered into a relationship with Exchange Health, a technology company providing an online platform for
manufacturers and suppliers to sell and purchase pharmaceuticals. In connection therewith, SOSRx was formed
in February 2022, which is owned 51% by the Company and 49% by Exchange Health. On February 15, 2022, the Company contributed cash to
SOSRx in the amount of $325,000, issued a promissory note to SOSRx in the amount of $500,000, which was immediately assigned to Exchange
Health (the “Promissory Note”), and agreed to make an earn out payment of up to $400,000, payable, at the Company’s
discretion, in cash or common stock of the Company, based on SOSRx achieving certain revenue targets of SOSRx (the “Earn Out Payments”);
and entered into a Distribution Services Agreement with SOSRx (the “Distribution Agreement”). Exchange Health contributed
$792,000 in software and contracts which was recorded as an intangible asset on the balance sheet of SOSRx. The intangible asset was
determined to be impaired and was written off on December 31, 2022.
At
September 30, 2023, total related party debt was $0.
On
and effective on, February 1, 2023, the Company, Exchange Health and SOSRx, entered into a Voluntary Withdrawal and Release Agreement,
which was replaced in its entirety and corrected on February 4, 2023 and effective February 4, 2023 (as replaced and corrected, the “Release
Agreement”). Pursuant to the Release Agreement, the Company voluntarily withdrew as a member of SOSRx pursuant to the terms of
the Operating Agreement of SOSRx, which provided that the Company would withdraw from SOSRx if certain revenue targets were not met,
which targets have not been met.
Also
pursuant to the Withdrawal Agreement, (a) the Company agreed to the termination of its interests in SOSRx and its withdrawal as a member
thereof for no consideration (the “Withdrawal”); (b) the Promissory Note, and all of the Company’s obligations under
such Promissory Note were terminated; and (c) the parties agreed that no Earn Out Payments will be due. The Release Agreement also (i)
provides that all accumulated losses of SOSRx through December 20, 2022, will be allocated 51% to the Company and 49% to Exchange Health;
(ii) provides for a total of approximately $15,000 in outstanding invoices owed by the Company to SOSRx to be waived; (iii) includes
certain indemnification obligations of SOSRx and Exchange Health; (iv) requires SOSRx to pay certain pre-agreed outstanding invoices
of SOSRx; (v) includes mutual releases of the Company and SOSRx and Exchange Health; and (vi) includes customary representations and
warranties of the parties.
NOTE
5 – REVENUE RECOGNITION
The
Company derives revenue from two primary sources—product revenue and service revenue.
Product
revenue consists of shipments of:
| ● | Resale
of pharmaceutical products to pharmacies; and |
Revenues
for our products are recognized and invoiced when the product is shipped to the customer.
Service
revenue consists primarily of:
| ● | Transaction
fees from the facilitation of buyer generated purchase orders to suppliers, billed monthly; |
| ● | Data
service fees associated with providing vendors of pharmaceutical products with data analysis
of their catalogues and branding of their products or company to the Company’s registered
buyers, billed monthly or as a one-time fee; and |
| ● | Software-as-a-Service
(“SaaS”) fees for a platform for virtual healthcare provider visits, billed monthly. |
Revenues
for the Company’s services that are billed monthly are recognized and invoiced when the at the beginning of the month. Revenues
for one-time services are recognized at the point in time when services are rendered.
Payment
terms for products and services are generally 0 to 60 days and the Company has no contract assets or liabilities.
The
following table presents disaggregated revenue by major product and service categories during the three and nine months ended September
30, 2023 and 2022:
SCHEDULE
OF DISAGGREGATED REVENUE
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
Three months ended September 30, | | |
Nine months ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Product revenues | |
| | | |
| | | |
| | | |
| | |
Pharmaceutical product resale income | |
$ | 394,849 | | |
$ | 707,807 | | |
$ | 1,237,731 | | |
$ | 3,949,771 | |
Total product revenues | |
$ | 394,849 | | |
$ | 707,807 | | |
$ | 1,237,731 | | |
$ | 3,949,771 | |
| |
| | | |
| | | |
| | | |
| | |
Service revenues | |
| | | |
| | | |
| | | |
| | |
Transaction fee income | |
$ | 1,617,129 | | |
$ | 1,319,483 | | |
$ | 4,531,731 | | |
$ | 3,947,621 | |
Data service fee income | |
| 46,050 | | |
| 17,950 | | |
| 132,025 | | |
| 54,050 | |
SaaS fee income | |
| - | | |
| 10,563 | | |
| 18,299 | | |
| 42,363 | |
Total service revenues | |
$ | 1,663,179 | | |
$ | 1,347,996 | | |
$ | 4,682,055 | | |
$ | 4,044,034 | |
Total revenues | |
$ | 2,058,028 | | |
$ | 2,055,803 | | |
$ | 5,919,786 | | |
$ | 7,993,805 | |
NOTE
6 – INVENTORY
Inventory
value is determined using the weighted average cost method and is stated at the lower of cost or net realizable value. As of September
30, 2023 and December 31, 2022, inventory was comprised of the following:
SCHEDULE
OF INVENTORY
As of | |
September 30, 2023 | | |
December 31, 2022 | |
Raw materials | |
$ | 1,895,406 | | |
$ | 68,448 | |
Finished goods | |
| 1,131,512 | | |
| - | |
Inventory | |
$ | 3,026,918 | | |
$ | 68,448 | |
NOTE
7 – NOTES RECEIVABLE
On
August 22, 2023, issued a Promissory Note Agreement (the “Wood Sage Note”) in the amount of $1,300,000 to Wood Sage, LLC
and entered into the APS MIPA and CSP MIPA for the Company to sell APS and CSP and entered into a Master Service Agreement (“Wood
Sage MSA”). The Wood Sage Note bears no interest and is due and payable within thirty days of a change in control, as defined by
the Wood Sage Note, of the borrower. As of September 30, 2023, the outstanding balance of the Wood Sage Note was $1,275,000.
NOTE
8 – INTANGIBLE ASSETS
As
of September 30, 2023, intangible assets, net consisted of the following:
SCHEDULE
OF INTANGIBLE ASSETS NET
| |
Weighted Average | | |
| | |
| | |
| |
| |
Useful Life | | |
| | |
Accumulated | | |
| |
| |
(years) | | |
Cost | | |
Amortization | | |
Net | |
Developed technology | |
| 5.0 | | |
$ | 9,777,478 | | |
$ | (325,916 | ) | |
$ | 9,451,562 | |
NOTE
9 – OTHER CURRENT LIABILITIES
As
of September 30, 2023 and December 31, 2022, other current liabilities consisted of the following:
SCHEDULE
OF OTHER CURRENT LIABILITIES
| |
September 30, 2023 | | |
December 31, 2022 | |
Purchase price payable | |
$ | 350,000 | | |
$ | - | |
Insurance refunds payable | |
| 62,390 | | |
| 62,390 | |
Deferred revenue | |
| - | | |
| 5,127 | |
Other current liabilities | |
$ | 412,390 | | |
$ | 67,517 | |
NOTE
10 – CONTINGENT FUNDING LIABILITIES
On
June 27, 2023, the Company entered into a non-recourse funding agreement with a third-party for the purchase and sale of future receivables
(the “Receivables Agreement”). Pursuant to the Receivables Agreement, the third-party agreed to fund the Company $1,250,000
to purchase $1,800,000 of future receivables. Under the funding agreement, the third-party receives a priority interest in the receivables
of Trxade Inc. The Company also paid $62,500 as a one-time origination fee in connection with the Receivables Agreement. The Receivables
Agreement also allows for the third-party funder to file UCCs securing their interest in the receivables and includes customary events
of default. As of September 30, 2023, the Company owed $452,348 under this agreement.
On
March 14, 2023, the Company entered into a non-recourse funding agreement with a third-party for the purchase and sale of future receivables
(the “Receivables Agreement”). Pursuant to the Receivables Agreement, the third-party agreed to fund the Company $875,000
to purchase $1,224,000 of future receivables. Under the funding agreement, the third-party receives a priority interest in the receivables
of Trxade Inc. The Company also paid $42,500 as a one-time origination fee in connection with the Receivables Agreement. The Receivables
Agreement also allows for the third-party funder to file UCCs securing their interest in the receivables and includes customary events
of default.
On
September 14, 2022, the Company entered into a non-recourse funding agreement with a third-party for the purchase and sale of future
receivables (the “Receivables Agreement”). Pursuant to the Receivables Agreement, the third-party agreed to fund the Company
$275,000 to purchase $396,000 of future receivables. Under the funding agreement, the third-party receives a priority interest in the
receivables of Trxade Inc. The Company also paid $15,000 as a one-time origination fee in connection with the Receivables Agreement.
The Receivables Agreement also allows for the third-party funder to file UCCs securing their interest in the receivables and includes
customary events of default. This agreement was fully paid off in January 2023.
On
June 27, 2022, the Company entered into a non-recourse funding agreement with a third-party funder for the purchase and sale of future
receivables. Pursuant to the Receivables Agreement, the third-party agreed to fund the Company $550,000 to purchase $792,000 of future
receivables. Under the funding agreement, the third-party receives a priority interest in the receivables of Trxade Inc. The Company
also paid $27,500 as a one-time origination fee in connection with the Receivables Agreement. The Receivables Agreement also allows for
the third-party funder to file UCCs securing their interest in the receivables and includes customary events of default. This agreement
was fully paid off in January 2023.
The
Company’s relationship with the funding source meets the criteria in ASC 470-10-25 – Sales of Future Revenues or Various
Other Measures of Income (“ASC 470”), which relates to cash received from a funding source in exchange for a specified percentage
or amount of revenue or other measure of income of a particular product line, business segment, trademark, patent or contractual right
for a defined period. Under this guidance, the Company recognized the fair value of its contingent obligation to the funding source,
as of the acquisition date, as a current liability in its consolidated balance sheet.
Under
ASC 470, amounts recorded as debt are to be amortized under the interest method. The Company made an accounting policy election to
utilize the prospective method when there is a change in the estimated future cash flows, whereby a new effective interest rate is
determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value
of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest
expense for the remaining period. Under this method, the effective interest rate is not constant, and any change in expected cash
flows is recognized prospectively as an adjustment to the effective yield. As of September 30, 2023 and December 31, 2022 the total
contingent funding liability was $452,348
and $108,036, respectively, and the effective interest rate was approximately 31%
and 31%, respectively. This rate represents the discount rate that equates the estimated future cash flows with the fair value of the debt and is used to
compute the amount of interest to be recognized each period. Any future payments made to the funding source will decrease the
contingent funding liability balance accordingly.
NOTE
11 – NOTES PAYABLE
On
September 27, 2023, the Company issued a promissory note to Perfect Day, Inc. (the “Perfect Day Note”) in the amount of $3,150,000
as consideration for the TUC APA (see Note 3). The promissory note does not accrue interest and is payable upon demand at any time after
October 31, 2023. The entire aggregate, unpaid principal sum of the note is immediately due and payable upon the occurrence of a change
in control, as defined in the agreement.
On
September 14, 2023, the Company issued a promissory note to Danam Health, Inc. (the “Danam Note”) in the amount of $300,000.
The Company received a deposit of $200,000 on September 14, 2023 and an additional deposit of $100,000 on October 13, 2023. The Danam
Note accrues interest at 0% per annum and is due and payable no later than 30 days after a change in control of borrower, as defined
in the note agreement. As of September 30, 2023, the balance of the Danam Note is $200,000. The Company repaid $250,000 on the loan in
October 2023. As of the date of this filing, the balance on the loan is $50,000.
On
June 16, 2023, the Company issued a secured debenture to Eat Well Investment Group, Inc. (the “Eat Well June 2023 Note”)
in the amount of $1,150,000 for the purchase of Sapientia, a wholly-owned subsidiary of Superlatus. The Eat Well June 2023 Note is secured
by 100% of the membership interests in Sapientia. The Eat Well June 2023 Note began accruing interest at 12% per annum, compounded monthly,
as of October 31, 2023. The Eat Well June 2023 matured on December 31, 2023. As of September 30, 2023, the balance of the Eat Well June
2023 Note is $1,150,000. As of the date of this filing, the parties are working on an amendment for an extension.
On
February 8, 2023, Sapientia, a wholly-owned subsidiary of Superlatus, entered into a Loan Agreement with Eat Well Investment Group, Inc.
(the “Eat Well February 2023 Note”) in the amount of $25,000. The Eat Well February 2023 Note is unsecured, accrues interest
at a rate of 1.87% per annum, and matures February 7, 2025. As of September 30, 2023, the balance of the Eat Well February 2023 Note
is $25,000. The Company has accrued interest of $350 as of September 30, 2023.
On
September 14, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well September 2022
Note”) in the amount of $50,000. The Eat Well September 2022 Note is unsecured, accrues interest at a rate of 1.87% per annum,
and matures September 13, 2024. As of September 30, 2023, the balance of the Eat Well September 2022 Note is $50,000. The Company has
accrued interest of $1,140 as of September 30, 2023.
On
July 26, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well July 26, 2022 Note”)
in the amount of $35,000. The Eat Well July 26, 2022 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matures July
25, 2024. As of September 30, 2023, the balance of the Eat Well July 26, 2022 Note is $35,000. The Company has accrued interest of $798
as of September 30, 2023.
On
July 12, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well July 12, 2022 Note”)
in the amount of $25,000. The Eat Well July 12, 2022 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matures July
11, 2024. As of September 30, 2023, the balance of the Eat Well July 12, 2022 Note is $25,000. The Company has accrued interest of $585
as of September 30, 2023.
On
March 15, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well March 2022 Note”)
in the amount of $100,000. The Eat Well March 2022 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matures March
14, 2024. As of September 30, 2023, the balance of the Eat Well March 2022 Note is $100,000. The Company has accrued interest of $2,966
as of September 30, 2023.
On
February 1, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well February 2022 Note”)
in the amount of $100,000. The Eat Well February 2022 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matures February
1, 2024. As of September 30, 2023, the balance of the Eat Well February 2022 Note is $100,000. The Company has accrued interest of $3,110
as of September 30, 2023.
On
January 20, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well January 2022 Note”)
in the amount of $20,000. The Eat Well January 2022 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matures January
20, 2024. As of September 30, 2023, the balance of the Eat Well January 2022 Note is $20,000. The Company has accrued interest of $653
as of September 30, 2023.
On
December 24, 2021, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well December 2021 Note”)
in the amount of $100,000. The Eat Well December 2021 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matured December
24, 2023. As of September 30, 2023, the balance of the Eat Well December 2021 Note is $100,000. The Company has accrued interest of $3,427
as of September 30, 2023. As of the date of this filing, the parties are working on an amendment for an extension.
On
November 10, 2021, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well November 2021 Note”)
in the amount of $50,000. The Eat Well Novemer 2021 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matured November
10, 2023. As of September 30, 2023, the balance of the Eat Well November 2021 Note is $50,000. The Company has accrued interest of $1,790
as of September 30, 2023. As of the date of this filing, the parties are working on an amendment for an extension.
On
August 18, 2021, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well August 2021 Note”)
in the amount of $250,000. The Eat Well August 2021 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matured August
18, 2023. As of September 30, 2023, the balance of the Eat Well August 2021 Note is $250,000. The Company has accrued interest of $9,900
as of September 30, 2023. As of the date of this filing, the parties are working on an amendment for an extension.
The
following table summarizes notes payable balances as of September 30, 2023:
SCHEDULE OF
NOTES PAYABLE BALANCES
| |
Current | | |
Noncurrent | | |
| | |
Accrued | |
| |
Portion | | |
Portion | | |
Total | | |
Interest | |
| |
Current Portion | | |
Non current Portion | | |
Note
Payable Total | | |
Accrued Interest | |
Perfect Day Note | |
$ | 3,150,000 | | |
$ | - | | |
$ | 3,150,000 | | |
$ | - | |
Danam Note | |
| 200,000 | | |
| - | | |
| 200,000 | | |
| - | |
Eat Well June 2023 Note | |
| 1,150,000 | | |
| - | | |
| 1,150,000 | | |
| - | |
Eat Well February 2023 Note | |
| - | | |
| 25,000 | | |
| 25,000 | | |
| 350 | |
Eat Well September 2022 Note | |
| 50,000 | | |
| - | | |
| 50,000 | | |
| 1,104 | |
Eat Well July 26, 2022 Note | |
| 35,000 | | |
| - | | |
| 35,000 | | |
| 798 | |
Eat Well July 12, 2022 Note | |
| 25,000 | | |
| - | | |
| 25,000 | | |
| 585 | |
Eat Well March 2022 Note | |
| 100,000 | | |
| - | | |
| 100,000 | | |
| 2,966 | |
Eat Well February 2022 Note | |
| 100,000 | | |
| - | | |
| 100,000 | | |
| 3,110 | |
Eat Well January 2022 Note | |
| 20,000 | | |
| - | | |
| 20,000 | | |
| 653 | |
Eat Well December 2021 Note | |
| 100,000 | | |
| - | | |
| 100,000 | | |
| 3,427 | |
Eat Well November 2021 Note | |
| 50,000 | | |
| - | | |
| 50,000 | | |
| 1,790 | |
Eat Well August 2021 Note | |
| 250,000 | | |
| - | | |
| 250,000 | | |
| 9,900 | |
| |
$ | 5,230,000 | | |
$ | 25,000 | | |
$ | 5,255,000 | | |
$ | 24,683 | |
NOTE 12 – STOCKHOLDERS’ EQUITY
Designation
of Series B Preferred Stock
Effective
June 26, 2023 the Company’s Board of Directors issued a Certificate of Designation, which designated 787,754
shares of the Company’s authorized and unissued preferred stock as convertible Series B Preferred Stock at a par value of
$0.00001
per share.
2023
1:15 Stock Split
Effective
June 21, 2023 the Company executed a 1:15 reverse stock split for stockholders of record on that date. This was executed to comply with
the Nasdaq Listing Rule 5550(a)(2) to have the price of the stock above $1.
2022
Equity Compensation Awards
Effective
September 1, 2022, the Board of Directors and Compensation Committee of the Company, with the approval of each of the following officers,
agreed to reduce the annual cash compensation payable to Suren Ajjarapu, the Company’s Chief Executive Officer; Prashant Patel,
the Company’s President and Chief Operating Officer and Janet Huffman, the Company’s former Chief Financial Officer, in an
effort to conserve cash.
In
lieu of the reduced cash salary payable to each officer, the Board and Compensation Committee agreed to issue such officers shares of
the Company’s common stock equal to the amount of reduced cash salary, divided by the closing sales price of the Company’s
common stock on the NASDAQ Capital Market on August 31, 2022, the date approved by the Board of Directors. The total amount of shares
of common stock issued on August 31, 2022 to the officers was 5,460.
The
shares of common stock issuable to the officers vested at the rate of 1/4th of such shares on each of September 30, 2022, October 31, 2022,
November 30, 2022, and December 31, 2022, subject to each applicable Officer’s continued service to the Company on such dates and
subject to the restricted stock award agreements entered into as evidence of such awards.
Separately,
certain employees of the Company agreed to reduce their cash salaries by an aggregate of $37,000 in consideration for an aggregate of
2,126 shares of the Company’s restricted common stock, with the same vesting terms as the officer shares discussed above.
Effective
on August 31, 2022, the Board of Directors approved the issuance of 3,635 shares of common stock of the Company to each independent member
of the Board of Directors, for services rendered to the Company during fiscal 2022, which shares were valued at $63,250, based on the
closing sales price of the Company’s common stock on the date approved by the Board of Directors. The shares vested at the rate of
1/4th of such shares immediately on the grant date, and 1/4th of such shares on each of October 1, 2022, January 1, 2023 and April 1,
2023, subject to each applicable independent director’s continued service to the Company on such dates.
All
of the awards discussed above were issued under the Company’s Second Amended and Restated 2019 Equity Incentive Plan (the “Plan”)
and all restricted stock awards discussed above were evidenced by Restricted Stock Grant Agreements.
NOTE
13 – PREFUNDED AND PRIVATE PLACEMENT WARRANTS
On October 4, 2022 the Company entered into a securities purchase agreement (the “Purchase Agreement”)
with a certain institutional investor (the “Purchaser”) which provided for the sale and issuance by the Company of (i) the
Company’s common stock (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) and (iii)
warrants (the “Private Placement Warrants” and, together with the Shares and the Pre-Funded Warrants, the “Securities”).
The Private Placement Warrants were sold in a concurrent private placement (the “Private Placement”), exempt from registration
pursuant to Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933, as amended (the “Securities Act”).
Simultaneously
with the closing of the stock placement, the investor pre-purchased 40,116
Private Warrants at a purchase price of $17.25
per warrant. The Pre-Funded Warrants are immediately exercisable into one share of common stock per warrant, have an exercise price of $0.00015
per share, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. On January 4, 2023, the
investor exercised the 40,116
warrants for a purchase price of $6.02.
The investor was issued the shares on this date. Each Private Warrant has an exercise price of $22.50
per share, will be exercisable following Stockholder Approval, which was obtained in December 2022, and will expire on the fifth
anniversary of the date on which the Private Warrants become exercisable. The Private Warrants contain standard adjustments to the
exercise price including for stock splits, stock dividend, rights offerings and pro rata distributions, and include full ratchet
anti-dilutive rights in the event the Company issues shares of Common Stock or Common Stock equivalents within fifteen months of the
initial exercise date, with a value less than the then exercise price of such Private Warrants, subject to certain customary
exceptions, and further subject to a minimum exercise price of $3.48
per share. The Private Warrants also include certain rights upon ‘fundamental transactions’ as described in the Private
Warrants, including allowing the holders thereof to require that the Company re-purchase such Private Warrants at the Black Scholes
Value of such securities.
NOTE
14 – WARRANTS
For
the nine-month period ended September 30, 2023, no warrants were granted, and none expired. For the nine-month period ended September
30, 2023, 40,116 prefunded warrants and 1,795 granted warrants to purchase shares of common stock were exercised for a total purchase
price of $1,622. See Note 13- Prefunded and Private Placement Warrants for further description.
The
Company uses the Black-Scholes pricing model to estimate the fair value of stock-based awards on the date of the grant.
There
was no compensation cost related to the warrants for the nine months ended September 30, 2023, and 2022, respectively.
The
Company’s outstanding and exercisable warrants As of September 30, 2023, are presented below:
SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS
| |
Number Outstanding | | |
Weighted Average Exercise Price | | |
Contractual Life In Years | | |
Intrinsic Value | |
Warrants outstanding as of December 31, 2022 | |
| 179,331 | | |
| 22.50 | | |
| 4.72 | | |
| 6,731 | |
Warrants granted | |
| | | |
| - | | |
| - | | |
| - | |
Warrants forfeited, expired, cancelled | |
| | | |
| - | | |
| - | | |
| - | |
Warrants exercised | |
| (1,795 | ) | |
| 22.50 | | |
| - | | |
| - | |
Warrants outstanding as of September 30, 2023 | |
| 177,536 | | |
| 22.50 | | |
| 4.02 | | |
| 0 | |
Warrants exercisable as of September 30, 2023 | |
| 177,536 | | |
| 22.50 | | |
| 4.02 | | |
| - | |
NOTE
15 – OPTIONS
The
Company maintains stock option plans under which certain employees are awarded option grants based on a combination of performance and
tenure. The stock option plans provide for the grant of up to 155,556 shares, and the Company’s Second Amended and Restated 2019
Equity Incentive Plan provides for automatic increases in the number of shares available under such plan (currently 133,333 shares) on
April 1st of each calendar year, beginning in 2021 and ending in 2029 (each a “Date of Determination”), in each
case subject to the approval and determination of the administrator of the plan (the Board of Directors or Compensation Committee) on
or prior to the applicable Date of Determination, equal to the lesser of (A) ten percent (10%) of the total shares of common stock of
the Company outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares as determined
by the administrator. The administrator as a result of the annual meeting shareholder vote increased the number of shares available to
grant to employees under the 2019 incentive plan by 2 million. The administrator did not approve an increase in the number of shares
covered under the plan as of April 1, 2022.
For
the nine-month period ended September 30, 2023, 603 options to purchase shares were granted, 140 options to purchase shares were forfeited
and 2,319 options expired. For the nine-month period ended September 30, 2023, no options to purchase shares of common stock were exercised.
Total
compensation cost related to stock options granted was $25,978 and $67,439 for the nine-months ended September 30, 2023, and 2022, respectively.
The
following table represents stock option activity for the nine-month period ended September 30, 2023:
SCHEDULE OF STOCK OPTION ACTIVITY
| |
Number Outstanding | | |
Weighted- Average Exercise Price | | |
Weighted- Average Contractual Life in Years | | |
Intrinsic Value | |
Options outstanding as of December 31, 2022 | |
| 19,708 | | |
$ | 66.00 | | |
| 3.92 | | |
$ | - | |
Options exercisable as of December 31, 2022 | |
| 17,167 | | |
| 66.30 | | |
| 3.89 | | |
| - | |
Options granted | |
| 603 | | |
| 6.08 | | |
| 4.51 | | |
| 59,976 | |
Options forfeited | |
| (140 | ) | |
| 82.33 | | |
| 2.00 | | |
| - | |
Options expired | |
| (2,319 | ) | |
| 89.88 | | |
| 0.08 | | |
| - | |
Options exercised | |
| - | | |
| - | | |
| - | | |
| - | |
Options outstanding As of September 30, 2023 | |
| 17,852 | | |
| 66.10 | | |
| 3.95 | | |
| 112,073 | |
Options exercisable As of September 30, 2023 | |
| 17,252 | | |
| 62.43 | | |
| 2.99 | | |
| 52,097 | |
NOTE
16 – CONTINGENCIES
Studebaker
Defense Group, LLC
In
July 2020, the Company’s wholly-owned subsidiary, IPS, entered into an agreement with Studebaker Defense Group, LLC
(“Studebaker”) wherein IPS would pay Studebaker a down payment of $550,000
and Studebaker would deliver 180,000
boxes of nitrile gloves by August 14, 2020. IPS wired the $550,000
to Studebaker, but to date, Studebaker has not delivered the gloves or provided a refund of the deposit. In December 2020, we filed
a complaint against Studebaker in Florida state court, Case No. 20-CA-010118 in the Circuit Court for the Thirteenth Judicial
Circuit in Hillsborough County, for among other things, breach of contract. Studebaker did not answer the complaint, nor did counsel
for Studebaker file an appearance. Accordingly, in February 2021, the Company filed for a default judgment; however, on March 22,
2021, counsel for Studebaker filed an appearance and shortly thereafter filed a motion totion vacate the default judgment and
dismiss the complaint on jurisdictional grounds. The court granted Studebaker’s motion to set aside the default judgment but
denied the motion to dismiss. The Company has filed several pretrial motions; the next step in the litigation after the pre-trial
motions are resolved will be a motion for summary judgment. The Company believes it will prevail on the merits but cannot determine
the timing of the judgment or the amount ultimately collected. At June 30, 2021, the $500,000
was recorded as Loss on Inventory Investment. The Company won this case but has not collected any settlement yet, another lawsuit
has been filed to collect.
On
April 13, 2023, a settlement was reached in the Studebaker Defense Group LLC. and IPS legal case. The court found in favor of IPS
and ordered Studebaker Defense Group, LLC. to pay $550,000 IPS. The payments were to commence on May 1, 2023 and continue monthly in 17 installments until the full
amount is paid in full but as of the filing date, no payment has been received by IPS.
Sandwave
Group Dsn Bhd and Crecom Burj Group SDN BHD
In
August 2020, IPS entered into an agreement with Sandwave Group Dsn Bhd (“Sandwave”), wherein IPS would pay Sandwave a
down payment of $581,250
and Sandwave’s supplier, Crecom Burj Group SDN BHD (“Crecom”), would deliver 150,000
boxes of nitrile gloves within 45 days. IPS wired the $581,250
to Sandwave, which in turn wired the purchase price to Crecom, which Crecom accepted; however, to date, Crecom has not delivered the
nitrile gloves. IPS demanded return of its $581,250
and Crecom acknowledged that IPS was entitled to a refund. As of February 2021, Crecom had not returned any funds and IPS filed a
complaint against Crecom in Malaysia: Case No. WA-22NCC-55-02/2021 in the High Court of Malaysia at Kuala Lumpur in the Federal
Territory, Malaysia for the Malaysian equivalent of breach of contract. On September 1, 2022 counsel for Crecom informed the court
that Crecom had been wound up on August 23, 2022; under Section 471 of the Malaysian Companies Act 2016, the suit filed by IPS was
stayed until leave of the court is obtained to proceed. Given this new information regarding Crecom the Company has decided at this
time to stop its pursuit of this lawsuit until or unless additional information is obtained by counsel for IPS. At June 30,
2021, the $581,250
was recorded as Loss on Inventory Investment.
GSG
PPE, LLC
On
November 19, 2021, IPS filed a complaint against GSG PPE, LLC (“GSG”) and Gary Waxman (“Waxman”), the owner,
alleging three counts of breach of contract for a purchase agreement, a promissory note, and a personal guaranty. Collectively, the
company alleges that GSG and Waxman have materially breached all three contracts. In late 2020, GSG and IPS executed a valid initial
contract setting the terms of a business transaction. GSG failed to pay IPS approximately 75% of the amount owed to IPS. GSG
acknowledged it owed the money and executed a promissory note in favor of IPS in the amount of $630,000
which matured on September 30, 2021. The note provides for attorney fees and interest in addition to the $630,000.
Waxman’s personal guaranty confirmed that GSG owed IPS $630,000.
On September 30, 2021, the $630,000
was recorded as Bad Debt Expense. A settlement was entered into between the parties in June 2022, whereby GSG and Waxman agreed to
pay $743,000 which included
attorney fees and interest, which is required to be paid to the Company in monthly installments over 17 months. The Company received
additional monthly installment payments as part of the agreement through January 2023. As of September 30, 2023, and through the
date of this filing, the Company has not received the monthly installment payments due to the Company from GSG since January
of 2023.
NOTE
17 – SEGMENT REPORTING
Operating
segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly
by the chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company’s chief
operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth
opportunities of each respective segment.
The
Company classifies its business interests into reportable segments which are:
|
● |
Trxade,
Inc. - Web based pharmaceutical marketplace platform – B2B sales |
|
● |
IPS
- Integra Pharma, LLC - Licensed wholesaler of brand, generic and non-drug products – B2B sales |
|
● |
Superlatus
– holds Sapientia’s intellectual property for advanced food extrusion technology and The Urgent Company – Manufacturer
of ice cream that is animal product-free, vegan, lactose-free, and made with plants – B2B sales |
|
● |
Unallocated - Other – corporate overhead expense, discontinued operations and Bonum Health, LLC. |
SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS
Nine
months ended September 30, 2023 | |
Trxade, Inc. | | |
IPS | | |
Superlatus | | |
Unallocated | | |
Total | |
Revenue | |
$ | 4,663,756 | | |
$ | 1,237,731 | | |
$ | - | | |
$ | 18,299 | | |
$ | 5,919,786 | |
Gross Profit | |
| 4,663,756 | | |
| 165,553 | | |
| (756 | ) | |
| 18,299 | | |
| 4,846,852 | |
Segment Assets | |
| - | | |
| - | | |
| 18,029,077 | | |
| 3,624,766 | | |
| 21,653,843 | |
Segment Profit (Loss) | |
| 1,570,796 | | |
| (388,900 | ) | |
| (440,268 | ) | |
| (6,869,237 | ) | |
| (6,127,609 | ) |
Cost of Sales | |
| - | | |
| 1,072,178 | | |
| 756 | | |
| - | | |
| 1,072,934 | |
Nine months ended September 30, 2022 | |
Trxade, Inc. | | |
IPS | | |
Superlatus | | |
Unallocated | | |
Total | |
Revenue | |
$ | 4,001,670 | | |
$ | 3,949,772 | | |
$ | - | | |
$ | 42,363 | | |
$ | 7,993,805 | |
Gross Profit | |
| 4,001,670 | | |
| (41,462 | ) | |
| - | | |
| 42,363 | | |
| 4,002,571 | |
Segment Assets | |
| 1,853,474 | | |
| 454,783 | | |
| - | | |
| 2,172,060 | | |
| 4,480,317 | |
Segment Profit (Loss) | |
| 1,320,138 | | |
| (493,203 | ) | |
| - | | |
| (3,433,774 | ) | |
| (2,606,839 | ) |
Cost of Sales | |
| - | | |
| 3,991,234 | | |
| - | | |
| - | | |
| 3,991,234 | |
NOTE
18 – SUBSEQUENT EVENTS
Stock
Swap Agreement
Upon
conclusion of the Stock Swap Transaction and Merger (see Note 1), the remaining operations within TRxADE will only consist of legacy
Superlatus operations. Management has determined that Superlatus will be the accounting acquirer in the merger based upon a detailed
analysis of the relevant U.S. GAAP guidance and the facts and circumstances outlined above. Consequently, Superlatus will apply acquisition
accounting to the assets and liabilities of TRxADE that are acquired or assumed upon the consummation of the merger. The historical financial
statements of Superlatus for periods ended prior to the consummation of the merger will reflect only the operations and financial condition
of Superlatus. Subsequent to the consummation of the merger, the financial statements of Superlatus will include the combined operations
and financial condition of Superlatus and remaining TRxADE operations.
As
a condition and inducement to Superlatus’s willingness to enter into the Merger Agreement, on June 28, 2023, Suren Ajjarapu and
Prashant Patel (the “Principal Stockholders”) entered into an agreement with the Company (the “Stock Swap Agreement”),
pursuant to which, the Company will transfer all of the shares or membership interest of a variety of operating subsidiaries currently
owned by the Company to Principal Stockholders, in exchange for Suren Ajjarapu to surrender 85,000 shares of the common stock of the
Company and Prashant Patel to surrender 81,666 shares of the common stock of the Company (the “Stock Swap Transaction”).
The closing of the Stock Swap Transaction shall take place simultaneously with the approval by the Company’s stockholders of the
conversion of the Series B preferred Stock into common stock. As of the date of this filing, the stockholders have not approved the conversion.
As discussed in Note 1 and Note
3, the closing conditions were not met and the Merger Agreement was amended on January 8, 2024.
Spero Asset
Purchase Agreement
On October
4, 2023, the Company entered into an all-cash asset purchase agreement to acquire the assets of Spero Foods, Inc. for $500,000. As of
the date of this filing, the Company is still working to complete the purchase.
Unregistered Sales of
Equity Securities Hudson Global Ventures, LLC
On October 4, 2023,
the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Hudson Global Ventures, LLC (the
“Purchaser”), pursuant to which the Company sold, in a private placement, (i) 290 shares of the Company’s Series C
Convertible Preferred Stock (the “Series C Preferred Stock”), stated value $1,000 per share (the “Stated Value”),
at a price of $1,000 per share, convertible into shares (the “Conversion Shares”) of the Company’s common stock, par
value $0.00001 per share (the “Common Stock”) and (ii) a warrant (the “Warrant”) to purchase up to 41,193 shares
of Common Stock. As additional consideration for entering into the Purchase Agreement, the Company issued to the Purchaser an additional
40,000 shares of Common Stock to be delivered to the Purchaser at the closing (the “Commitment Shares,” together with the
Series C Preferred Shares and the Warrant, the “Securities”). The offering resulted in gross proceeds to the company of $290,000.
Non-recourse funding agreement
On October 25, 2023,
the Company entered into a non-recourse funding agreement with a third-party for the purchase and sale of future receivables (the “Receivables
Agreement”). Pursuant to the Receivables Agreement, the third-party agreed to fund the Company $1,200,000 to purchase $1,728,000
of future receivables. Under the funding agreement, the third-party receives a priority interest in the receivables of Trxade Inc. The
Company also paid $60,000 as a one-time origination fee in connection with the Receivables Agreement. The Receivables Agreement also
allows for the third-party funder to file UCCs securing their interest in the receivables and includes customary events of default.
ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
General
Information
This
information should be read in conjunction with the interim unaudited financial statements and the notes thereto included in this Quarterly
Report on Form 10-Q, and the audited financial statements and notes thereto and “Part II. Other Information – Item 7. Management’s
Discussion and Analysis of Financial Condition and Results of Operations”, contained in our Annual Report on Form 10-K for the
year ended December 31, 2022, filed with the SEC on March 27, 2023 (the “Annual Report”).
Certain
capitalized terms used below and otherwise defined below, have the meanings given to such terms in the footnotes to our unaudited consolidated
financial statements included above under “Part I – Financial Information” – “Item 1. Financial Statements”.
Please
see the section entitled “Glossary” in our Annual Report for a list of abbreviations and definitions used throughout this
Report.
Unless
the context requires otherwise, references to the “Company,” “we,” “us,” “our,” and “Trxade”,
refer specifically to TRxADE HEALTH, INC. and its consolidated subsidiaries. References to “Q1”, “Q2”, “Q3”,
and “Q4” refer to the first, second, third, and fourth quarter, respectively, of the applicable year. Unless otherwise stated
or the context otherwise requires, comparisons from one period to another are to the same period of the prior fiscal year.
In
addition, unless the context otherwise requires and for the purposes of this report only:
|
● |
“Exchange
Act” refers to the Securities Exchange Act of 1934, as amended; |
|
● |
“Securities
Act” refers to the Securities Act of 1933, as amended. |
Summary
of The Information Contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations
Our
Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is provided in addition to the
accompanying consolidated financial statements and notes to assist readers in understanding our results of operations, financial condition,
and cash flows. MD&A is organized as follows:
|
● |
Company
Overview. Discussion of our business and overall analysis of financial and other highlights affecting us, to provide context
for the remainder of MD&A. |
|
● |
Recent
Events. Summary of material transactions occurring during the three and nine months ended September 30, 2023. |
|
● |
Liquidity
and Capital Resources. An analysis of changes in our consolidated balance sheets and cash flows and discussion of our financial
condition. |
|
● |
Results
of Operations. An analysis of our financial results comparing the three and nine months ended September 30, 2023, and 2022. |
|
● |
Critical
Accounting Policies. Accounting estimates that we believe are important to understanding the assumptions and judgments incorporated
in our reported financial results and forecasts. |
Company
Overview
TRxADE
HEALTH is a technology-enabled health services platform. Through our subsidiary companies we focus on digitalizing the retail pharmacy
and health services experience by optimizing drug procurement, the prescription journey, access to physicians in the patient’s
home and patient engagement in the U.S.
Our
services provide pricing transparency, purchasing capabilities and other value-added services on a single platform focused on serving
the nation’s approximately 19,397 independent pharmacies with annual purchasing power of $67.1 billion (according to the National
Community of Pharmacists Association’s 2021 Digest). Our national wholesale supply partners are able to fulfill orders on our platform
in real-time and provide pharmacies with cost-saving payment terms and next-day delivery capabilities in unrestrictive states under the
Model State Pharmacy Act and Model Rules of the National Association of Boards of Pharmacy (Model Act). We have expanded significantly
since 2015 and now have around 14,100+ registered members on our sales platform.
The
Company changed its name on June 1, 2021, from “Trxade Group, Inc” to “TRxADE HEALTH, INC.”. TRxADE HEALTH, INC.
owns 100% of Trxade, Inc., Integra Pharma Solutions, LLC (formerly Pinnacle Tek, Inc.), Alliance Pharma Solutions, LLC, Community Specialty
Pharmacy, LLC, Bonum Health, LLC, Superlatus, Inc. and The Urgent Company, Inc. Trxade, Inc. is a web-based market platform that enables
commerce among healthcare buyers and sellers of pharmaceuticals, accessories and services.
On September 27, 2023, the Company entered into an Asset Purchase Agreement (“APA”) with The Urgent Company,
Inc. (“TUC”) and its wholly owned subsidiaries, pursuant to which, the Company was assigned certain inventory and property
and equipment for consideration of a $3,150,000 promissory note. This
acquisition is expected to enhance the Company’s production of sustainable food products and enable the expansion of market share.
On July 14,
2023, the Company entered into an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”) with
Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities
(“Superlatus”) and Foods Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company
(“Merger Sub”).
On
July 31, 2023 (the “Closing Date”), the Company completed its acquisition of Superlatus in accordance with the terms and
conditions of the Merger Agreement (the “Merger”), pursuant to which the Company acquired Superlatus by way of a merger of
the Merge Sub with and into Superlatus, with Superlatus being a wholly owned subsidiary of the Company and the surviving entity in the
Merger.
Under
the terms of the Merger Agreement, at the closing of the Merger (the “Closing”), shareholders of Superlatus received in
aggregate 136,441 shares of common stock of the Company, representing 19.9% of the total issued and outstanding common stock of the
Company after the consummation of the Merger and 306,855 shares of Company’s Series B Preferred Stock, par value $0.00001 per
share (the “Series B Preferred Stock”), with a conversion ratio of 100 to one. Upon consummation of the Merger, the
Company will continue to trade under the current ticker symbol “MEDS.”
As
a condition and inducement to Superlatus’ willingness to enter into the Merger Agreement, on June 28, 2023, Suren Ajjarapu and
Prashant Patel (the “Principal Stockholders”) entered into an agreement with TRxADE (the “Stock Swap Agreement”),
pursuant to which, TRxADE will transfer all of the shares or membership interest of a variety of operating subsidiaries currently own
by TRxADE to Principal Stockholders, in exchange for Suran Ajjarapu to surrender 85,000 share of common stock of TRxADE and Prashant
Patel to surrender 81,666 shares of the common stock of TRxADE (the “Stock Swap Transaction”). The closing of the Stock Swap
Transaction shall take place simultaneously with the approval of TRxADE stockholders of the conversion of the Series B preferred Stock
into common stock. The closing of the Stock Swap Transaction is subject to the simultaneous condition that the Merger is successfully
closed. As of the date of this filing, TRxADE stockholders have not approved the conversion.
In
connection with the Merger, on July 31, 2023, certain Superlatus shareholders as of immediately prior to the Merger, and certain
directors and officers of TRxADE as of immediately prior to the Merger, entered into lock-up agreements with the Company, pursuant
to which each such stockholder will be subject to a 360 day lockup on the sale or transfer of shares of common stock or securities
nued into or exercisable for or exchangeable for common stock held by each such stockholder at the closing of the Merger (the
“Lock-up Agreements”).
In
connection with the Merger, effective one (1) business day immediately prior to the Closing Date (the “MEDS Rights Record Date”),
the Company issued to the shareholders of the Company as of the MEDS Rights Record Date, including the independent directors who are
entitled to certain amount of common stock of the Company in connection with their 2023 annual compensation and regardless of whether
the common stock has been issued or vest before the MEDS Rights Records Date (collectively, the “MEDS Rights Shareholders”)
a non-transferrable right to receive one share of common stock of the Company at no cost (the “MEDS Rights”), with seven
(7) MEDS Rights issued per share of common stock of the Company held as of the MEDS Rights Record Date, conditioned upon their execution
of a Registration Rights Agreement. Such issuances will be made in reliance on the exemption from registration pursuant to Section 3(a)(9)
or Section 4(a)(2) of the Securities Act, Regulation D under the Securities Act promulgated thereunder, and corresponding provisions
of state securities or “blue sky” laws. The MEDS Rights are not actionable or transferable until registration; provided they
become transferable one year after the date of the Merger if no registration has occurred. As of the date of this filing, no shares of
common stock were issued to MEDS Rights Shareholders.
On January 20, 2023, the Company
entered into Membership Interest Purchase Agreements to sell 100% of the outstanding membership interests of Alliance Pharma Solutions,
LLC and Community Specialty Pharmacy, LLC. The transactions closed on August 22, 2023.
On February 15, 2022, the Company
entered into a relationship with Exchange Health, LLC, a technology company providing an online platform for manufacturers and suppliers
to sell and purchase pharmaceuticals (“Exchange Health”). SOSRx LLC, the created entity relating to the relationship, a Delaware
limited liability company, was formed in February 2022, and was owned 51% by the Company and 49% by Exchange Health (“SOSRx”).
On February 4, 2023, and effective as of February 1, 2023, the Company entered into a Voluntary Withdrawal and Release
Agreement, (the “Release Agreement”). Pursuant to the Release Agreement, (a) the Company voluntarily withdrew as a member
of SOSRx pursuant to the terms of the Operating Agreement of SOSRx, (b) the Company’s interests in SOSRx were terminated; (c) the
Company’s promissory note in favor of SOSRx was canceled; and (d) the parties agreed that no earn out payments will be due.
TRxADE
Inc
Trxade.com
is a web-based pharmaceutical marketplace engaged in promoting and enabling commerce among independent pharmacies, small chains, hospitals,
clinics and alternate dispensing sites with large pharmaceutical suppliers nationally. Our marketplace has over 72 national and regional
pharmaceutical suppliers providing over 120,000 branded and generic drugs, including over the counter drugs and drugs available for purchase
by pharmacists. We generate revenue from these services by charging a transaction fee to the seller of the products for sales conducted
on the Trxade platform. The buyers do not bear the cost of transaction fees for the purchases that they make, nor do they pay a fee to
join or register with our platform. Our core service has the goal of bringing the nation’s independent pharmacies and accredited
national suppliers of pharmaceuticals together to provide efficient and transparent buying and selling opportunities.
As
of September 30, 2023, the TRxADE platform increased its registered users by 870 or 6.17% compared to September 30, 2022. For the nine
months ended September 30, 2023, new registrations were 196 compared to 296 for the same period in 2022. As of September 30, 2023, total
registered users were approximately 14,900+ compared to 14,100+ at September 30, 2022.
The
table below summarizes the key metrics that management evaluated in relation to the activity on the Trxade platform for the nine-month
period ended September 30, 2023 compared to the same period in 2022:
Processed Sales Volume | |
| 19 | % | |
![](https://www.sec.gov/Archives/edgar/data/1382574/000149315224002429/form10q_003.jpg) |
Total Revenue | |
| 21 | % | |
![](https://www.sec.gov/Archives/edgar/data/1382574/000149315224002429/form10q_003.jpg) |
Registered Users | |
| 6 | % | |
![](https://www.sec.gov/Archives/edgar/data/1382574/000149315224002429/form10q_003.jpg) |
Integra
Pharma Solutions, LLC
Integra
Pharma Solutions, LLC (“Trxade Prime”) is a licensed wholesaler of brand, generic and non-drug products to customers. Trxade
Prime takes orders for products, creates invoices for each order and recognizes revenue at the time the customer receives the product.
We utilize “just in time” inventory and drop ship partnerships to ship orders to customers. The focus of Trxade Prime is
to be the pharmaceutical supplier of choice for healthcare organizations of all sizes. Our expertise in the distribution of products
extends to all healthcare markets including government organizations, hospitals, clinics, and independent pharmacies nationwide.
Community
Specialty Pharmacy, LLC
Community
Specialty Pharmacy, LLC (“CSP”) is a licensed retail pharmacy. CSP was founded in 2010 with a goal of providing customer
care at a level above and beyond anything the market had experienced before. CSP has carved a niche in the competitive independent pharmacy
industry with its patient-driven approach. As discussed below, we have started a process to explore strategic alternatives for CSP, as
well as our other business-to-consumer (B2C) subsidiaries.
Alliance
Pharma Solutions, LLC
Alliance
Pharma Solutions, LLC, a.k.a. DelivMeds, (“APS”) was established in 2018 as a digital option to traditional prescription
delivery. APS is currently being rebranded and the digital technology continues to be developed. APS has generated no revenue and we
continue to incur significant technology expenses. As discussed above, we entered
into a Membership Purchase Agreement in January of 2023 to sell 100% of the outstanding membership interests of Alliance Pharma
Solutions, LLC and Community Specialty Pharmacy, LLC. The sale closed on August 22, 2023. The financial results of APS and CSP are presented in discontinued operations
on the Consolidated Balance Sheets and Consolidated Statements of Operations.
Bonum
Health, LLC
Our
Bonum Health, LLC (“Bonum”) operations were acquired in October of 2019. Bonum is a digital healthcare technology platform
focused on making healthcare affordable, accessible and convenient through Telehealth services. Patients can use the Bonum Health mobile
app or website to access board-certified medical providers, for non-emergent services. As of May 2022, Bonum also announced agreements
to offer telehealth veterinary services. Additional services also available include Men’s and Women’s Health, Dermatology,
Pediatrics and Ophthalmology in the comfort of their home or from anywhere. These services can be affordably accessed by the under-insured,
non-insured and under-served communities seeking access to essential healthcare services. For employers, Bonum provides Telehealth solutions
allowing employers to provide convenient and affordable health coverage to their employees without requiring health insurance. Our Bonum
health subsidiary provides affordable access to medical professionals in the patient’s home. As discussed below, we have started
a process to explore strategic alternatives for Bonum, as well as our other business-to-consumer (B2C) subsidiaries.
SOSRx,
LLC
On
February 15, 2022, the Company entered into a relationship with Exchange Health, LLC. On February 4, 2023, a voluntary withdrawal agreement
was signed by both parties.
Superlatus,
Inc.
On
July 31, 2023, the Company merged with Superlatus, Inc. (see above), a U.S.-based holding company of food products and distribution
capabilities. With its subsidiary, Sapientia,
Inc. (“Sapientia”), a food tech business, Superlatus is a diversified food
technology company with distribution capabilities and systems to optimize food security and population health via innovative Consumer Packaged Goods (“CPG”)
products, agritech, foodtech, plant-based proteins and alt-proteins. Superlatus provides industry-leading processing and forming
technologies that create high nutrition, high taste, and textured foods.
The
Urgent Company, Inc.
The
Urgent Company and its consumer brands focus on creating sustainable, animal-free products.
Recent
Events
Nasdaq
Listing Rule 5550(b)
As
previously disclosed in the Current Report on Form 8-K, filed by the Company with the SEC on August 1, 2022, on July 29, 2022, the Company
received a letter from Nasdaq notifying the Company that it was not in compliance with the minimum $2,500,000 stockholders’ equity
requirement in Nasdaq Listing Rule 5550(b)(1) (the “Rule”) for continued listing on the Nasdaq Capital Market, and did not
meet the alternative listing requirements under Nasdaq Listing Rule 5550(b). On October 17, 2022, Nasdaq granted the Company’s
request for an extension until January 25, 2023, to regain compliance with this requirement.
On
January 30, 2023, the Company received a delist determination letter from Nasdaq advising the Company that Nasdaq had determined that
the Company did not meet the terms of the extension. Specifically, the Company did not complete its proposed transactions and was unable
to file a Current Report on Form 8-K by January 25, 2023, evidencing compliance with the Rule.
On
February 6, 2023, the Company submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request stayed
any delisting action by Nasdaq at least until the hearing process concludes and any extension granted by the Panel expires.
A
hearing before the Panel was held on March 23, 2023, at which the Company presented a plan to regain compliance with the Rule that included
an underwritten public offering of Company securities of up to $15,000,000 and expense reductions. On April 5, 2023, the Company received
a letter from Nasdaq advising the Company that the Panel was granting the Company’s request for an exception to permit the continued
listing of the Company’s stock on the Nasdaq Capital Market while it completes a public offering of its Company securities up to
$15,000,000. The Panel’s grant of the Company’s request for continued listing is subject to the conditions that (i) on or
before April 15, 2023, the Company must advise the Panel on the status of the filing of an S-1 registration statement for the offering,
and (ii) on or before June 21, 2023, the Company must demonstrate compliance with the Rule.
The
Company received a notice from the Panel that the Panel had granted the Company an extension until July 31, 2023, to demonstrate compliance
with the $2,500,000 minimum stockholders’ equity requirement, as outlined in the Nasdaq’s listing rule 5550(b)(1). As a result
of the Merger as described below, the Company now has stockholders’ equity above the minimum stockholders’ equity requirement
for continued listing of $2,500,000.
Liquidity
and Capital Resources
Cash
Cash
was $34,031 as of September 30, 2023, compared to $1,094,891 as of December 31, 2022. The decrease in cash was mainly due to the increased
operating expenses as a result of the Merger and the TUC acquisition, partially offset by cash generated from increased revenues. We
expect that our future available capital resources will consist primarily of cash generated from operations, remaining cash balances,
borrowings, and additional funds raised through sales of debt and/or equity securities.
Liquidity
Cash,
current assets, current liabilities, short term debt and working capital at the end of each period were as follows:
| |
September 30, 2023 | | |
December 31, 2022 | | |
Change | | |
Percent Change | |
Cash | |
$ | 34,031 | | |
$ | 1,094,891 | | |
$ | (1,060,860 | ) | |
| (97 | )% |
Current assets (excluding cash) | |
| 5,513,798 | | |
| 988,230 | | |
| 4,515,568 | | |
| 452 | % |
Current liabilities (excluding short term debt) | |
| 3,862,289 | | |
| 1,980,124 | | |
| 1,882,165 | | |
| 95 | % |
Short term debt (notes payable related party) | |
| 5,230,000 | | |
| 166,667 | | |
| 5,063,333 | | |
| 3,038 | % |
Working capital | |
| (3,544,460 | ) | |
| (53,670 | ) | |
| (3,490,790 | ) | |
| (6,504 | )% |
Our
principal sources of liquidity have historically been cash provided by operations, sales of equity, and borrowings under various debt
arrangements. Our principal uses of cash have been for operating expenses, technology development, and acquisitions. We anticipate these
uses will continue to be our principal sources of, and uses of, cash in the future.
The
decrease in cash as of September 30, 2023, compared to December 31, 2022, was primarily due to increases in professional fees and accounting
and legal expense of $525,479 and $215,409, respectively, from the nine months ended September 30, 2023 compared to the nine months ended
September 30, 2022. Increased expenses were mainly the result of the Merger and the TUC acquisition. Additionally, technology expense increased as a result of an increase in the primary vendor’s rates. The effect of
these increases was partially offset by decreases in wage and salary expense as a result of the departure of two members of management
during the nine months ended September 30, 2023.
Liquidity
Outlook cash explanation
Cash
Requirements
Our
primary objectives for the remainder of 2023 are to take steps in an effort to increase our client base and operational revenue on our
Trxade Inc. and Trxade Prime platforms, and to complete potential strategic transactions of our business-to-consumer subsidiaries, which
may include a potential sale, spin-off, fund raising, combination or other strategic transaction, and also include the winding down of
such entities. There can be no assurance that our operations will generate significant positive cash flow, or that additional funds will
be available to us, through borrowings or otherwise, on favorable terms if required in the future, or at all. We may also raise additional
funding in the future through the sale of equity.
We
estimate our operating expenses and working capital requirements for the next 12 months to be approximately as follows:
Projected
Expenses from October 2023 to September 2024 |
|
Amount |
|
General
and administrative (1) |
|
$ |
8,000,000 |
|
Total |
|
$ |
8,000,000 |
|
(1)
Includes estimated wages and payroll, legal and accounting, marketing, rent and web development.
We
will still require additional funding in the future to support our operations.
Cash
Flows
The
following table summarizes our Consolidated Statements of Cash Flows for the following periods:
| |
Nine Months Ended September 30, | | |
| | |
Percent | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
Net loss from continuing operations | |
$ | (2,004,581 | ) | |
$ | (1,983,743 | ) | |
$ | (20,838 | ) | |
| (1 | )% |
Net cash provided by (used in): | |
| | | |
| | | |
| | | |
| | |
Net cash used in operating activities from continuing operations | |
| (612,184 | ) | |
| (2,132,883 | ) | |
| 1,520,699 | | |
| 73 | % |
Net cash used in (provided by) operating activities from discontinued operations | |
| (593,893 | ) | |
| (623,096 | ) | |
| 29,203 | | |
| 5 | % |
Operating Activities | |
| (1,206,077 | ) | |
| (2,755,979 | ) | |
| 1,549,902 | | |
| 56 | % |
| |
| | | |
| | | |
| | | |
| | |
Net cash used in investing activities from continuing operations | |
| 5,546 | | |
| (312,902 | ) | |
| 318,448 | | |
| (102 | )% |
Net cash provided by investing activities from discontinued operations | |
| 68,737 | | |
| - | | |
| 68,737 | | |
| 100 | % |
Investing Activities | |
| 74,283 | | |
| (312,902 | ) | |
| 387,185 | | |
| 124 | % |
| |
| | | |
| | | |
| | | |
| | |
Net cash used in (provided by) financing activities from continuing operations | |
| 570,934 | | |
| 268,018 | | |
| 302,916 | | |
| 113 | % |
Net cash used in financing activities from discontinued operations | |
| (500,000 | ) | |
| - | | |
| (500,000 | ) | |
| 100 | % |
Financing Activities | |
| 70,934 | | |
| 268,018 | | |
| (197,084 | ) | |
| (74 | )% |
Net change in cash | |
$ | (1,060,860 | ) | |
$ | (2,800,863 | ) | |
$ | 1,740,003 | | |
| 62 | % |
Cash
used in operations for the nine months ended September 30, 2023, was $(1,206,077), compared to cash used in operations for the nine
months ended September 30, 2022, of $(2,755,979). The decrease in cash used in operations for the nine months ended September 30,
2023, compared to September 30, 2022, was mainly due to increased professional fees and accounting and legal expense for the
comparable periods as a result of the Merger and the purchase of TUC, partially offset by decreased wage and salary expense due to the departure of
two members of management during the nine months ended September 30, 2023.
Cash
provided by investing activities for the nine months ended September 30, 2023, was $74,283 and cash used in investing activities was
$(312,902) for the nine months ended September 30, 2022. The decrease in cash provided by investing activities is related to the
discontinuation of SOSRx.
Cash
provided by financing activities for the nine months ended September 30, 2023, was $70,934 compared to cash provided by financing
activities for the nine months ended September 30, 2022, which was $268,018. The decrease was mainly due to a decrease in the net
balance of the contingent funding liability.
Results
of Operations
The
following selected consolidated financial data should be read in conjunction with the unaudited consolidated financial statements and
the notes to these statements included above.
Three
Month Period Ended September 30, 2023, compared to Three Month Period Ended September 30, 2022
| |
Three Months Ended September 30, | | |
| | |
Percentage | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
Revenues | |
$ | 2,058,028 | | |
$ | 2,055,803 | | |
$ | 2,225 | | |
| 0 | % |
Cost of sales | |
| 353,450 | | |
| 683,375 | | |
| (329,925 | ) | |
| (48 | )% |
Gross profit | |
| 1,704,578 | | |
| 1,372,428 | | |
| 332,150 | | |
| 24 | % |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Technology, research & development | |
| 410,612 | | |
| 238,577 | | |
| 172,035 | | |
| 72 | % |
Wages and salary expense | |
| 698,030 | | |
| 849,371 | | |
| (151,341 | ) | |
| (18 | )% |
Accounting and legal | |
| 408,957 | | |
| 191,007 | | |
| 217,950 | | |
| 114 | % |
Professional fees | |
| 418,294 | | |
| 82,710 | | |
| 335,584 | | |
| 406 | % |
Other general and administrative (less stock-based compensation expense) | |
| 610,074 | | |
| 200,310 | | |
| 409,764 | | |
| 205 | % |
Warrants and options expense | |
| 3,760 | | |
| 29,216 | | |
| (25,456 | ) | |
| (87 | )% |
Total operating expenses | |
| 2,549,727 | | |
| 1,591,191 | | |
| 958,536 | | |
| 60 | % |
Change in fair value of warrant liability | |
| 925,320 | | |
| - | | |
| 925,320 | | |
| 100 | % |
Interest, net | |
| (251,778 | ) | |
| (121,711 | ) | |
| (130,067 | ) | |
| 107 | % |
Gain (loss) on disposal of asset | |
| - | | |
| - | | |
| - | | |
| 0 | % |
Net loss from operations | |
$ | (171,607 | ) | |
$ | (340,474 | ) | |
$ | 168,867 | | |
| (50 | )% |
Loss
on discontinued operations | |
| (3,353,507 | ) | |
| (188,268 | ) | |
| (3,165,239 | ) | |
| (1,681 | )% |
Net loss attributable to TRxADE Health, Inc. | |
| (3,525,114 | ) | |
| (503,003 | ) | |
| (3,022,111 | ) | |
| (601 | )% |
Net loss attributable to non-controlling interests | |
| - | | |
| (25,739 | ) | |
| 25,739 | | |
| 100 | % |
Our
revenues for the three months ended September 30, 2023, were from the Trxade platform and Integra Pharma Solutions. Revenues increased by $2,225, compared to the same period ended September 30, 2022. Revenue generated by Trxade Inc from platform sales and Trxade Prime increase
approximately 0% for the three months ended September 30, 2023 compared to the same period ended September 30, 2022.
For
the three-month period ended September 30, 2023, cost of goods sold and gross profit were $353,450 and $1,704,578 respectively, and
$683,375 and $1,372,428, respectively for the same period in 2022. Gross profit as a percentage of sales was 83% for the three months
ended September 30, 2023, compared to 67% for the three months ended September 30, 2022.
Accounting
and legal expenses increased $217,950 for the three months ended September 30, 2023 to $408,957 compared to $191,007 for the
comparable period in 2022 and professional fees increased $335,584 to $418,294 compared to $82,710 for the comparable period in
2022. These increases were due to the Merger and purchase of TUC. General and administrative expenses (less stock-based compensation
expense) increased $409,764 for the three months ended September 30, 2023, to $610,074 compared to $200,310 for the comparable
period in 2022. The increase was mainly due to increased operations as a result of the Merger. Technology, research and development
increased $172,035 for the three months ended September 30, 2023 to $410,612 compared to $238,577 for the comparable period in 2022.
The increase was mainly due to increased billing rates from the primary vendor. These increases were partially offset by decreases
in wages and salary expense as a result of the departure of two members of management as well as the effects of other cost-cutting efforts.
We
had interest expense, net, of $251,778 for the three months ended September 30, 2023, compared to interest expense, net, of $121,711
for the three months ended September 30, 2022. The increase is due to the increase balance of the accounts receivable advances as a
result of advances taken in 2023 and 2022.
We
recognized a gain on the change in the fair value of the warrant liability of $925,320 for the three months ended September 30, 2023.
As the warrants were issued in October 2022, no gain or loss was recognized during the three months ended September 30, 2022.
During
the three months ended September 30, 2023, the Company generated a net loss from operations of $171,607 compared to a net loss from
operations of $340,474 for the three months ended September 30, 2023. The increase in net loss is mainly driven by the increased
operating costs as a result of the Merger, partially offset by an increase in gross profit.
Net loss from discontinued operations increased $3,165,239 to a net loss of $3,353,507 for the three months ended
September 30, 2023, compared to a net loss from discontinued operations of $188,268 for the three months ended September 30, 2022. The
increase was due to the disposal of APS and CSP during the three months ended September 30, 2023.
Nine Month Period Ended
September 30, 2023, compared to Three Month Period Ended September 30, 2022
| |
Nine
Months Ended September 30, | | |
| | |
Percentage | |
| |
2023 | | |
2022 | | |
Change | | |
Change | |
Revenues | |
$ | 5,919,786 | | |
$ | 7,993,805 | | |
$ | (2,074,019 | ) | |
| (26 | )% |
Cost
of sales | |
| 1,072,934 | | |
| 3,991,234 | | |
| (2,918,300 | ) | |
| (73 | )% |
Gross
profit | |
| 4,846,852 | | |
| 4,002,571 | | |
| 844,281 | | |
| 21 | % |
Operating
expenses: | |
| | | |
| | | |
| | | |
| | |
Technology,
research & development | |
| 1,010,374 | | |
| 690,875 | | |
| 319,499 | | |
| 46 | % |
Wages
and salary expense | |
| 2,077,362 | | |
| 2,949,386 | | |
| (872,024 | ) | |
| (30 | )% |
Accounting
and legal | |
| 782,495 | | |
| 567,086 | | |
| 215,409 | | |
| 38 | % |
Professional
fees | |
| 782,286 | | |
| 256,807 | | |
| 525,479 | | |
| 205 | % |
Other
general and administrative (less stock-based compensation expense) | |
| 1,238,924 | | |
| 1,324,691 | | |
| (85,767 | ) | |
| (6 | )% |
Warrants
and options expense | |
| 25,978 | | |
| 67,439 | | |
| (41,461 | ) | |
| (61 | )% |
Total
operating expenses | |
| 5,917,419 | | |
| 5,856,284 | | |
| 61,135 | | |
| 1 | % |
Change
in fair value of warrant liability | |
| (443,308 | ) | |
| - | | |
| (443,308 | ) | |
| (100 | )% |
Interest,
net | |
| (490,706 | ) | |
| (132,230 | ) | |
| (358,476 | ) | |
| 271 | % |
Loss
on disposal of asset | |
| - | | |
| 2,220 | | |
| (2,220 | ) | |
| (100 | )% |
Net
loss from operations | |
$ | (2,004,581 | ) | |
$ | (1,983,743 | ) | |
$ | (20,838 | ) | |
| 1 | % |
Loss
on discontinued operations | |
| (4,123,028 | ) | |
| (623,096 | ) | |
| (3,499,932 | ) | |
| 562 | % |
Net
loss attributable to TRxADE Health, Inc. | |
$ | (6,127,609 | ) | |
| (2,546,913 | ) | |
| (3,580,696 | ) | |
| (141 | )% |
Net
loss attributable to non-controlling interests | |
| - | | |
| (59,926 | ) | |
| 59,926 | | |
| 100 | % |
Our
revenues for the nine months ended September 30, 2023, were from the Trxade platform and Integra Pharma Solutions. Revenues
decreased by $2,074,019 compared to the same period ended September 30, 2022. Trxade Inc revenue generated from platform sales and
Trxade Prime decreased approximately 26% for the nine months ended September 30, 2023 compared to the same period ended
September 30, 2022. The decrease in revenue for Trxade Prime is related to decreased sales, see “Company Overview - Integra
Pharma Solutions”.
For
the nine-month period ended September 30, 2023, cost of goods sold and gross profit were $1,072,934 and $4,846,852 respectively, and
$3,991,234 and $4,002,571, respectively for the same period in 2022. Gross profit as a percentage of sales was 82% for the nine months
ended September 30, 2023, compared to 50% for the nine months ended September 30, 2022.
Accounting
and legal expenses increased $215,409 for the nine months ended September 30, 2023 to $782,495 compared to $567,086 for the
comparable period in 2022 and professional fees increased $525,479 to $782,286 compared to $256,807 for the comparable period in
2022. These increases were due to the Merger and purchase of TUC. Technology, research and development increased $319,499 for the
nine months ended September 30, 2023 to $1,010,374 compared to $690,875 for the comparable period in 2022. The increase was mainly
due to increased billing rates from the primary vendor. These increases were partially offset by decreases in wages and salary expense as a result of
the departure of two members of management.
We
had interest expense, net of $490,706 for the nine months ended September 30, 2023, compared to interest expense of $132,230 for the
nine months ended September 30, 2022. The reason for the increase was the increase in the balance of the contingent funding
liability due to the accounts receivable advances taken in 2023 and 2022, off set by interest income from the GSG legal settlement
(see discussion above under “Recent Events”).
During
the nine months ended September 30, 2023, the Company recognized a loss the change in the fair value of warrants of $443,308. As the
warrants were issued in October 2022, no gain or loss was recognized during the three months ended September 30, 2022.
Net
loss from operations increased $20,838 to a net loss of $2,004,581 for the nine months ended September 30, 2023, compared to a net
loss of $1,983,743 for the nine months ended September 30, 2022. The increase in net loss is mainly due to an increase in gross
profit, partially offset but increases in spending related to the Merger and purchase of TUC.
Net loss from discontinued operations increased $3,499,932 to a net loss of $4,123,028 for the nine months ended
September 30, 2023, compared to a net loss from discontinued operations of $623,096 for the nine months ended September 30, 2022.
Critical
Accounting Policies
Our
discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which
have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these
financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amount of net sales and expenses for each
period. The following represents a summary of our critical accounting policies, defined as those policies that we believe are the most
important to the portrayal of our financial condition and results of operations and that require management’s most difficult, subjective
or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain.
Revenue
Recognition
In
general, the Company accounts for revenue recognition in accordance with Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers.”
Trxade,
Inc. provides an online web-based buying and selling platform for licensed pharmaceutical wholesalers (“Suppliers”)
to sell products and services to licensed pharmacies (“Customers”). Trxade, Inc. charges Suppliers a transaction fee,
a percentage of the purchase price of the prescription drugs and other products sold through its website service. Fulfillment of confirmed
orders, including delivery and shipment of prescription drugs and other products, is the responsibility of the Supplier, not Trxade,
Inc. Trxade, Inc. holds no inventory and assumes no responsibility for the shipment or delivery of any products or services from our
website. Trxade, Inc. considers itself an agent for this revenue stream and as such, reports revenue as net. Step One: Identify the contract
with the Customers – Trxade, Inc.’s Terms and Use “Agreement,” which outlines the terms and conditions
between Trxade, Inc. and the Supplier, is acknowledged and agreed to by the Supplier. Collection is probable based on a credit evaluation
of the Supplier. Step Two: Identify the performance obligations in the Agreement – Trxade, Inc. provides the Supplier access to
the online website, ability to upload catalogs of products and Dashboard access to review status of inventory as well as posted and processed
orders. The Agreement requires the Supplier to post a catalog of pharmaceuticals on the platform, deliver the pharmaceuticals and, upon
shipment, remit the stated platform fee. Step Three: Determine the transaction price – the Agreement outlines the fee, which is
based on the type of product: generic, brand or non-drug. There are no discounts for volume transactions or early payment of invoices.
Step Four: Allocate the transaction price – the Agreement details the fee. There is no difference between contract price and “stand-alone
selling price”. Step Five: Recognize revenue when or as the entity satisfies a performance obligation – revenue is recognized
upon Supplier’s fulfillment of the applicable order.
Integra
Pharma Solutions, LLC (“Trxade Prime”) is a licensed wholesaler of brand, generic and non-drug products to Customers.
Integra LLC takes orders for products, creates invoices for each order and recognizes revenue at the time the Customer receives the product.
Customer returns are not material. Step One: Identify the contract with the Customer – Integra LLC requires that an application
and a credit card for payment be completed by the Customer prior to the first order. Each transaction is evidenced by an order form sent
by the Customer and an invoice for the product is sent by Integra LLC. The collection is probable based on the application and credit
card information provided prior to the first order. Step Two: Identify the performance obligations in the contract – Each order
is distinct and evidenced by the shipping order and invoice. Step Three: Determine the transaction price – The consideration is
variable if product is returned. The variability is determined based on the return policy of the product manufacturer. There are no sales
or volume discounts. The transaction price is determined at the time of the order evidenced by the invoice. Step Four: Allocate the transaction
price – There is no difference between contract price and “stand-alone selling price”. Step Five: Recognize
revenue when or as the entity satisfies a performance obligation – The Revenue is recognized when the Customer receives the product.
Bonum,
LLC is a telehealth company that provides services to its subscribers. We derive our revenues from subscription-based services through
our mobile application on a business-to-business or business-to-customer models. Business-to-business – Organizations contract
with Bonum to provide tele-health services to their members on a per-member basis. Organizations are invoiced by Bonum, and revenue is
recognized as services are provided each month. Bonum also generates revenues through business-to-customer relationships, where customers
can download and subscribe to the Bonum mobile application on their digital device. Subscriptions can be monthly, annual or per encounter.
Revenue is recognized as it is earned. Deferred revenue is recorded for unearned subscriptions income and recognized in the financial
statements in the period earned.
Stock-Based
Compensation
The
Company accounts for stock-based compensation to employees in accordance with ASC 718, “Compensation-Stock Compensation”.
ASC 718 requires companies to measure the cost of employee services received in exchange for an award of equity instruments, including
stock options, based on the grant date fair value of the award and to recognize it as compensation expense over the period the employee
is required to provide service in exchange for the award, usually the vesting period. Stock option forfeitures are recognized at the
date of employee termination. Effective January 1, 2019, the Company adopted ASU 2018-07 for the accounting of share-based payments granted
to non-employees for goods and services.
Recently
Issued Accounting Standards
For
more information on recently issued accounting standards, see “NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION”,
to the Notes to Consolidated Financial Statements included herein under “PART I. - ITEM 1. FINANCIAL STATEMENTS”.
ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Because
we are a smaller reporting company, we are not required to provide the information required by this Item.
ITEM
4. CONTROLS AND PROCEDURES
Disclosure
Controls and Procedures
Under
the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer (our
principal executive officer and principal accounting/financial officer), Mr. Ajjarapu and Mr Patel, respectively, we conducted an evaluation
of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e)
under the Exchange Act, as of the end of the period covered by this Quarterly Report. Based on this evaluation, our Chief Executive Officer
and our Chief Financial Officer concluded that as of September 30, 2023, our disclosure controls and procedures were not effective to
provide reasonable assurance that information required to be disclosed in our reports filed with the SEC pursuant to the Exchange Act,
is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information
is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required
disclosures.
As
a result of the formative stage of our development, the Company has not fully implemented the necessary internal controls. The
matters involving internal controls and procedures that the Company’s management considered to be material weaknesses under
the standards of the Committee of Sponsoring Organizations of the Treadway Commission (COSO) were: (1) insufficient written policies
and procedures for accounting and financial reporting with respect to the requirements and application of accounting principles
generally accepted in the United States of America (“U.S. GAAP”) and SEC disclosure requirements; and (2)
ineffective controls over period end financial disclosure and reporting processes.
Management
believes that the material weaknesses set forth above did not have an effect on the Company’s financial results reported herein.
We are committed to improving our financial organization. As part of this commitment, we have increased our personnel resources and technical
accounting expertise as we develop the internal and financial resources of the Company. In addition, the Company will prepare and implement
sufficient written policies and checklists which will set forth procedures for accounting and financial reporting with respect to the
requirements and application of U.S. GAAP and SEC disclosure requirements.
Management
believes that preparing and implementing sufficient written policies and checklists will remedy the following material weaknesses
(i) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and
application of U.S. GAAP and SEC disclosure requirements; and (ii) ineffective controls over period end financial close and
reporting processes.
We
have improved our financial organization as we have increased our personnel resources and technical accounting expertise. We will continue
to monitor and evaluate the effectiveness of our internal controls and procedures and our internal controls over financial reporting
on an ongoing basis.
Limitations
on Effectiveness of Controls and Procedures
In
designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how
well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design
of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply
its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Changes
in Internal Control over Financial Reporting
There
has not been any change in our internal control over financial reporting that occurred during the quarter ended September 30, 2023, that
has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART
II. OTHER INFORMATION
ITEM
1. LEGAL PROCEEDINGS
In
the ordinary course of business, we may become a party to lawsuits involving various matters. The impact and outcome of litigation, if
any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm
our business. We believe the ultimate resolution of any such current proceeding will not have a material adverse effect on our continued
financial position, results of operations or cash flows.
Such
current litigation or other legal proceedings are described in, and incorporated by reference in, this “ITEM 1. LEGAL PROCEEDINGS”
of this Quarterly Report on Form 10-Q from, “PART I – ITEM 1. FINANCIAL STATEMENTS” in the Notes to Consolidated
Financial Statements in “NOTE 8 – CONTINGENCIES”. The Company believes that the resolution of currently pending
matters will not individually or in the aggregate have a material adverse effect on our financial condition or results of operations.
However, assessment of the current litigation or other legal claims could change in light of the discovery of facts not presently known
to the Company or by judges, juries or other finders of fact, which are not in accord with management’s evaluation of the possible
liability or outcome of such litigation or claims.
Additionally,
the outcome of litigation is inherently uncertain. If one or more legal matters were resolved against the Company in a reporting period
for amounts in excess of management’s expectations, the Company’s financial condition and operating results for that reporting
period could be materially adversely affected.
ITEM
1A. RISK FACTORS
There
have been no material changes from the risk factors previously disclosed in Part I, Item 1A of the Company’s Annual Report on Form
10-K for the year ended December 31, 2022, filed with the SEC on March 27, 2023 (the “Form 10-K”), under the heading “Risk
Factors”, except as set forth below, and investors should review the risks provided in the Form 10-K and below, prior to making
an investment in the Company. The business, financial condition and operating results of the Company can be affected by a number of factors,
whether currently known or unknown, including but not limited to those described in the Form 10-K for the year ended December 31, 2022,
under “Risk Factors”, and below, any one or more of which could, directly or indirectly, cause the Company’s actual
financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating
results. Any of these factors, in whole or in part, could materially and adversely affect the Company’s business, financial condition,
operating results and stock price.
Risks
Relating to Our Business:
We
need additional capital which may not be available on commercially acceptable terms, if at all, which creates substantial doubt about
our ability to continue as a going concern.
Our
historical financial statements have been prepared under the assumption that we will continue as a going concern. As of September 30,
2023, the Company had an accumulated deficit of $21.5 million. We have limited financial resources, As of September 30, 2023, we had
a working capital deficit of $3.5 million and a cash balance of approximately $34,000. We will need to raise additional capital or secure
debt funding to support on-going operations. The sources of this capital are expected to be the sale of equity and debt, which may not
be available on favorable terms, if at all, and may, if sold, cause significant dilution to existing stockholders. If we are unable to
access additional capital moving forward, it may hurt our ability to grow and to generate future revenues, our financial position, and
liquidity. These matters, when considered in the aggregate, raise substantial doubt about the Company’s ability to continue as
a going concern for a reasonable period of time, which is defined as within one year after the date that our condensed financial statements
are issued. The financial herein do not contain any adjustments to reflect the possible future effects on the classification of assets
or the amounts and classification of liabilities that might result from the outcome of this uncertainty. The doubt regarding our potential
ability to continue as a going concern may adversely affect our ability to obtain new financing on reasonable terms or at all. Additionally,
if we are unable to continue as a going concern, our stockholders may lose some or all of their investment in the Company.
Additional
financing may not be available to us when needed or, if available, it may not be obtained on commercially reasonable terms. If we are
not able to obtain the necessary additional financing on a timely or commercially reasonable basis, we will be forced to delay or scale
down some or all of our development activities (or perhaps even cease the operation of our business). Our access to additional capital
may be negatively affected by future recessions, downturns in the economy or the markets as a whole, or inflation.
We
have no commitments for any additional financing and such commitments may not be obtained on favorable terms, if at all. Any additional
equity financing will be dilutive to our stockholders, and debt financing, if available, may involve restrictive covenants with respect
to dividends, raising future capital, and other financial and operational matters. If we are unable to obtain additional financing as
needed, we may be required to reduce the scope of our operations or our anticipated expansion, which could have a material adverse effect
on us.
Our
industry and the broader US economy have experienced higher than expected inflationary pressures in 2022 and the first half of 2023,
related to continued supply chain disruptions, labor shortages and geopolitical instability. Should these conditions persist our business,
results of operations and cash flows could be materially and adversely affected.
The
first three quarters of 2022 and the first three quarters of 2023 have seen significant increases in the costs of certain materials,
products and shipping costs, as a result of availability constraints, supply chain disruption, increased demand, labor shortages associated
with a fully employed US labor force, high inflation and other factors. Supply and demand fundamentals have been further aggravated by
disruptions in global energy supply caused by multiple geopolitical events, including the ongoing conflict between Russia and Ukraine.
Service, materials and shipping costs have also increased accordingly with general supply chain and inflation issues seen throughout
the United States leading to increased operating costs. Recent supply chain constraints and inflationary pressures may continue to adversely
impact our operating costs and may negatively impact our ability to procure and ship products in a timely and cost-effective manner,
if at all, which could result in reduced margins and lack of products and, as a result, our business, financial condition, results of
operations and cash flows could be materially and adversely affected.
Upon
the occurrence of an event of default under our Receivables Agreement, our cash flows may be adversely affected.
On
June 27, 2023, March 14, 2023, June 27, 2022 and September 14, 2022, the Company entered into non-recourse funding agreements with the
same third-party funder for the purchase and sale of future receivables (the “Receivables Agreements”), Pursuant to the Receivables
Agreements, the third-party agreed to fund the Company on June 27, 2022 $550,000 to purchase $792,000 of future receivables; and fund
the Company again on September 14, 2022 $275,000 to purchase $396,000 of future receivables, again on March 14, 2023 $875,000 to purchase
$1,224,000 and again on June 27, 2023 $1,250,000 to purchase $1,800,000 of future receivables. Under the Receivables Agreements, the
third-party receives a priority interest in the receivables of Trxade Inc. The Company also paid $62,500, $42,500, $27,500, and $15,000
as origination fees in connection with the Receivables Agreements. The Receivables Agreements also allows for the third-party funder
to file UCCs securing their interest in the receivables and includes customary events of default,
Upon
the occurrence of an event of default under the Receivables Agreement, we are required to pay the third-party funder 100% of future receivables
equal to the entire purchased amount. While the Receivables Agreement is in place, we are prohibited from selling any other receivables.
As a result, if an event of default occurs under the Receivables Agreement, 100% of our sales revenue would be required to be paid until
such time as the amount owed under the Receivables Agreement is paid in full. If this were to occur, our cash flows would be adversely
affected and we may not have sufficient liquidity to pay our debt obligations and expenses, may be forced to raise additional funds which
may not be available on favorable terms, if at all, and may be forced to curtail certain of our business activities, any of which may
cause the value of our securities to decline in value.
Risks
Relating to our Securities:
We
are not currently in compliance with Nasdaq’s continued listing standards and may not be able to maintain the listing of our common
stock on the Nasdaq Capital Market.
Our
common stock was approved for listing on The Nasdaq Capital Market under the symbol “MEDS”, in February 2020. On July
29, 2022, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that we are not in
compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing
Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000.
In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, we reported stockholders’ equity
of $1,356,578, which is below the minimum stockholders’ equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1)
(the “Rule”). Nasdaq gave us until September 12, 2022 to submit to Nasdaq a plan to regain compliance, and we submitted
a compliance plan prior to that deadline.
We
submitted the plan to regain compliance in a timely manner, and on October 17, 2022, Nasdaq advised the Company that it has determined
to grant the Company an extension to regain compliance with the Rule.
The
terms of the extension are as follows: on or before January 25, 2023, the Company must complete certain contemplated transactions which
the Company has advised Nasdaq will allow it to re-meet the requirements of the Rule (including the public sale of $1.75 million of common
stock (or pre-funded warrants), which transaction was completed on October 7, 2022), and opt for one of the two following alternatives
to evidence compliance with the Rule: Alternative 1, completion of a transaction or event that enabled the Company to satisfy
the stockholders’ equity requirement for continued listing, and disclosure of that event, along with certain other information,
in a public filing with the SEC, including that as of the date of the report, the Company believes it has regained compliance with the
stockholders’ equity requirement and a disclosure stating that Nasdaq will continue to monitor the Company’s ongoing compliance
with the stockholders’ equity requirement; or Alternative 2, completion of a transaction or event that enabled the Company
to satisfy the stockholders’ equity requirement for continued listing, and disclosure of that event, along with certain other information,
in a public filing with the SEC, including pro forma adjustments and a pro forma balance sheet must evidence compliance with the Rule,
and disclosure that the Company believes it has regained compliance with the stockholders’ equity requirement and a disclosure
stating that Nasdaq will continue to monitor the Company’s ongoing compliance with the stockholders’ equity requirement.
Additionally, in either case the Company is required to disclose that if at the time of its next periodic report, the Company does not
evidence compliance, that it may be subject to delisting.
Regardless
of which alternative the Company chooses, if the Company fails to evidence compliance upon filing its next periodic report with the SEC
and Nasdaq, the Company may be subject to delisting. In the event the Company does not satisfy these terms, Nasdaq will provide written
notification that its securities will be delisted. At that time, the Company may appeal Nasdaq’s determination to a Hearings Panel.
There
is also no guarantee that we will be able to maintain our listing on The Nasdaq Capital Market for any period of time by perpetually
satisfying Nasdaq’s continued listing requirements. Our failure to continue to meet these requirements may result in our securities
being delisted from Nasdaq.
Among
the conditions required for continued listing on The Nasdaq Capital Market, Nasdaq requires us to maintain at least $2.5 million in stockholders’
equity or $500,000 in net income over the prior two years or two of the prior three years. As discussed above of June 30, 2022, September
30, 2022 and December 31, 2022, our stockholders’ equity was below $2.5 million and we did not otherwise meet the net income requirements
described above, and as such, we are not currently in compliance with Nasdaq’s continue listing standards. If we fail to timely
remedy our compliance with the applicable requirements, our stock may be delisted.
Additional
requirements we must meet to continue our listing on The Nasdaq Capital Market include the requirement that we maintain a stock price
over $1.00 per share.
Even
if we demonstrate compliance with the requirements of Nasdaq, we will have to continue to meet other objective and subjective listing
requirements to continue to be listed on The Nasdaq Capital Market. Delisting from The Nasdaq Capital Market could make trading our common
stock more difficult for investors, potentially leading to declines in our share price and liquidity. Without a Nasdaq Capital Market
listing, stockholders may have a difficult time getting a quote for the sale or purchase of our stock, the sale or purchase of our stock
would likely be made more difficult, and the trading volume and liquidity of our stock could decline. Delisting from The Nasdaq Capital
Market could also result in negative publicity and could also make it more difficult for us to raise additional capital. The absence
of such a listing may adversely affect the acceptance of our common stock as currency or the value accorded by other parties. Further,
if we are delisted, we would also incur additional costs under state blue sky laws in connection with any sales of our securities. These
requirements could severely limit the market liquidity of our common stock and the ability of our stockholders to sell our common stock
in the secondary market. If our common stock is delisted by Nasdaq, our common stock may be eligible to trade on an over-the-counter
quotation system, such as the OTCQB Market or the OTC Pink market, where an investor may find it more difficult to sell our stock or
obtain accurate quotations as to the market value of our common stock. In the event our common stock is delisted from The Nasdaq Capital
Market, we may not be able to list our common stock on another national securities exchange or obtain quotation on an over-the counter
quotation system.
ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Recent
Sales of Unregistered Securities
On
January 6, 2023, an investor exercised 601,740 “pre-funded warrants” for an aggregate purchase price of $6.02 and was issued
601,740 shares of common stock on that date. The terms of these warrants were previously described in our Current Report on Form 8-K
dated October 4, 2022.
In
the first quarter of 2023, we issued 50,000 shares of common stock to White Lion Capital, LLC as the “commitment shares”
pursuant to the terms of a Common Stock Purchase Agreement dated September 7, 2022, as described in our Current Report on Form 8-K dated
September 7, 2022.
Under
the terms of the Merger Agreement, at the closing of the Merger (the “Closing”), shareholders of Superlatus received in aggregate
136,441 shares of common stock of the Company, representing 19.9% of the total issued and outstanding common stock of the Company after
the consummation of the Merger and 306,855 shares of Company’s Series B Preferred Stock, par value $0.00001 per share (the “Series
B Preferred Stock”), with a conversion ratio of 100 to one.
In
each case, the issuance did not involve a public offering and was made without general solicitation or general advertising, and the recipient
of the shares was an accredited investor.
Purchases
of Equity Securities by the Issuer and Affiliated Purchasers
The
Company repurchased no shares of common stock during the first two quarters of 2023.
ITEM
3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM
4. MINE SAFETY DISCLOSURES
None.
ITEM
5. OTHER INFORMATION
(a)
During the quarter ended September 30, 2023, there was no information required to be disclosed in a report on Form 8-K which was not
disclosed in a report on Form 8-K.
(b)
During the quarter ended September 30, 2023, there were no material changes to the procedures by which stockholders may recommend nominees
to our board of directors.
ITEM
6. EXHIBITS
* Filed herewith.
** Furnished herewith.
+ Certain information has been redacted pursuant to Item 601(a)(6) of Regulation S-K, as the disclosure of such information
would constitute a clearly unwarranted invasion of personal privacy.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
TRxADE
HEALTH, INC. |
|
|
|
|
By: |
/s/
Suren Ajjarapu |
|
|
Suren
Ajjarapu |
|
|
Chief
Executive Officer
(Principal
Executive Officer) |
|
|
|
|
|
Date:
January 16, 2024 |
|
|
|
|
By: |
/s/
Prashant Patel |
|
|
Prashant
Patel |
|
|
Interim
Chief Financial Officer
(Principal
Accounting/Financial Officer) |
|
|
|
|
|
Date:
January 16, 2024 |
Exhibit
31.1
31.1
Certification of Chief Executive Officer
I,
Suren Ajjarapu, certify that:
1. |
I
have reviewed this quarterly report on Form 10-Q of TRxADE HEALTH, INC. (the “registrant”); |
|
|
2. |
Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
the period covered by this report; |
|
|
3. |
Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
this report; |
|
|
4. |
The
registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a) |
Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared; |
|
|
|
|
b) |
Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles; |
|
|
|
|
c) |
Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and |
|
|
|
|
d) |
Disclosed
in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. |
The
registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing
the equivalent functions): |
|
a) |
All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;
and |
|
|
|
|
b) |
Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting. |
Date:
January 16, 2024 |
|
|
|
/s/
Suren Ajjarapu |
|
Suren
Ajjarapu |
|
Chief
Executive Officer (Principal Executive Officer) |
|
Exhibit
31.2
Certification
of Chief Financial Officer
I,
Prashant Patel, certify that:
1. |
I
have reviewed this quarterly report on Form 10-Q of TRxADE HEALTH, INC. (the “registrant”); |
|
|
2. |
Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
the period covered by this report; |
|
|
3. |
Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
this report; |
|
|
4. |
The
registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a) |
Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared; |
|
|
|
|
b) |
Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles; |
|
|
|
|
c) |
Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and |
|
|
|
|
d) |
Disclosed
in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. |
The
registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing
the equivalent functions): |
|
a) |
All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;
and |
|
|
|
|
b) |
Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting. |
Date:
January 16, 2024 |
|
|
|
/s/
Prashant Patel |
|
Prashant
Patel |
|
Chief
Financial Officer (Principal Accounting/Financial Officer) |
|
Exhibit
32.1
Certification
of Chief Executive Officer
Pursuant
to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of The Sarbanes-Oxley Act of 2002
I,
Suren Ajjarapu, Chief Executive Officer of TRxADE HEALTH, INC. (the “Company”), certify, pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:
|
(i) |
The
Quarterly Report on Form 10-Q of TRxADE HEALTH, INC. for the quarter ended September 30, 2023 (the “Report”) fully
complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, and |
|
|
|
|
(ii) |
The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company at the dates and for the periods indicated. |
Date:
January 16, 2024 |
|
|
|
/s/
SUREN AJJARAPU |
|
Suren
Ajjarapu |
|
Chief
Executive Officer (Principal Executive Officer) |
|
Exhibit
32.2
Certification
of Chief Financial Officer
Pursuant
to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of The Sarbanes-Oxley Act of 2002
I,
Prashant Patel, Chief Financial Officer of TRxADE HEALTH, INC. (the “Company”), certify, pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:
|
(i) |
The
Quarterly Report on Form 10-Q of TRxADE HEALTH, INC. for the quarter ended September 30, 2023 (the “Report”) fully
complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, and |
|
|
|
|
(ii) |
The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company at the dates and for the periods indicated. |
Date:
January 16, 2024 |
|
|
|
/s/
Prashant Patel |
|
Prashant
Patel |
|
Chief
Financial Officer (Principal Accounting/Financial Officer) |
|
v3.23.4
Cover - shares
|
9 Months Ended |
|
Sep. 30, 2023 |
Jan. 16, 2024 |
Cover [Abstract] |
|
|
Document Type |
10-Q
|
|
Amendment Flag |
false
|
|
Document Quarterly Report |
true
|
|
Document Transition Report |
false
|
|
Document Period End Date |
Sep. 30, 2023
|
|
Document Fiscal Period Focus |
Q3
|
|
Document Fiscal Year Focus |
2023
|
|
Current Fiscal Year End Date |
--12-31
|
|
Entity File Number |
001-39199
|
|
Entity Registrant Name |
TRxADE
HEALTH, INC.
|
|
Entity Central Index Key |
0001382574
|
|
Entity Tax Identification Number |
46-3673928
|
|
Entity Incorporation, State or Country Code |
DE
|
|
Entity Address, Address Line One |
2420
Brunello Trace
|
|
Entity Address, City or Town |
Lutz
|
|
Entity Address, State or Province |
FL
|
|
Entity Address, Postal Zip Code |
33558
|
|
City Area Code |
(800)
|
|
Local Phone Number |
261-0281
|
|
Title of 12(b) Security |
Common
Stock, $0.00001 Par Value Per Share
|
|
Trading Symbol |
MEDS
|
|
Security Exchange Name |
NASDAQ
|
|
Entity Current Reporting Status |
Yes
|
|
Entity Interactive Data Current |
Yes
|
|
Entity Filer Category |
Non-accelerated Filer
|
|
Entity Small Business |
true
|
|
Entity Emerging Growth Company |
true
|
|
Elected Not To Use the Extended Transition Period |
false
|
|
Entity Shell Company |
false
|
|
Entity Common Stock, Shares Outstanding |
|
1,205,008
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as an quarterly report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a
+ Details
Name: |
dei_DocumentQuarterlyReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as a transition report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1
+ Details
Name: |
dei_DocumentTransitionReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
+ Details
Name: |
dei_EntityCommonStockSharesOutstanding |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityCurrentReportingStatus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405
+ Details
Name: |
dei_EntityInteractiveDataCurrent |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityShellCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates that the company is a Smaller Reporting Company (SRC).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntitySmallBusiness |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Consolidated Balance Sheets (Unaudited) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Current Assets |
|
|
Cash |
$ 34,031
|
$ 1,094,891
|
Accounts receivable, net |
850,103
|
649,263
|
Inventory |
3,026,918
|
68,448
|
Prepaid assets |
246,093
|
104,462
|
Notes receivable |
1,275,000
|
|
Other receivables |
115,684
|
|
Current assets of discontinued operations |
|
176,057
|
Total Current Assets |
5,547,829
|
2,093,121
|
Property plant and equipment, net |
287,920
|
65,214
|
Deposits |
49,031
|
49,031
|
Intangible assets, net |
9,451,562
|
|
Goodwill |
5,129,116
|
|
Other assets |
|
|
Operating lease right-of-use assets |
1,188,385
|
1,051,815
|
Noncurrent assets of discontinued operations |
|
450,845
|
Total Assets |
21,653,843
|
3,710,026
|
Current Liabilities |
|
|
Accounts payable |
1,328,599
|
527,984
|
Accrued liabilities |
386,024
|
271,230
|
Other current liabilities |
412,390
|
67,517
|
Contingent funding liabilities |
452,348
|
108,036
|
Current portion of operating lease liabilities |
251,087
|
196,872
|
Notes payable— related party, current portion |
5,230,000
|
|
Warrant liability |
1,031,841
|
588,533
|
Current liabilities of discontinued operations |
|
219,952
|
Total Current Liabilities |
9,092,289
|
2,146,791
|
Long Term Liabilities |
|
|
Operating lease liabilities, net of current portion |
976,869
|
887,035
|
Notes payable- related party, net of current portion |
25,000
|
|
Total Liabilities |
10,094,158
|
3,367,159
|
Stockholders’ Equity |
|
|
Common stock, $0.00001 par value; 6,666,667 shares authorized; 818,961 and 626,247 shares issued and outstanding, as of September 30, 2023 and December 31, 2022, respectively |
8
|
6
|
Additional paid-in capital |
33,089,652
|
20,482,666
|
Retained deficit |
(21,529,975)
|
(19,719,536)
|
Total TRxADE Health Inc. Stockholders’ Equity |
11,559,685
|
763,136
|
Non-controlling interest in subsidiary |
|
(420,269)
|
Total Stockholders’ Equity |
11,559,685
|
342,867
|
Total Liabilities and Stockholders’ Equity |
21,653,843
|
3,710,026
|
Series A Preferred Stock [Member] |
|
|
Stockholders’ Equity |
|
|
Preferred stock, value |
|
|
Series B Preferred Stock [Member] |
|
|
Stockholders’ Equity |
|
|
Preferred stock, value |
|
|
Nonrelated Party [Member] |
|
|
Current Liabilities |
|
|
Notes payable— related party, current portion |
5,230,000
|
|
Long Term Liabilities |
|
|
Notes payable- related party, net of current portion |
25,000
|
|
Related Party [Member] |
|
|
Current Liabilities |
|
|
Notes payable— related party, current portion |
|
166,667
|
Long Term Liabilities |
|
|
Notes payable- related party, net of current portion |
|
$ 333,333
|
X |
- DefinitionContingent funding liabilities.
+ References
+ Details
Name: |
MEDS_ContingentFundingLiabilities |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.
+ References
+ Details
Name: |
us-gaap_AccountsAndOtherReceivablesNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccountsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9
+ Details
Name: |
us-gaap_AccountsReceivableNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AdditionalPaidInCapital |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DepositsAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Goodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1
+ Details
Name: |
us-gaap_IntangibleAssetsNetExcludingGoodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_Liabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesNoncurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LongTermNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_MinorityInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9
+ Details
Name: |
us-gaap_NotesAndLoansReceivableNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_NotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncurrent assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1
+ Details
Name: |
us-gaap_PrepaidExpenseCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15
Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16
Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I
+ Details
Name: |
us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Common stock, par value |
$ 0.00001
|
$ 0.00001
|
Common stock, shares authorized |
6,666,667
|
6,666,667
|
Common stock, shares issued |
818,961
|
626,247
|
Common stock, shares outstanding |
818,961
|
626,247
|
Series A Preferred Stock [Member] |
|
|
Preferred stock, par value |
$ 0.00001
|
$ 0.00001
|
Preferred stock, shares authorized |
9,212,246
|
9,212,246
|
Preferred stock, shares issued |
0
|
0
|
Preferred stock, shares outstanding |
0
|
0
|
Series B Preferred Stock [Member] |
|
|
Preferred stock, par value |
$ 0.00001
|
$ 0.00001
|
Preferred stock, shares authorized |
787,754
|
787,754
|
Preferred stock, shares issued |
306,855
|
306,855
|
Preferred stock, shares outstanding |
306,855
|
306,855
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
Consolidated Statements of Operations (Unaudited) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Income Statement [Abstract] |
|
|
|
|
Revenues |
$ 2,058,028
|
$ 2,055,803
|
$ 5,919,786
|
$ 7,993,805
|
Cost of sales |
353,450
|
683,375
|
1,072,934
|
3,991,234
|
Gross profit |
1,704,578
|
1,372,428
|
4,846,852
|
4,002,571
|
Operating expenses: |
|
|
|
|
Wage and salary expense |
698,030
|
849,371
|
2,077,362
|
2,949,386
|
Professional fees |
418,294
|
82,710
|
782,286
|
256,807
|
Accounting and legal expense |
408,957
|
191,007
|
782,495
|
567,086
|
Technology expense |
410,612
|
238,577
|
1,010,374
|
690,875
|
General and administrative expense |
613,834
|
229,526
|
1,264,902
|
1,392,130
|
Total operating expenses |
2,549,727
|
1,591,191
|
5,917,419
|
5,856,284
|
Operating loss |
(845,149)
|
(218,763)
|
(1,070,567)
|
(1,853,713)
|
Nonoperating income (expense) |
|
|
|
|
Change in fair value of warrant liability |
925,320
|
|
(443,308)
|
|
Interest income |
|
8,396
|
4,198
|
8,396
|
Gain (loss) on disposal of assets |
|
|
|
2,200
|
Interest expense |
(251,778)
|
(130,107)
|
(494,904)
|
(140,626)
|
Total nonoperating income (expense) |
673,542
|
(121,711)
|
(934,014)
|
(130,030)
|
Net loss from continuing operations |
(171,607)
|
(340,474)
|
(2,004,581)
|
(1,983,743)
|
Net loss on discontinued operations |
(3,353,507)
|
(188,268)
|
(4,123,028)
|
(623,096)
|
Net loss |
(3,525,114)
|
(528,742)
|
(6,127,609)
|
(2,606,839)
|
Net loss attributable to TRxADE Health, Inc. |
(3,525,114)
|
(503,003)
|
(6,127,609)
|
(2,546,913)
|
Net loss attributable to non-controlling interests |
|
$ (25,739)
|
|
$ (59,926)
|
Net loss per common share from continuing operations |
|
|
|
|
Basic |
$ (0.22)
|
$ (0.57)
|
$ (2.83)
|
$ (3.52)
|
Diluted |
(0.07)
|
(0.57)
|
(0.87)
|
(3.51)
|
Net loss per common share from discontinued operations |
|
|
|
|
Basic |
(4.35)
|
(0.34)
|
(5.82)
|
(1.14)
|
Diluted |
(1.42)
|
(0.34)
|
(1.79)
|
(1.14)
|
Net loss attributable to common stockholders |
|
|
|
|
Basic |
(4.57)
|
(0.91)
|
(8.65)
|
(4.66)
|
Diluted |
$ (1.49)
|
$ (0.91)
|
$ (2.66)
|
$ (4.64)
|
Weighted average common shares outstanding |
|
|
|
|
Basic |
771,192
|
549,977
|
708,116
|
546,879
|
Diluted |
2,363,233
|
551,724
|
2,300,157
|
548,626
|
X |
- DefinitionChange in fair value of warrant liability.
+ References
+ Details
Name: |
MEDS_ChangeInFairValueOfWarrantLiability |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNetLossPerCommonShareFromContinuingOperationsAbstract
+ References
+ Details
Name: |
MEDS_NetLossPerCommonShareFromContinuingOperationsAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNetLossPerCommonShareFromDiscontinuedOperationsAbstract
+ References
+ Details
Name: |
MEDS_NetLossPerCommonShareFromDiscontinuedOperationsAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_CostOfGoodsAndServicesSold |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_GainLossOnDispositionOfAssets1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GrossProfit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of income (loss) from continuing operations attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.13) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_IncomeLossFromContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_IncomeLossFromContinuingOperationsPerBasicShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1
+ Details
Name: |
us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3
+ Details
Name: |
us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionPer basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 5.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5
+ Details
Name: |
us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncomeStatementAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1
+ Details
Name: |
us-gaap_InterestExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of interest income earned from interest bearing assets classified as other.
+ References
+ Details
Name: |
us-gaap_InterestIncomeOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.
+ References
+ Details
Name: |
us-gaap_LitigationSettlementExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
+ Details
Name: |
us-gaap_NetIncomeLossAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_NonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NonoperatingIncomeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
+ Details
Name: |
us-gaap_OperatingExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionA fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
+ Details
Name: |
us-gaap_ProfessionalFees |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2
Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_SalariesAndWages |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
|
Preferred Stock [Member]
Series B Preferred Stock [Member]
|
Preferred Stock [Member]
Series A Preferred Stock [Member]
|
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Retained Earnings [Member] |
Noncontrolling Interest [Member] |
Total |
Balance at Dec. 31, 2021 |
|
|
$ 5
|
$ 20,017,605
|
$ (16,247,437)
|
|
$ 3,770,173
|
Balance, shares at Dec. 31, 2021 |
|
|
544,430
|
|
|
|
|
Common stock issued for services |
|
|
|
32,083
|
|
|
32,083
|
Warrants exercised for cash |
|
|
|
875
|
|
|
875
|
Warrants exercised for cash, shares |
|
|
972
|
|
|
|
|
Options expense |
|
|
|
32,783
|
|
|
32,783
|
Net Loss |
|
|
|
|
(960,147)
|
(5,689)
|
(965,836)
|
Capital contributions |
|
|
|
|
|
792,500
|
792,500
|
Capital distributions |
|
|
|
|
|
(775,000)
|
(775,000)
|
Balance at Mar. 31, 2022 |
|
|
$ 5
|
20,083,346
|
(17,207,584)
|
11,811
|
2,887,578
|
Balance, shares at Mar. 31, 2022 |
|
|
545,402
|
|
|
|
|
Balance at Dec. 31, 2021 |
|
|
$ 5
|
20,017,605
|
(16,247,437)
|
|
3,770,173
|
Balance, shares at Dec. 31, 2021 |
|
|
544,430
|
|
|
|
|
Net Loss |
|
|
|
|
|
|
(2,606,839)
|
Balance at Sep. 30, 2022 |
|
|
$ 6
|
20,193,348
|
(18,794,350)
|
(42,426)
|
1,356,578
|
Balance, shares at Sep. 30, 2022 |
|
|
559,913
|
|
|
|
|
Balance at Mar. 31, 2022 |
|
|
$ 5
|
20,083,346
|
(17,207,584)
|
11,811
|
2,887,578
|
Balance, shares at Mar. 31, 2022 |
|
|
545,402
|
|
|
|
|
Common stock issued for services |
|
|
|
12,222
|
|
|
12,222
|
Options expense |
|
|
|
16,994
|
|
|
16,994
|
Net Loss |
|
|
|
|
(1,083,763)
|
(28,498)
|
(1,112,261)
|
Balance at Jun. 30, 2022 |
|
|
$ 5
|
20,112,562
|
(18,291,347)
|
(16,687)
|
1,804,533
|
Balance, shares at Jun. 30, 2022 |
|
|
545,402
|
|
|
|
|
Common stock issued for services |
|
|
$ 1
|
63,125
|
|
|
63,126
|
Common stock issued for services, shares |
|
|
14,511
|
|
|
|
|
Warrants exercised for cash |
|
|
|
|
|
|
|
Options expense |
|
|
|
17,661
|
|
|
17,661
|
Net Loss |
|
|
|
|
(503,003)
|
(25,739)
|
(528,742)
|
Balance at Sep. 30, 2022 |
|
|
$ 6
|
20,193,348
|
(18,794,350)
|
(42,426)
|
1,356,578
|
Balance, shares at Sep. 30, 2022 |
|
|
559,913
|
|
|
|
|
Balance at Dec. 31, 2022 |
|
|
$ 6
|
20,482,666
|
(19,719,536)
|
(420,269)
|
342,867
|
Balance, shares at Dec. 31, 2022 |
|
|
626,247
|
|
|
|
|
Common stock issued for services |
|
|
|
63,486
|
|
|
63,486
|
Common stock issued for services, shares |
|
|
14,362
|
|
|
|
|
Warrants exercised for cash |
|
|
$ 1
|
6
|
|
|
7
|
Warrants exercised for cash, shares |
|
|
40,116
|
|
|
|
|
Disposition of assets, related party |
|
|
|
|
492,030
|
420,269
|
912,299
|
Options expense |
|
|
|
14,434
|
|
|
14,434
|
Net Loss |
|
|
|
|
(677,953)
|
|
(677,953)
|
Balance at Mar. 31, 2023 |
|
|
$ 7
|
20,560,592
|
(19,905,459)
|
|
655,140
|
Balance, shares at Mar. 31, 2023 |
|
|
680,725
|
|
|
|
|
Balance at Dec. 31, 2022 |
|
|
$ 6
|
20,482,666
|
(19,719,536)
|
(420,269)
|
342,867
|
Balance, shares at Dec. 31, 2022 |
|
|
626,247
|
|
|
|
|
Net Loss |
|
|
|
|
|
|
(6,127,609)
|
Balance at Sep. 30, 2023 |
|
|
$ 8
|
33,089,652
|
(21,529,975)
|
|
11,559,685
|
Balance, shares at Sep. 30, 2023 |
|
15,759
|
818,961
|
|
|
|
|
Balance at Mar. 31, 2023 |
|
|
$ 7
|
20,560,592
|
(19,905,459)
|
|
655,140
|
Balance, shares at Mar. 31, 2023 |
|
|
680,725
|
|
|
|
|
Common stock issued for services |
|
|
|
15,813
|
|
|
15,813
|
Warrants exercised for cash |
|
|
|
1,615
|
|
|
1,615
|
Warrants exercised for cash, shares |
|
|
1,795
|
|
|
|
|
Net Loss |
|
|
|
|
(1,974,878)
|
|
(1,974,878)
|
Options expense |
|
|
|
7,783
|
|
|
7,783
|
Balance at Jun. 30, 2023 |
|
|
$ 7
|
20,585,803
|
(21,880,337)
|
|
(1,294,527)
|
Balance, shares at Jun. 30, 2023 |
|
|
682,520
|
|
|
|
|
Options expense |
|
|
|
3,761
|
|
|
3,761
|
Net Loss |
|
|
|
|
(3,525,114)
|
|
(3,525,114)
|
Disposition of assets |
|
|
|
|
3,875,476
|
|
3,875,476
|
Shares issued pursuant to merger agreement |
|
|
$ 1
|
12,500,088
|
|
|
12,500,089
|
Shares issued pursuant to merger agreement, shares |
|
15,759
|
136,441
|
|
|
|
|
Balance at Sep. 30, 2023 |
|
|
$ 8
|
$ 33,089,652
|
$ (21,529,975)
|
|
$ 11,559,685
|
Balance, shares at Sep. 30, 2023 |
|
15,759
|
818,961
|
|
|
|
|
X |
- DefinitionNon controlling interest of capital contributions.
+ References
+ Details
Name: |
MEDS_NoncontrollingInterestOfCapitalContributions |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNon controlling interest of capital distributions.
+ References
+ Details
Name: |
MEDS_NoncontrollingInterestOfCapitalDistributions |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period shares warrants exercised for cash shares.
+ References
+ Details
Name: |
MEDS_StockIssuedDuringPeriodSharesWarrantsExercisedForCashShares |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value warrants exercised for cash.
+ References
+ Details
Name: |
MEDS_StockIssuedDuringPeriodValueWarrantsExercisedForCash |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.
+ References
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2
Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of stock issued during the period pursuant to acquisitions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesAcquisitions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued pursuant to acquisitions during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueAcquisitions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued as a result of the exercise of stock options.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15
Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16
Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I
+ Details
Name: |
us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.4
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
|
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Cash flows from operating activities: |
|
|
Net loss from continuing operations |
$ (2,004,581)
|
$ (1,983,743)
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
Depreciation expense |
8,464
|
11,815
|
Options expense |
25,978
|
67,439
|
Common stock issued for services |
79,299
|
107,430
|
Bad debt recovery |
|
(98,841)
|
Gain on disposal of asset |
|
(4,100)
|
Amortization of intangible assets |
325,916
|
29,400
|
Changes in operating assets and liabilities: |
|
|
Accounts receivable, net |
(212,292)
|
227,508
|
Prepaid assets and deposits |
(138,450)
|
198,088
|
Inventory |
(39,013)
|
(19,671)
|
Other receivables |
|
(875,250)
|
Operating lease right-of-use assets |
152,121
|
132,847
|
Other assets |
|
|
Operating lease liabilities |
(145,707)
|
(120,401)
|
Accounts payable |
854,171
|
267,384
|
Accrued liabilities |
43,729
|
(178,714)
|
Inventory deposits |
|
|
Current liabilities |
(5,127)
|
105,926
|
Warrant liability |
443,308
|
|
Net cash used in operating activities from continuing operations |
(612,184)
|
(2,132,883)
|
Net cash used in operating activities from discontinued operations |
(593,893)
|
(623,096)
|
Net cash used in operating activities |
(1,206,077)
|
(2,755,979)
|
Cash flows from investing activities: |
|
|
Proceeds from sale of fixed assets |
|
23,000
|
Cash received in acquisitions |
5,546
|
|
Investment in capitalized software |
|
(335,902)
|
Net cash provided by (used in) investing activities from continuing operations |
5,546
|
(312,902)
|
Net cash provided by investing activities from discontinued operations |
68,737
|
|
Net cash provided by (used in) investing activities |
74,283
|
(312,902)
|
Cash flows from financing activities: |
|
|
Proceeds from the issuance of debt |
200,000
|
|
Proceeds from repayment of notes receivable |
25,000
|
|
Repayment of contingent liability |
(1,755,688)
|
(282,857)
|
Proceeds from sale of future revenue |
2,100,000
|
825,000
|
Distributions to non-controlling interest |
|
(275,000)
|
Proceeds from exercise of warrants |
1,622
|
875
|
Net cash provided by financing activities from continuing operations |
570,934
|
268,018
|
Net cash used in financing activities from discontinued operations |
(500,000)
|
|
Net cash provided by financing activities |
70,934
|
268,018
|
Net change in cash |
(1,060,860)
|
(2,800,863)
|
Cash at beginning of the year |
1,094,891
|
3,122,578
|
Cash at end of the period |
34,031
|
321,715
|
Supplemental disclosure of cash flow information |
|
|
Cash paid for interest |
494,408
|
3,328
|
Cash paid for income taxes |
|
|
Non-cash Transactions |
|
|
Insurance premium financed |
306,152
|
220,354
|
Note cancelled from SOSRx agreement termination |
500,000
|
|
Note issued as SOSRx contribution |
|
500,000
|
Intangible asset contribution from non-controlling interest |
|
792,500
|
Disposition of assets, related party |
492,030
|
|
Issuance of notes receivable |
$ 1,300,000
|
|
X |
- DefinitionIncrease decrease in current liabilities
+ References
+ Details
Name: |
MEDS_IncreaseDecreaseInCurrentLiabilities |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIncrease (decrease) in inventory deposits.
+ References
+ Details
Name: |
MEDS_IncreaseDecreaseInInventoryDeposits |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIncrease decrease in operating lease right of use assets.
+ References
+ Details
Name: |
MEDS_IncreaseDecreaseInOperatingLeaseRightofuseAssets |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIncrease decrease in warrant liability.
+ References
+ Details
Name: |
MEDS_IncreaseDecreaseInWarrantLiability |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionInsurance premium financed.
+ References
+ Details
Name: |
MEDS_InsurancePremiumFinanced |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIntangible asset contribution from noncontrolling interest.
+ References
+ Details
Name: |
MEDS_IntangibleAssetContributionFromNoncontrollingInterest |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIssuance of notes receivable.
+ References
+ Details
Name: |
MEDS_IssuanceOfNotesReceivable |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionProceeds from payments for notes receivable.
+ References
+ Details
Name: |
MEDS_ProceedsFromPaymentsForNotesReceivable |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionProceeds from sale of future revenue.
+ References
+ Details
Name: |
MEDS_ProceedsFromSaleOfFutureRevenue |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase in allowance for credit loss on accounts receivable, from recovery.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13
+ Details
Name: |
us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_AmortizationOfIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12
+ Details
Name: |
us-gaap_CashAcquiredFromAcquisition |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
+ Details
Name: |
us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
+ Details
Name: |
us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_Depreciation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
+ Details
Name: |
us-gaap_GainLossOnDispositionOfAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of income (loss) from continuing operations attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.13) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_IncomeLossFromContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccruedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInInventories |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in obligation for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in operating assets classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherOperatingAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in receivables classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherReceivables |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2
+ Details
Name: |
us-gaap_InterestPaidNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe fair value of notes issued in noncash investing and financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_NotesIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (f) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsForSoftware |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_PaymentsToMinorityShareholders |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12
+ Details
Name: |
us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromShortTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromWarrantExercises |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for option under share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_StockOptionPlanExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.23.4
ORGANIZATION AND BASIS OF PRESENTATION
|
9 Months Ended |
Sep. 30, 2023 |
Accounting Policies [Abstract] |
|
ORGANIZATION AND BASIS OF PRESENTATION |
NOTE
1 – ORGANIZATION AND BASIS OF PRESENTATION
Overview
TRxADE
HEALTH, INC. (“we”, “our”, “Trxade”, and the “Company”)
owns 100%
of Trxade, Inc., Integra Pharma Solutions, LLC, Community Specialty Pharmacy, LLC, Alliance Pharma Solutions, LLC, Bonum Health,
LLC, Superlatus, Inc. and its wholly-owned subsidiary, Sapientia Technologies, LLC (“Sapientia”), and The Urgent
Company, Inc. On July 31, 2023, the Company merged with
Superlatus, Inc. (see “Merger”, below). On September 27, 2023, the Company acquired The Urgent Company, Inc. (see Note
3).
Trxade,
Inc., operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories
and services.
Integra
Pharma Solutions, LLC (“IPS”, d.b.a. Trxade Prime), is a licensed pharmaceutical wholesaler and sells brand, generic
and non-drug products to customers. IPS customers include all healthcare markets including government organizations,
hospitals, clinics and independent pharmacies nationwide.
Community Specialty Pharmacy, LLC, (“CSP”) is an accredited independent retail pharmacy with a focus
on a community-based model offering home delivery services to patients.
Alliance
Pharma Solutions, LLC (“APS”, d.b.a. DelivMeds) is currently being rebranded and the consumer-based app is
still being developed. To date, we have not generated any revenue from this product.
On
January 20, 2023, the Company entered into Membership Interest Purchase Agreements to sell 100%
of the outstanding membership interests of the Company’s subsidiaries, CSP and APS. The Company will receive consideration in
the amount of $125,000
for APS and $
for CSP. The Company also agreed to enter into a Master Service Agreement to operate the businesses prior to closing. Additional
amounts owed to the Company as a result of this Master Service Agreement totaled $1,075,000
as of the closing date of August 22, 2023 (see Note 3 and Note 6).
Bonum
Health, LLC (“Bonum Health”), was formed to hold certain telehealth assets acquired in October 2019. The “Bonum Health
Hub” was launched in February 2020; however, due to the COVID-19 pandemic, the Company does not anticipate installations moving
forward. The Bonum Health mobile application is available on a subscription basis, primarily as a stand-alone telehealth software application
that can be licensed on a business-to-business (B2B) model to clients as an employment health benefit for the clients’ employees.
SOSRx,
LLC (“SOSRx”) was formed on February 15, 2022. The Company entered into a relationship with Exchange Health, LLC (“Exchange
Health”), a technology company providing an online platform for manufacturers and suppliers to sell and purchase pharmaceuticals.
SOSRx, a Delaware limited liability company, was formed, which was owned 51%
by the Company and 49%
by Exchange Health. SOSRx did not generate material revenue and in February of 2023, the Company voluntarily withdrew from the joint
venture agreement. As part of the voluntary withdrawal the Company has recorded a loss of $352,244 from disposal of assets, which is
included in net loss on discontinued operations in the unaudited consolidated statement of operations in the amount of for the nine-month
period ended September 30, 2023.
Merger
On
July 14, 2023, the Company entered into an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”) with
Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities (“Superlatus”) and Foods Merger
Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”).
Superlatus
is a diversified food technology company with distribution capabilities and systems to optimize food security and population health
via innovative Consumer Packaged Goods (“CPG”) products, agritech, foodtech, plant-based proteins and alt-protein and
includes wholly-owned subsidiary, Sapientia,
Inc. (“Sapientia”), a food tech business.
On
July 31, 2023 (the “Closing Date”), the Company completed its acquisition of Superlatus in accordance with the terms and
conditions of the Merger Agreement (the “Merger”), pursuant to which the Company acquired Superlatus by way of a merger of
the Merger Sub with and into Superlatus, with Superlatus being a wholly owned subsidiary of the Company and the surviving entity in the
Merger.
Under
the terms of the Merger Agreement, at the closing of the Merger (the “Closing”), shareholders of Superlatus received in aggregate
136,441 shares of common stock of the Company, representing 19.99% of the total issued and outstanding common stock of the Company after
the consummation of the Merger and 306,855 shares of Company’s Series B Preferred Stock, par value $0.00001 per share (the “Series
B Preferred Stock”), with a conversion ratio of 100 shares of Series B Preferred Stock to one share of common stock. At Closing,
the value of the common stock was $7.30 per share, resulting in a total value of $225,000,169. Upon consummation of the Merger, the Company
continued to trade under the current ticker symbol “MEDS.”
As
a condition and inducement to Superlatus’ willingness to enter into the Merger Agreement, on June 28, 2023, Suren Ajjarapu and
Prashant Patel (the “Principal Stockholders”) entered into an agreement with TRxADE (the “Stock Swap Agreement”),
pursuant to which, TRxADE will transfer all of the shares or membership interest of the operating subsidiaries currently owned
by TRxADE to Principal Stockholders, in exchange for Suran Ajjarapu to surrender 85,000 share of common stock of TRxADE and Prashant
Patel to surrender 81,666 shares of the common stock of TRxADE (the “Stock Swap Transaction”). The closing of the Stock Swap
Transaction shall take place simultaneously with the approval of TRxADE stockholders of the conversion of the Series B preferred stock
into common stock. The closing of the Stock Swap Transaction is subject to the simultaneous condition that the Merger. As of the date of this filing, TRxADE stockholders have not approved the conversion. The Company is in the process of preparing
a proxy merger, which is expected to occur in 2024. This will complete all contingencies of Merger Agreement and Stock Swap Agreement
and result in a reverse capitalization.
In
connection with the Merger, on July 31, 2023, certain Superlatus shareholders as of immediately prior to the Merger, and certain directors
and officers of MEDS as of immediately prior to the Merger, entered into lock-up agreements with the Company, pursuant to which each
such stockholder will be subject to a 360 day lockup on the sale or transfer of shares of common stock or securities convertible into
or exercisable for or exchangeable for common stock held by each such stockholder at the closing of the Merger (the “Lock-up Agreements”).
In
connection with the Merger, effective one (1) business day immediately prior to the Closing Date (the “MEDS Rights Record Date”),
the Company issued to the shareholders of the Company as of the MEDS Rights Record Date, including the independent directors who are
entitled to certain amount of common stock of the Company in connection with their 2023 annual compensation and regardless of whether
the common stock has been issued or vest before the MEDS Rights Records Date (collectively, the “MEDS Rights Shareholders”)
a non-transferrable right to receive one share of common stock of the Company at no cost (the “MEDS Rights”), with seven
(7) MEDS Rights issued per share of common stock of the Company held as of the MEDS Rights Record Date, conditioned upon their execution
of a Registration Rights Agreement. Such issuances will be made in reliance on the exemption from registration pursuant to Section 3(a)(9)
or Section 4(a)(2) of the Securities Act, Regulation D under the Securities Act promulgated thereunder, and corresponding provisions
of state securities or “blue sky” laws. The MEDS Rights are not actionable or transferable until registration; provided they
become transferable one year after the date of the Merger if no registration has occurred. As of the date of this filing, no MEDS Rights
shares have been issued.
Not
all of the closing conditions of the Merger Agreement were met. As a result, the Company entered into Amendment No. 1 to the Amended
and Restated Agreement and Plan of Merger (the “Amendment”) on January 8, 2024.Under the terms of the Amendment, the
merger consideration to the shareholders of Superlatus was adjusted to the aggregate of 136,441
shares of common stock of the Company, representing 19.99%
of the total issued and outstanding common stock of the Company after the consummation of the Merger and 15,759
shares of Company’s Series B Preferred Stock, par value $0.00001
per share (the “Series B Preferred Stock”), with a conversion ratio of 100
shares of Series B Preferred Stock to one share of common stock. At Closing, the value of the common stock was $7.30
per share, resulting in a total value of $12,500,089.
Additionally, the shareholders of Superlatus agreed to surrender back to the Company 289,731 shares of the Company’s Series B
Preferred Stock. Upon consummation of the Amended Merger Agreement, the Company continues to trade under the current ticker symbol
“MEDS.”
Basis
of Presentation and Principles of Consolidation
The
accompanying unaudited interim consolidated financial statements of TRxADE HEALTH, Inc. have been prepared in accordance with
accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the SEC and
should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report
on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 27, 2023.
In
the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of
financial position and the results of operations for the interim periods presented have been reflected herein. All significant
intercompany balances and transactions have been eliminated in consolidation. The results of operations for the interim periods are
not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would
substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2022, as
reported in the Company’s Annual Report on Form 10-K have been omitted.
Use of Estimates
The preparation of condensed consolidated financial
statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The
Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable
under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities
and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company
may differ materially and adversely from its estimates. To the extent there are material differences between estimates and the actual
results, future results of operations will be affected. Significant estimates for the nine months ended September 30, 2023 and 2022 include
the valuation of intangible assets, including goodwill.
Fair value of financial instruments
The carrying amounts for cash, accounts
receivable, accounts payable, accrued liabilities, and other current liabilities approximate their fair value because of their short-term
maturity.
Stock
Split
Effective
June 21, 2023, the Company executed a 1:15 reverse stock split for stockholders of record on that date. This was executed to comply with
the Nasdaq Listing Rule 5550(a)(2) to have the price of the stock above $1.
Recently
Issued Accounting Pronouncements
In
June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”
(“ASU 2016-13”). ASU 2016-13 requires companies to measure credit losses utilizing a methodology that reflects expected
credit losses and requires a consideration of a broader range of reasonable and supportable information to inform credit loss
estimates. ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those
fiscal years. The Company adopted ASU 2016-13 effective January 1, 2023. The Company determined that the update applied to trade
receivables, but that there was no material impact to the consolidated financial statements from the adoption of ASU
2016-13.
In August 2020, the FASB issued ASU 2020-06, “Debt - Debt with Conversion and Other Options (Subtopic 470-20)
and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting
models for convertible debt instruments and convertible preferred stock and amends the guidance for the derivatives scope exception for
contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and
amends the related earnings per share guidance. This standard is effective for us on January 1, 2022, including interim periods within
those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. The adoption of
ASU 2020-06 did not have a material impact on our financial statements.
Accounts
Receivable, net
On January 1, 2023, the Company adopted ASU 2016-13 “Financial
Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” and
its related amendments using the prospective method. The new standard requires the use of a current expected credit loss impairment
model to develop and recognize credit losses for financial instruments at amortized cost when the asset is first originated or acquired,
and each subsequent reporting period.
The
Company’s receivables are from customers and are typically collected within 90 days. The Company determines the allowance based
on known troubled accounts, historical experience, and other currently available evidence.
The
Company had an account receivable with a single customer, GSG PPE, LLC (“GSG”), for the amount of $630,000,
which was past due. The Company
had obtained a Note Receivable which was due on September 30, 2021 and remained unpaid. The Company did not believe the amount to be
collectible without legal actions, and therefore, recorded bad debt expense reflected on the consolidated statement of operations during
the year ended December 31, 2021. The note was not paid pursuant to its terms and the Company had filed a suit to collect on the note
and the personal guaranty securing the note. The Company settled the lawsuit in June of 2022. During the nine months ended September 30, 2023, and 2022, there was a bad debt recovery from the GSG lawsuit of
$32,074 and $98,841 respectively.
Other
Receivables, net
The
Company’s other receivables balance is from one vendor. On May 20, 2022, effective as of May 18, 2022, Community Specialty
Pharmacy, LLC (“CSP”) entered into an agreement to acquire COVID-19 testing kits from a third-party vendor for an
aggregate of $,
of which $
was paid on May 23, 2022. The Company received the COVID-19 testing kits in July 2022. On August 18, 2022 the Company was informed
by the vendor that the vendor had received a letter from the U.S. Food and Drug Administration (“FDA”) that the COVID-19
test kits were misbranded under Section 502(o) of the Federal Food, Drug, and Cosmetic Act (“FDC Act”) (21 USC 352(o))
and adulterated under Section 501(f) of the FDC Act (21 USC 351(f)). Furthermore, the vendor informed the Company that the letter
from the FDA also stated that because of the FDA’s prohibition on the distribution of adulterated and/or misbranded devices
applies to all parties along the distribution chain, the FDA was advising the vendor against furthering the distribution of the
COVID-19 test kits in interstate commerce. The company wrote the amount off as a loss of inventory as of December 31, 2022. As of September 30, 2023 and December 31, 2022, the balance of this receivable was $0.
On
August 22, 2023, the Company completed the sale of CSP and APS (see Note 3). The net balance due to the Company from these entities,
in excess of the Note Receivable (see Note 6), was $115,684 as of September 30, 2023.
Acquisitions
The
Company accounts for acquisitions and investments in businesses as business combinations if the target meets the definition of a
business and (a) the target is a variable interest entity (“VIE”) and the Company is the target’s primary
beneficiary, and therefore the Company must consolidate its financial statements, or (b) the Company acquires more than 50% of the
voting interest of the target and it was not previously consolidated. The Company records business combinations using the
acquisition method of accounting, which requires all the assets acquired and liabilities assumed to be recorded at fair value as of
the acquisition date. The excess of the purchase price over the estimated fair values of the net tangible and intangible assets
acquired is recorded as goodwill.
The
application of the acquisition method of accounting for business combinations requires management to make significant estimates and assumptions
in the determination of the fair value of assets acquired and liabilities assumed in order to properly allocate purchase price consideration
between assets that are depreciated and amortized from goodwill. The fair value assigned to tangible and intangible assets acquired and
liabilities assumed are based on management’s estimates and assumptions, as well as other information compiled by management, including
valuations that utilize customary valuation procedures and techniques. Significant assumptions and estimates include, but are not limited
to, the cash flows that an asset is expected to generate in the future, the appropriate weighted-average cost of capital, and the cost
savings expected to be derived from acquiring an asset, if applicable.
If
the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the Company’s financial
statements may be exposed to potential impairment of the intangible assets and goodwill.
If
the Company’s investment involves the acquisition of an asset or group of assets that does not meet the definition of a business,
the transaction is accounted for as an asset acquisition. An asset acquisition is recorded at cost, which includes capitalizing transaction
costs, and does not result in the recognition of goodwill.
Intangible Assets and Goodwill
The Company
tests indefinite-lived intangible assets for impairment on an annual basis or whenever events or changes occur that would more-likely-than
not reduce the fair value of the indefinite-lived intangible asset below its carrying value between annual impairment tests. Any indefinite-lived
intangible asset assessment is performed at the Company level.
The Company did not record an indefinite-lived intangible asset impairment charge for the three and nine months ended
September 30, 2023 and 2022.
Income
(loss) Per Common Share
Basic
net income per common share is computed by dividing net income available to common stockholders by the weighted average number of common
shares outstanding. Diluted net income per common share is computed similar to basic net income per common share except that the denominator
is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been
issued and if the additional common shares were dilutive. The dilutive effect of the Company’s options and warrants is computed
using the treasury stock method. As of September 30, 2023, we had 177,536 outstanding warrants to purchase shares of common stock and
17,852 options to purchase shares of common stock. As part of the termination of the White Lion deal, White Lion was issued 50,000 shares
of stock per the agreement on March 1, 2023. Armistice Capital executed its pre-funded warrants on January 4, 2023, and purchased 601,740
shares of stock with a purchase price of $6.02.
The
following table sets forth the computation of basic and diluted loss per share:
SCHEDULE
OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
For the Three Months Ended
September 30, | | |
For the Nine Months Ended
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Numerator: | |
| | | |
| | | |
| | | |
| | |
Net loss from continuing operations | |
$ | (171,607 | ) | |
$ | (314,735 | ) | |
$ | (2,004,581 | ) | |
$ | (1,923,817 | ) |
Net loss from discontinued operations | |
$ | (3,353,507 | ) | |
$ | (188,268 | ) | |
| (4,123,028 | ) | |
$ | (623,096 | ) |
Numerator for basic and diluted EPS - income available to common stockholders | |
| (3,525,114 | ) | |
$ | (503,003 | ) | |
| (6,127,609 | ) | |
$ | (2,546,913 | ) |
Denominator: | |
| | | |
| | | |
| | | |
| | |
Denominator for EPS – weighted average shares | |
| | | |
| | | |
| | | |
| | |
Basic | |
| 771,192 | | |
| 549,977 | | |
| 708,116 | | |
| 546,879 | |
Diluted | |
| 2,363,233 | | |
| 551,724 | | |
| 2,300,157 | | |
| 548,626 | |
Net loss per common share attributable to common stockholders | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (4.57 | ) | |
$ | (0.91 | ) | |
$ | (8.65 | ) | |
$ | (4.66 | ) |
Diluted | |
$ | (1.49 | ) | |
$ | (0.91 | ) | |
$ | (2.66 | ) | |
$ | (4.64 | ) |
Net loss per common share from continuing operations | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (0.22 | ) | |
$ | (0.57 | ) | |
$ | (2.83 | ) | |
$ | (3.52 | ) |
Diluted | |
$ | (0.07 | ) | |
$ | (0.57 | ) | |
$ | (0.87 | ) | |
$ | (3.51 | ) |
Net loss per common share from discontinued operations | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (4.35 | ) | |
$ | (0.34 | ) | |
$ | (5.82 | ) | |
$ | (1.14 | ) |
Diluted | |
$ | (1.42 | ) | |
$ | (0.34 | ) | |
$ | (1.79 | ) | |
$ | (1.14 | ) |
Income taxes
The Company’s provision for income taxes was $0 for the three and nine months ended September 30, 2023, and
$0 for the three and nine months ended September 30, 2022, respectively. The income tax provisions for these three and nine month periods
are based upon estimates of annual income (loss), annual permanent differences and statutory tax rates in the various jurisdictions in
which the Company operates. For all periods presented, the Company utilized net operating loss carryforwards to offset the impact of any
taxable income. The Company’s tax rate differs from the applicable statutory rates due primarily to establishment of a valuation
allowance, utilization of deferred and the effect of permanent differences and adjustments.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//275/tableOfContent
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContent
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//250/tableOfContent
+ Details
Name: |
us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
GOING CONCERN
|
9 Months Ended |
Sep. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
GOING CONCERN |
NOTE
2 – GOING CONCERN
The
accompanying interim consolidated financial statements have been prepared assuming that the Company will continue as a going concern,
which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the
date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board, or the FASB, Accounting
Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether
there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern
within one year after the date that the financial statements are issued.
As
of September 30, 2023, the Company had a retained deficit of $21,529,975.
The Company has limited financial resources. As of September 30, 2023, the Company had a working capital deficit of $3,544,460 and
a cash balance of $34,031. The
Company will need to raise additional capital or secure debt funding to support on-going operations. The sources of this capital are
expected to be the sale of equity and debt, which may not be available on favorable terms, if at all, and may, if sold, cause
significant dilution to existing stockholders. If the Company is unable to access additional capital moving forward, it may hurt the
Company’s ability to grow and to generate future revenues, financial position, and liquidity. These factors raise substantial
doubt about the ability of the Company to continue as a going concern. Unless Management is able to obtain additional financing, it
is unlikely that the Company will be able to meet its funding requirements during the next 12 months. The financial statements do
not include any adjustments that might result from the outcome of this uncertainty.
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205-40/tableOfContent
+ Details
Name: |
us-gaap_SubstantialDoubtAboutGoingConcernTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
ACQUISITIONS AND DISPOSITIONS
|
9 Months Ended |
Sep. 30, 2023 |
Acquisitions And Dispositions |
|
ACQUISITIONS AND DISPOSITIONS |
NOTE
3 – ACQUISITIONS AND DISPOSITIONS
Acquisitions
- Provisional
Superlatus,
Inc.
On
July 31, 2023, the Company entered into the Merger Agreement (see Note 1) with Superlatus (“Seller”) whereby the Company
acquired 100%
of the stock of the Seller (the “Acquisition”). Superlatus includes a wholly-owned subsidiary, Sapientia. Consideration
for the Acquisition consisted of (i) 136,441
shares of the Company’s common stock at a fair value of $7.30
per share, representing 19.99%
of the total issued and outstanding share of the Company’s common stock at Closing, and (ii) 306,855
shares of the Company’s Series B Preferred Stock, a new class of the Company’s non-voting convertible preferred stock
with a conversion ratio of 100 to one. The total fair value of the common stock and Series B Preferred Stock on the Closing Date was
$225,000,169
(“Purchase Price”). On January 8, 2024, the Company entered into Amendment No. 1 to the Agreement and Plan of Merger
(the “Amendment”). Under the terms of the Amendment, the merger consideration to the shareholders of Superlatus was
adjusted to an aggregate of 136,441
shares of common stock of the Company, representing 19.99%
of the total issued and outstanding common stock of the Company after the consummation of the Merger and 15,759
shares of Company’s Series B Preferred Stock, par value $0.00001
per share, with a conversion ratio of 100
shares of Series B Preferred Stock to one share of common stock. The total fair value of the common stock and Series B Preferred
Stock on the Closing Date was adjusted to $12,500,089
(“Amended Purchase Price”). Additionally, the shareholders of Superlatus agreed to surrender back to the Company 289,731 shares of the Company’s
Series B Preferred Stock previously received before the amendment.
The
acquisition of Superlatus was accounted for as a business combination using the acquisition method pursuant to FASB ASC Topic 805. As
the acquirer for accounting purposes, the Company had estimated the Purchase Price, assets acquired and liabilities assumed as of the
acquisition date, with the excess of the Purchase Price over the fair value of net assets acquired recognized as goodwill. An independent
valuation expert assisted the Company in determining these fair values.
Accounting
guidance provides that an acquirer must recognize adjustments to provisional amounts that are identified during the measurement period,
which runs through July 31, 2024, in the measurement period in which the adjustment amounts are determined. The acquirer must record
in the financial statements, the effect on earnings of changes in depreciation, amortization or other income effects, if any, as a result
of the changes to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. Items that could
be subject to adjustment include credit fair value adjustments on loans, core deposit intangible and the deferred income tax assets resulting
from the acquisition.
The
provisional Amended Purchase Price allocation as of the acquisition date is presented as follows:
SCHEDULE
OF PURCHASE PRICE ALLOCATION
| |
July 31, 2023 | |
Purchase consideration: | |
| | |
Common Stock, at fair value | |
$ | 996,019 | |
Series B Preferred Stock, at fair value | |
| 11,504,070 | |
Total purchase consideration | |
$ | 12,500,089 | |
| |
| | |
Purchase price allocation: | |
| | |
Cash | |
$ | 5,546 | |
Prepaid expenses | |
| 3,705 | |
Inventory | |
| 122,792 | |
Intangible assets, net | |
| 9,777,478 | |
Goodwill | |
| 5,129,116 | |
Assets acquired | |
| 15,038,637 | |
Accounts payable and other current liabilities | |
| (633,548 | ) |
Notes payable | |
| (1,905,000 | ) |
Liabilities assumed | |
| (2,538,548 | ) |
Net assets acquired | |
$ | 12,500,089 | |
The
Urgent Company, Inc.
On
September 27, 2023, the Company entered into an Asset Purchase Agreement (“APA”) with The Urgent Company, Inc.
(“TUC”) and its wholly owned subsidiaries, pursuant to which, the Company was assigned certain inventory and property
and equipment and assumed certain operating leases for consideration of a $3,150,000
promissory note (“Purchase Price”, see Note 11). This acquisition is expected to enhance the
Company’s production of sustainable food products and enable the expansion of market share.
The
transaction was accounted for as an asset acquisition pursuant to FASB ASC Topic 805. As the acquirer
for accounting purposes, the Company allocated the cost of the asset acquisition to the assets acquired and liabilities assumed as of the acquisition
date based on their respective relative fair value as of the date of the transaction.
The
following summarizes the provisional relative fair values of the assets acquired as of the acquisition date based on the allocation
of the cost of the asset acquisition:
SCHEDULE
OF FAIR VALUES OF ASSETS ACQUIRED
| |
September 27, 2023 | |
Purchase consideration: | |
| | |
Promissory note | |
$ | 3,150,000 | |
Total purchase consideration | |
$ | 3,150,000 | |
| |
| | |
Allocation of cost of assets acquired: | |
| | |
Inventory | |
$ | 2,960,235 | |
Property and equipment | |
| 231,170 | |
Operating right-of-use assets | |
| 383,218 | |
Assets acquired | |
| 3,574,623 | |
Liabilities assumed | |
| (424,623 | ) |
Net assets acquired | |
$ | 3,150,000 | |
Dispositions
and Divestitures
SOSRx, LLC
On
and effective on, February 1, 2023, the Company, Exchange Health and SOSRx, entered into a Voluntary Withdrawal and Release Agreement,
which was replaced in its entirety, corrected, and became effective on February 4, 2023 (as replaced and corrected, the “Release
Agreement”).
As
part of the Release Agreement, a note payable to Exchange Health was forgiven in the amount of $500,000 and $15,000 in accounts payable
was waived. Effective February 4, 2023, the operations of SOSRx were discontinued and operations were shut down. As a result of this,
the assets and liabilities of SOSRx have been reflected as assets and liabilities of discontinued operations in the Company’s consolidated
balance sheets. As of September 30, 2023 and December 31, 2022 as follows:
SCHEDULE OF FINANCIAL STATEMENTS OF DISCONTINUED OPERATIONS
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Cash | |
$ | - | | |
$ | 22,474 | |
Accounts receivable | |
| - | | |
| 363 | |
Total assets of discontinued operations | |
$ | - | | |
$ | 22,837 | |
| |
| | | |
| | |
Accounts payable | |
$ | - | | |
$ | 46,500 | |
Total liabilities of discontinued operations | |
$ | - | | |
$ | 46,500 | |
The
terms of the Release Agreement qualifies the transaction as a discontinued operation in accordance with U.S. GAAP. As a result,
operating results and cash flows related to the SOSRx operations have been reflected as discontinued operations in the
Company’s consolidated statements of operations, consolidated statements of cash flows and consolidated statements of
shareholders’ equity.
Alliance Pharma Solutions, LLC and Community Specialty
Pharmacy, LLC
On August 22, 2023, the Company
and Wood Sage, LCC (“Wood Sage”) entered into a Membership Interest Purchase Agreement, pursuant to which the Company sold
100% of the membership interest in Alliance Pharma Solutions, LLC (“ASP MIPA”) for consideration of a $125,000 promissory
note (“ASP Sale Price”) and a Membership Interest Purchase Agreement, pursuant to which the Company sold 100% of the membership
interest in Community Specialty Pharmacy, LLC (“CSP MIPA”) in exchange for a $ promissory note (“CSP Sale Price”).
The divestiture
of APS and CSP represents an intentional strategic shift in the Company’s operations and will allow the Company to become focused
on food technology As a result, the results of APS and CSP were classified as discontinued operations in our condensed statements of operations
and excluded from both continuing operations and segment results for the three and nine months ended September 30, 2022.
As part
of recognizing the business as held for sale in accordance with U.S. GAAP, the Company was required to measure APS and CSP at the lower
of its carrying amount or fair value less cost to sell. As a result of this analysis, during the three and nine months ended September
30, 2023, the Company recognized a non-cash, pre-tax loss on disposal of $3,209,776. The loss is included in “Net loss from discontinued
operations” in the consolidated statements of operations. The loss was determined by comparing the fair value of the consideration
received for the sale of a 100% interest in APS and CSP with the net assets of APS and CSP, respectively, immediately prior to the transaction.
As a result of the transactions, the following assets and liabilities of APS and CSP were transferred to Wood Sage
as of August 22, 2023:
SCHEDULE
OF ASSETS AND LIABILITIES
| |
Alliance Pharma Solutions, LLC | | |
Community Specialty Pharmacy, LLC | |
Cash | |
$ | 1,050 | | |
$ | 61,988 | |
Accounts receivable, net | |
| - | | |
| 11,452 | |
Inventory | |
| - | | |
| 123,230 | |
Prepaid assets | |
| - | | |
| 525 | |
Intangible assets and capitalized software, net | |
| 739,337 | | |
| - | |
Accounts payable | |
| (23,982 | ) | |
| (231,876 | ) |
Accrued liabilities | |
| - | | |
| (10,182 | ) |
Net assets sold | |
$ | 716,405 | | |
$ | (44,863 | ) |
Discontinued Operations
The results of operations from discontinued operations for the three and nine months ended September 30, 2023 and
2022, have been reflected as discontinued operations in the consolidated statements of operations and consist of the following:
SCHEDULE
OF DISCONTINUED OPERATIONS
| |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
| |
| |
2023 | | |
2022 | |
| |
SOSRx | | |
APS | | |
CSP | | |
Total | |
| |
Three Months Ended September 30, | | |
Three Months Ended September 30, | | |
Three Months Ended September 30, | | |
Three Months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue | |
$ | - | | |
$ | 3,368 | | |
$ | - | | |
$ | - | | |
$ | 124,238 | | |
$ | 341,140 | | |
$ | 124,238 | | |
$ | 344,508 | |
Cost of sales | |
| - | | |
| - | | |
| - | | |
| - | | |
| 127,671 | | |
| 314,945 | | |
| 127,671 | | |
| 314,945 | |
Gross profit | |
| - | | |
| 3,368 | | |
| - | | |
| - | | |
| (3,433 | ) | |
| 26,195 | | |
| (3,433 | ) | |
| 29,563 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Operating expenses | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Wage and salary expense | |
| - | | |
| 17,689 | | |
| - | | |
| - | | |
| 108,772 | | |
| 70,002 | | |
| 108,772 | | |
| 87,691 | |
Professional fees | |
| - | | |
| - | | |
| - | | |
| 10,471 | | |
| 18,079 | | |
| 2,094 | | |
| 18,079 | | |
| 12,565 | |
Accounting and legal expense | |
| - | | |
| - | | |
| 1,948 | | |
| 104 | | |
| 700 | | |
| 500 | | |
| 2,648 | | |
| 604 | |
Technology expense | |
| - | | |
| 23,000 | | |
| 4,177 | | |
| 31,564 | | |
| 2,231 | | |
| 5,445 | | |
| 6,408 | | |
| 60,009 | |
General and administrative | |
| - | | |
| 29,907 | | |
| 134 | | |
| 3,527 | | |
| 4,257 | | |
| 25,428 | | |
| 4,391 | | |
| 58,862 | |
Total operating expense | |
| - | | |
| 70,596 | | |
| 6,259 | | |
| 45,666 | | |
| 134,039 | | |
| 103,469 | | |
| 140,298 | | |
| 219,731 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Operating loss from discontinued operations | |
| - | | |
| (67,228 | ) | |
| (6,259 | ) | |
| (45,666 | ) | |
| (137,472 | ) | |
| (77,274 | ) | |
| (143,731 | ) | |
| (190,168 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Other income (expense) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Gain (loss) on disposal of assets | |
| - | | |
| - | | |
| (1,783,209 | ) | |
| 1,900 | | |
| (1,426,567 | ) | |
| - | | |
| (3,209,776 | ) | |
| 1,900 | |
Total other income (expense) | |
| - | | |
| - | | |
| (1,783,209 | ) | |
| 1,900 | | |
| (1,426,567 | ) | |
| - | | |
| (3,209,776 | ) | |
| 1,900 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Loss from discontinued operations | |
$ | - | | |
$ | (67,228 | ) | |
$ | (1,789,468 | ) | |
$ | (43,766 | ) | |
$ | (1,564,039 | ) | |
$ | (77,274 | ) | |
$ | (3,353,507 | ) | |
$ | (188,268 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Loss per common share from discontinued operations | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | - | | |
$ | (0.12 | ) | |
$ | (2.32 | ) | |
$ | (0.08 | ) | |
$ | (2.03 | ) | |
$ | (0.14 | ) | |
$ | (4.35 | ) | |
$ | (0.34 | ) |
Diluted | |
$ | - | | |
$ | (0.12 | ) | |
$ | (0.76 | ) | |
$ | (0.08 | ) | |
$ | (0.66 | ) | |
$ | (0.14 | ) | |
$ | (1.42 | ) | |
$ | (0.34 | ) |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
| |
| |
2023 | | |
2022 | |
| |
SOSRx | | |
ASP | | |
CSP | | |
Total | |
| |
Nine months ended September 30, | | |
Nine months ended September 30, | | |
Nine months ended September 30, | | |
Nine months ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue | |
$ | - | | |
$ | 20,424 | | |
$ | - | | |
$ | - | | |
$ | 761,306 | | |
$ | 905,083 | | |
$ | 761,306 | | |
$ | 925,507 | |
Cost of sales | |
| - | | |
| - | | |
| - | | |
| - | | |
| 705,206 | | |
| 1,019,470 | | |
| 705,206 | | |
| 1,019,470 | |
Gross profit | |
| - | | |
| 20,424 | | |
| - | | |
| - | | |
| 56,100 | | |
| (114,387 | ) | |
| 56,100 | | |
| (93,963 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Operating expenses | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Wage and salary expense | |
| - | | |
| 54,939 | | |
| - | | |
| - | | |
| 456,297 | | |
| 180,819 | | |
| 456,297 | | |
| 235,758 | |
Professional fees | |
| - | | |
| - | | |
| 3,125 | | |
| 44,962 | | |
| 20,246 | | |
| 5,572 | | |
| 23,371 | | |
| 50,534 | |
Accounting and legal expense | |
| - | | |
| - | | |
| 7,773 | | |
| 104 | | |
| 63,000 | | |
| 500 | | |
| 70,773 | | |
| 604 | |
Technology expense | |
| - | | |
| 53,910 | | |
| 20,611 | | |
| 83,659 | | |
| 9,464 | | |
| 13,989 | | |
| 30,075 | | |
| 151,558 | |
General and administrative | |
| - | | |
| 33,873 | | |
| 3,762 | | |
| 10,761 | | |
| 32,830 | | |
| 47,945 | | |
| 36,592 | | |
| 92,579 | |
Total operating expense | |
| - | | |
| 142,722 | | |
| 35,271 | | |
| 139,486 | | |
| 581,837 | | |
| 248,825 | | |
| 617,108 | | |
| 531,033 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Operating loss from discontinued operations | |
| - | | |
| (122,298 | ) | |
| (35,271 | ) | |
| (139,486 | ) | |
| (525,737 | ) | |
| (363,212 | ) | |
| (561,008 | ) | |
| (624,996 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Other income (expense) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Gain (loss) on disposal of assets | |
| (352,244 | ) | |
| - | | |
| (1,783,209 | ) | |
| 1,900 | | |
| (1,426,567 | ) | |
| - | | |
| (3,562,020 | ) | |
| 1,900 | |
Total other income (expense) | |
| (352,244 | ) | |
| - | | |
| (1,783,209 | ) | |
| 1,900 | | |
| (1,426,567 | ) | |
| - | | |
| (3,562,020 | ) | |
| 1,900 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Loss from discontinued operations | |
$ | (352,244 | ) | |
$ | (122,298 | ) | |
$ | (1,818,480 | ) | |
$ | (137,586 | ) | |
$ | (1,952,304 | ) | |
$ | (363,212 | ) | |
$ | (4,123,028 | ) | |
$ | (623,096 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Loss per common share from discontinued operations | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (0.50 | ) | |
$ | (0.22 | ) | |
$ | (2.57 | ) | |
$ | (0.25 | ) | |
$ | (2.76 | ) | |
$ | (0.66 | ) | |
$ | (5.82 | ) | |
$ | (1.14 | ) |
Diluted | |
$ | (0.15 | ) | |
$ | (0.22 | ) | |
$ | (0.79 | ) | |
$ | (0.25 | ) | |
$ | (0.85 | ) | |
$ | (0.66 | ) | |
$ | (1.79 | ) | |
$ | (1.14 | ) |
|
X |
- DefinitionAcquisitions And Dispositions [Text Block]
+ References
+ Details
Name: |
MEDS_AcquisitionsAndDispositionsTextBlock |
Namespace Prefix: |
MEDS_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
MEDS_DisclosureAcquisitionsAndDispositionsAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
RELATED PARTY TRANSACTIONS
|
9 Months Ended |
Sep. 30, 2023 |
Related Party Transactions [Abstract] |
|
RELATED PARTY TRANSACTIONS |
NOTE
4- RELATED PARTY TRANSACTIONS
On
April 1, 2023 and July 1, 2023 the Company entered into a relationship with Scietech, LLC (“Scietech”) in an independent
contractor agreement to consult on increasing sales on the IPS and Trxade Inc. platforms. The agreement was for an annual fee of
$400,000 to be split
equally between IPS and Trxade Inc. A 31%
investor in Scietech is the spouse of the interim CFO, Prashant Patel, which qualifies as a related party. The company was chosen
because they were the most qualified to perform the desired qualifications.
On
February 15, 2022, the Company entered into a relationship with Exchange Health, a technology company providing an online platform for
manufacturers and suppliers to sell and purchase pharmaceuticals. In connection therewith, SOSRx was formed
in February 2022, which is owned 51% by the Company and 49% by Exchange Health. On February 15, 2022, the Company contributed cash to
SOSRx in the amount of $325,000, issued a promissory note to SOSRx in the amount of $500,000, which was immediately assigned to Exchange
Health (the “Promissory Note”), and agreed to make an earn out payment of up to $400,000, payable, at the Company’s
discretion, in cash or common stock of the Company, based on SOSRx achieving certain revenue targets of SOSRx (the “Earn Out Payments”);
and entered into a Distribution Services Agreement with SOSRx (the “Distribution Agreement”). Exchange Health contributed
$792,000 in software and contracts which was recorded as an intangible asset on the balance sheet of SOSRx. The intangible asset was
determined to be impaired and was written off on December 31, 2022.
At
September 30, 2023, total related party debt was $0.
On
and effective on, February 1, 2023, the Company, Exchange Health and SOSRx, entered into a Voluntary Withdrawal and Release Agreement,
which was replaced in its entirety and corrected on February 4, 2023 and effective February 4, 2023 (as replaced and corrected, the “Release
Agreement”). Pursuant to the Release Agreement, the Company voluntarily withdrew as a member of SOSRx pursuant to the terms of
the Operating Agreement of SOSRx, which provided that the Company would withdraw from SOSRx if certain revenue targets were not met,
which targets have not been met.
Also
pursuant to the Withdrawal Agreement, (a) the Company agreed to the termination of its interests in SOSRx and its withdrawal as a member
thereof for no consideration (the “Withdrawal”); (b) the Promissory Note, and all of the Company’s obligations under
such Promissory Note were terminated; and (c) the parties agreed that no Earn Out Payments will be due. The Release Agreement also (i)
provides that all accumulated losses of SOSRx through December 20, 2022, will be allocated 51% to the Company and 49% to Exchange Health;
(ii) provides for a total of approximately $15,000 in outstanding invoices owed by the Company to SOSRx to be waived; (iii) includes
certain indemnification obligations of SOSRx and Exchange Health; (iv) requires SOSRx to pay certain pre-agreed outstanding invoices
of SOSRx; (v) includes mutual releases of the Company and SOSRx and Exchange Health; and (vi) includes customary representations and
warranties of the parties.
|
X |
- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//850/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
+ Details
Name: |
us-gaap_RelatedPartyTransactionsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
REVENUE RECOGNITION
|
9 Months Ended |
Sep. 30, 2023 |
Revenue Recognition |
|
REVENUE RECOGNITION |
NOTE
5 – REVENUE RECOGNITION
The
Company derives revenue from two primary sources—product revenue and service revenue.
Product
revenue consists of shipments of:
| ● | Resale
of pharmaceutical products to pharmacies; and |
Revenues
for our products are recognized and invoiced when the product is shipped to the customer.
Service
revenue consists primarily of:
| ● | Transaction
fees from the facilitation of buyer generated purchase orders to suppliers, billed monthly; |
| ● | Data
service fees associated with providing vendors of pharmaceutical products with data analysis
of their catalogues and branding of their products or company to the Company’s registered
buyers, billed monthly or as a one-time fee; and |
| ● | Software-as-a-Service
(“SaaS”) fees for a platform for virtual healthcare provider visits, billed monthly. |
Revenues
for the Company’s services that are billed monthly are recognized and invoiced when the at the beginning of the month. Revenues
for one-time services are recognized at the point in time when services are rendered.
Payment
terms for products and services are generally 0 to 60 days and the Company has no contract assets or liabilities.
The
following table presents disaggregated revenue by major product and service categories during the three and nine months ended September
30, 2023 and 2022:
SCHEDULE
OF DISAGGREGATED REVENUE
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
Three months ended September 30, | | |
Nine months ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Product revenues | |
| | | |
| | | |
| | | |
| | |
Pharmaceutical product resale income | |
$ | 394,849 | | |
$ | 707,807 | | |
$ | 1,237,731 | | |
$ | 3,949,771 | |
Total product revenues | |
$ | 394,849 | | |
$ | 707,807 | | |
$ | 1,237,731 | | |
$ | 3,949,771 | |
| |
| | | |
| | | |
| | | |
| | |
Service revenues | |
| | | |
| | | |
| | | |
| | |
Transaction fee income | |
$ | 1,617,129 | | |
$ | 1,319,483 | | |
$ | 4,531,731 | | |
$ | 3,947,621 | |
Data service fee income | |
| 46,050 | | |
| 17,950 | | |
| 132,025 | | |
| 54,050 | |
SaaS fee income | |
| - | | |
| 10,563 | | |
| 18,299 | | |
| 42,363 | |
Total service revenues | |
$ | 1,663,179 | | |
$ | 1,347,996 | | |
$ | 4,682,055 | | |
$ | 4,044,034 | |
Total revenues | |
$ | 2,058,028 | | |
$ | 2,055,803 | | |
$ | 5,919,786 | | |
$ | 7,993,805 | |
|
X |
- References
+ Details
Name: |
MEDS_DisclosureRevenueRecognitionAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRevenue Recognition Disclosure [Text Block]
+ References
+ Details
Name: |
MEDS_RevenueRecognitionDisclosureTextBlock |
Namespace Prefix: |
MEDS_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
INVENTORY
|
9 Months Ended |
Sep. 30, 2023 |
Inventory Disclosure [Abstract] |
|
INVENTORY |
NOTE
6 – INVENTORY
Inventory
value is determined using the weighted average cost method and is stated at the lower of cost or net realizable value. As of September
30, 2023 and December 31, 2022, inventory was comprised of the following:
SCHEDULE
OF INVENTORY
As of | |
September 30, 2023 | | |
December 31, 2022 | |
Raw materials | |
$ | 1,895,406 | | |
$ | 68,448 | |
Finished goods | |
| 1,131,512 | | |
| - | |
Inventory | |
$ | 3,026,918 | | |
$ | 68,448 | |
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent
+ Details
Name: |
us-gaap_InventoryDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
NOTES RECEIVABLE
|
9 Months Ended |
Sep. 30, 2023 |
Receivables [Abstract] |
|
NOTES RECEIVABLE |
NOTE
7 – NOTES RECEIVABLE
On
August 22, 2023, issued a Promissory Note Agreement (the “Wood Sage Note”) in the amount of $1,300,000 to Wood Sage, LLC
and entered into the APS MIPA and CSP MIPA for the Company to sell APS and CSP and entered into a Master Service Agreement (“Wood
Sage MSA”). The Wood Sage Note bears no interest and is due and payable within thirty days of a change in control, as defined by
the Wood Sage Note, of the borrower. As of September 30, 2023, the outstanding balance of the Wood Sage Note was $1,275,000.
|
X |
- DefinitionThe entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//310-10/tableOfContent
+ Details
Name: |
us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_ReceivablesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
INTANGIBLE ASSETS
|
9 Months Ended |
Sep. 30, 2023 |
Goodwill and Intangible Assets Disclosure [Abstract] |
|
INTANGIBLE ASSETS |
NOTE
8 – INTANGIBLE ASSETS
As
of September 30, 2023, intangible assets, net consisted of the following:
SCHEDULE
OF INTANGIBLE ASSETS NET
| |
Weighted Average | | |
| | |
| | |
| |
| |
Useful Life | | |
| | |
Accumulated | | |
| |
| |
(years) | | |
Cost | | |
Amortization | | |
Net | |
Developed technology | |
| 5.0 | | |
$ | 9,777,478 | | |
$ | (325,916 | ) | |
$ | 9,451,562 | |
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all or part of the information related to intangible assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350-30/tableOfContent
+ Details
Name: |
us-gaap_IntangibleAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
OTHER CURRENT LIABILITIES
|
9 Months Ended |
Sep. 30, 2023 |
Other Liabilities Disclosure [Abstract] |
|
OTHER CURRENT LIABILITIES |
NOTE
9 – OTHER CURRENT LIABILITIES
As
of September 30, 2023 and December 31, 2022, other current liabilities consisted of the following:
SCHEDULE
OF OTHER CURRENT LIABILITIES
| |
September 30, 2023 | | |
December 31, 2022 | |
Purchase price payable | |
$ | 350,000 | | |
$ | - | |
Insurance refunds payable | |
| 62,390 | | |
| 62,390 | |
Deferred revenue | |
| - | | |
| 5,127 | |
Other current liabilities | |
$ | 412,390 | | |
$ | 67,517 | |
|
X |
- References
+ Details
Name: |
us-gaap_OtherLiabilitiesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for other liabilities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20,24) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherLiabilitiesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
CONTINGENT FUNDING LIABILITIES
|
9 Months Ended |
Sep. 30, 2023 |
Contingent Funding Liabilities |
|
CONTINGENT FUNDING LIABILITIES |
NOTE
10 – CONTINGENT FUNDING LIABILITIES
On
June 27, 2023, the Company entered into a non-recourse funding agreement with a third-party for the purchase and sale of future receivables
(the “Receivables Agreement”). Pursuant to the Receivables Agreement, the third-party agreed to fund the Company $1,250,000
to purchase $1,800,000 of future receivables. Under the funding agreement, the third-party receives a priority interest in the receivables
of Trxade Inc. The Company also paid $62,500 as a one-time origination fee in connection with the Receivables Agreement. The Receivables
Agreement also allows for the third-party funder to file UCCs securing their interest in the receivables and includes customary events
of default. As of September 30, 2023, the Company owed $452,348 under this agreement.
On
March 14, 2023, the Company entered into a non-recourse funding agreement with a third-party for the purchase and sale of future receivables
(the “Receivables Agreement”). Pursuant to the Receivables Agreement, the third-party agreed to fund the Company $875,000
to purchase $1,224,000 of future receivables. Under the funding agreement, the third-party receives a priority interest in the receivables
of Trxade Inc. The Company also paid $42,500 as a one-time origination fee in connection with the Receivables Agreement. The Receivables
Agreement also allows for the third-party funder to file UCCs securing their interest in the receivables and includes customary events
of default.
On
September 14, 2022, the Company entered into a non-recourse funding agreement with a third-party for the purchase and sale of future
receivables (the “Receivables Agreement”). Pursuant to the Receivables Agreement, the third-party agreed to fund the Company
$275,000 to purchase $396,000 of future receivables. Under the funding agreement, the third-party receives a priority interest in the
receivables of Trxade Inc. The Company also paid $15,000 as a one-time origination fee in connection with the Receivables Agreement.
The Receivables Agreement also allows for the third-party funder to file UCCs securing their interest in the receivables and includes
customary events of default. This agreement was fully paid off in January 2023.
On
June 27, 2022, the Company entered into a non-recourse funding agreement with a third-party funder for the purchase and sale of future
receivables. Pursuant to the Receivables Agreement, the third-party agreed to fund the Company $550,000 to purchase $792,000 of future
receivables. Under the funding agreement, the third-party receives a priority interest in the receivables of Trxade Inc. The Company
also paid $27,500 as a one-time origination fee in connection with the Receivables Agreement. The Receivables Agreement also allows for
the third-party funder to file UCCs securing their interest in the receivables and includes customary events of default. This agreement
was fully paid off in January 2023.
The
Company’s relationship with the funding source meets the criteria in ASC 470-10-25 – Sales of Future Revenues or Various
Other Measures of Income (“ASC 470”), which relates to cash received from a funding source in exchange for a specified percentage
or amount of revenue or other measure of income of a particular product line, business segment, trademark, patent or contractual right
for a defined period. Under this guidance, the Company recognized the fair value of its contingent obligation to the funding source,
as of the acquisition date, as a current liability in its consolidated balance sheet.
Under
ASC 470, amounts recorded as debt are to be amortized under the interest method. The Company made an accounting policy election to
utilize the prospective method when there is a change in the estimated future cash flows, whereby a new effective interest rate is
determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value
of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest
expense for the remaining period. Under this method, the effective interest rate is not constant, and any change in expected cash
flows is recognized prospectively as an adjustment to the effective yield. As of September 30, 2023 and December 31, 2022 the total
contingent funding liability was $452,348
and $108,036, respectively, and the effective interest rate was approximately 31%
and 31%, respectively. This rate represents the discount rate that equates the estimated future cash flows with the fair value of the debt and is used to
compute the amount of interest to be recognized each period. Any future payments made to the funding source will decrease the
contingent funding liability balance accordingly.
|
X |
- DefinitionContigent Funding Liabilities Disclosure [TextBlock]
+ References
+ Details
Name: |
MEDS_ContigentFundingLiabilitiesDisclosureTextBlock |
Namespace Prefix: |
MEDS_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
MEDS_DisclosureContingentFundingLiabilitiesAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
NOTES PAYABLE
|
9 Months Ended |
Sep. 30, 2023 |
Debt Disclosure [Abstract] |
|
NOTES PAYABLE |
NOTE
11 – NOTES PAYABLE
On
September 27, 2023, the Company issued a promissory note to Perfect Day, Inc. (the “Perfect Day Note”) in the amount of $3,150,000
as consideration for the TUC APA (see Note 3). The promissory note does not accrue interest and is payable upon demand at any time after
October 31, 2023. The entire aggregate, unpaid principal sum of the note is immediately due and payable upon the occurrence of a change
in control, as defined in the agreement.
On
September 14, 2023, the Company issued a promissory note to Danam Health, Inc. (the “Danam Note”) in the amount of $300,000.
The Company received a deposit of $200,000 on September 14, 2023 and an additional deposit of $100,000 on October 13, 2023. The Danam
Note accrues interest at 0% per annum and is due and payable no later than 30 days after a change in control of borrower, as defined
in the note agreement. As of September 30, 2023, the balance of the Danam Note is $200,000. The Company repaid $250,000 on the loan in
October 2023. As of the date of this filing, the balance on the loan is $50,000.
On
June 16, 2023, the Company issued a secured debenture to Eat Well Investment Group, Inc. (the “Eat Well June 2023 Note”)
in the amount of $1,150,000 for the purchase of Sapientia, a wholly-owned subsidiary of Superlatus. The Eat Well June 2023 Note is secured
by 100% of the membership interests in Sapientia. The Eat Well June 2023 Note began accruing interest at 12% per annum, compounded monthly,
as of October 31, 2023. The Eat Well June 2023 matured on December 31, 2023. As of September 30, 2023, the balance of the Eat Well June
2023 Note is $1,150,000. As of the date of this filing, the parties are working on an amendment for an extension.
On
February 8, 2023, Sapientia, a wholly-owned subsidiary of Superlatus, entered into a Loan Agreement with Eat Well Investment Group, Inc.
(the “Eat Well February 2023 Note”) in the amount of $25,000. The Eat Well February 2023 Note is unsecured, accrues interest
at a rate of 1.87% per annum, and matures February 7, 2025. As of September 30, 2023, the balance of the Eat Well February 2023 Note
is $25,000. The Company has accrued interest of $350 as of September 30, 2023.
On
September 14, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well September 2022
Note”) in the amount of $50,000. The Eat Well September 2022 Note is unsecured, accrues interest at a rate of 1.87% per annum,
and matures September 13, 2024. As of September 30, 2023, the balance of the Eat Well September 2022 Note is $50,000. The Company has
accrued interest of $1,140 as of September 30, 2023.
On
July 26, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well July 26, 2022 Note”)
in the amount of $35,000. The Eat Well July 26, 2022 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matures July
25, 2024. As of September 30, 2023, the balance of the Eat Well July 26, 2022 Note is $35,000. The Company has accrued interest of $798
as of September 30, 2023.
On
July 12, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well July 12, 2022 Note”)
in the amount of $25,000. The Eat Well July 12, 2022 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matures July
11, 2024. As of September 30, 2023, the balance of the Eat Well July 12, 2022 Note is $25,000. The Company has accrued interest of $585
as of September 30, 2023.
On
March 15, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well March 2022 Note”)
in the amount of $100,000. The Eat Well March 2022 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matures March
14, 2024. As of September 30, 2023, the balance of the Eat Well March 2022 Note is $100,000. The Company has accrued interest of $2,966
as of September 30, 2023.
On
February 1, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well February 2022 Note”)
in the amount of $100,000. The Eat Well February 2022 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matures February
1, 2024. As of September 30, 2023, the balance of the Eat Well February 2022 Note is $100,000. The Company has accrued interest of $3,110
as of September 30, 2023.
On
January 20, 2022, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well January 2022 Note”)
in the amount of $20,000. The Eat Well January 2022 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matures January
20, 2024. As of September 30, 2023, the balance of the Eat Well January 2022 Note is $20,000. The Company has accrued interest of $653
as of September 30, 2023.
On
December 24, 2021, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well December 2021 Note”)
in the amount of $100,000. The Eat Well December 2021 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matured December
24, 2023. As of September 30, 2023, the balance of the Eat Well December 2021 Note is $100,000. The Company has accrued interest of $3,427
as of September 30, 2023. As of the date of this filing, the parties are working on an amendment for an extension.
On
November 10, 2021, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well November 2021 Note”)
in the amount of $50,000. The Eat Well Novemer 2021 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matured November
10, 2023. As of September 30, 2023, the balance of the Eat Well November 2021 Note is $50,000. The Company has accrued interest of $1,790
as of September 30, 2023. As of the date of this filing, the parties are working on an amendment for an extension.
On
August 18, 2021, Sapientia entered into a Loan Agreement with Eat Well Investment Group, Inc. (the “Eat Well August 2021 Note”)
in the amount of $250,000. The Eat Well August 2021 Note is unsecured, accrues interest at a rate of 1.87% per annum, and matured August
18, 2023. As of September 30, 2023, the balance of the Eat Well August 2021 Note is $250,000. The Company has accrued interest of $9,900
as of September 30, 2023. As of the date of this filing, the parties are working on an amendment for an extension.
The
following table summarizes notes payable balances as of September 30, 2023:
SCHEDULE OF
NOTES PAYABLE BALANCES
| |
Current | | |
Noncurrent | | |
| | |
Accrued | |
| |
Portion | | |
Portion | | |
Total | | |
Interest | |
| |
Current Portion | | |
Non current Portion | | |
Note
Payable Total | | |
Accrued Interest | |
Perfect Day Note | |
$ | 3,150,000 | | |
$ | - | | |
$ | 3,150,000 | | |
$ | - | |
Danam Note | |
| 200,000 | | |
| - | | |
| 200,000 | | |
| - | |
Eat Well June 2023 Note | |
| 1,150,000 | | |
| - | | |
| 1,150,000 | | |
| - | |
Eat Well February 2023 Note | |
| - | | |
| 25,000 | | |
| 25,000 | | |
| 350 | |
Eat Well September 2022 Note | |
| 50,000 | | |
| - | | |
| 50,000 | | |
| 1,104 | |
Eat Well July 26, 2022 Note | |
| 35,000 | | |
| - | | |
| 35,000 | | |
| 798 | |
Eat Well July 12, 2022 Note | |
| 25,000 | | |
| - | | |
| 25,000 | | |
| 585 | |
Eat Well March 2022 Note | |
| 100,000 | | |
| - | | |
| 100,000 | | |
| 2,966 | |
Eat Well February 2022 Note | |
| 100,000 | | |
| - | | |
| 100,000 | | |
| 3,110 | |
Eat Well January 2022 Note | |
| 20,000 | | |
| - | | |
| 20,000 | | |
| 653 | |
Eat Well December 2021 Note | |
| 100,000 | | |
| - | | |
| 100,000 | | |
| 3,427 | |
Eat Well November 2021 Note | |
| 50,000 | | |
| - | | |
| 50,000 | | |
| 1,790 | |
Eat Well August 2021 Note | |
| 250,000 | | |
| - | | |
| 250,000 | | |
| 9,900 | |
| |
$ | 5,230,000 | | |
$ | 25,000 | | |
$ | 5,255,000 | | |
$ | 24,683 | |
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContent
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
+ Details
Name: |
us-gaap_DebtDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
STOCKHOLDERS’ EQUITY
|
9 Months Ended |
Sep. 30, 2023 |
Equity [Abstract] |
|
STOCKHOLDERS’ EQUITY |
NOTE 12 – STOCKHOLDERS’ EQUITY
Designation
of Series B Preferred Stock
Effective
June 26, 2023 the Company’s Board of Directors issued a Certificate of Designation, which designated 787,754
shares of the Company’s authorized and unissued preferred stock as convertible Series B Preferred Stock at a par value of
$0.00001
per share.
2023
1:15 Stock Split
Effective
June 21, 2023 the Company executed a 1:15 reverse stock split for stockholders of record on that date. This was executed to comply with
the Nasdaq Listing Rule 5550(a)(2) to have the price of the stock above $1.
2022
Equity Compensation Awards
Effective
September 1, 2022, the Board of Directors and Compensation Committee of the Company, with the approval of each of the following officers,
agreed to reduce the annual cash compensation payable to Suren Ajjarapu, the Company’s Chief Executive Officer; Prashant Patel,
the Company’s President and Chief Operating Officer and Janet Huffman, the Company’s former Chief Financial Officer, in an
effort to conserve cash.
In
lieu of the reduced cash salary payable to each officer, the Board and Compensation Committee agreed to issue such officers shares of
the Company’s common stock equal to the amount of reduced cash salary, divided by the closing sales price of the Company’s
common stock on the NASDAQ Capital Market on August 31, 2022, the date approved by the Board of Directors. The total amount of shares
of common stock issued on August 31, 2022 to the officers was 5,460.
The
shares of common stock issuable to the officers vested at the rate of 1/4th of such shares on each of September 30, 2022, October 31, 2022,
November 30, 2022, and December 31, 2022, subject to each applicable Officer’s continued service to the Company on such dates and
subject to the restricted stock award agreements entered into as evidence of such awards.
Separately,
certain employees of the Company agreed to reduce their cash salaries by an aggregate of $37,000 in consideration for an aggregate of
2,126 shares of the Company’s restricted common stock, with the same vesting terms as the officer shares discussed above.
Effective
on August 31, 2022, the Board of Directors approved the issuance of 3,635 shares of common stock of the Company to each independent member
of the Board of Directors, for services rendered to the Company during fiscal 2022, which shares were valued at $63,250, based on the
closing sales price of the Company’s common stock on the date approved by the Board of Directors. The shares vested at the rate of
1/4th of such shares immediately on the grant date, and 1/4th of such shares on each of October 1, 2022, January 1, 2023 and April 1,
2023, subject to each applicable independent director’s continued service to the Company on such dates.
All
of the awards discussed above were issued under the Company’s Second Amended and Restated 2019 Equity Incentive Plan (the “Plan”)
and all restricted stock awards discussed above were evidenced by Restricted Stock Grant Agreements.
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
PREFUNDED AND PRIVATE PLACEMENT WARRANTS
|
9 Months Ended |
Sep. 30, 2023 |
Prefunded And Private Placement Warrants |
|
PREFUNDED AND PRIVATE PLACEMENT WARRANTS |
NOTE
13 – PREFUNDED AND PRIVATE PLACEMENT WARRANTS
On October 4, 2022 the Company entered into a securities purchase agreement (the “Purchase Agreement”)
with a certain institutional investor (the “Purchaser”) which provided for the sale and issuance by the Company of (i) the
Company’s common stock (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) and (iii)
warrants (the “Private Placement Warrants” and, together with the Shares and the Pre-Funded Warrants, the “Securities”).
The Private Placement Warrants were sold in a concurrent private placement (the “Private Placement”), exempt from registration
pursuant to Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933, as amended (the “Securities Act”).
Simultaneously
with the closing of the stock placement, the investor pre-purchased 40,116
Private Warrants at a purchase price of $17.25
per warrant. The Pre-Funded Warrants are immediately exercisable into one share of common stock per warrant, have an exercise price of $0.00015
per share, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. On January 4, 2023, the
investor exercised the 40,116
warrants for a purchase price of $6.02.
The investor was issued the shares on this date. Each Private Warrant has an exercise price of $22.50
per share, will be exercisable following Stockholder Approval, which was obtained in December 2022, and will expire on the fifth
anniversary of the date on which the Private Warrants become exercisable. The Private Warrants contain standard adjustments to the
exercise price including for stock splits, stock dividend, rights offerings and pro rata distributions, and include full ratchet
anti-dilutive rights in the event the Company issues shares of Common Stock or Common Stock equivalents within fifteen months of the
initial exercise date, with a value less than the then exercise price of such Private Warrants, subject to certain customary
exceptions, and further subject to a minimum exercise price of $3.48
per share. The Private Warrants also include certain rights upon ‘fundamental transactions’ as described in the Private
Warrants, including allowing the holders thereof to require that the Company re-purchase such Private Warrants at the Black Scholes
Value of such securities.
|
X |
- References
+ Details
Name: |
MEDS_DisclosurePrefundedAndPrivatePlacementWarrantsAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrefunded and Private Placement Warrants Disclosure [Text Block]
+ References
+ Details
Name: |
MEDS_PrefundedAndPrivatePlacementWarrantsDisclosureTextBlock |
Namespace Prefix: |
MEDS_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
WARRANTS
|
9 Months Ended |
Sep. 30, 2023 |
Warrants |
|
WARRANTS |
NOTE
14 – WARRANTS
For
the nine-month period ended September 30, 2023, no warrants were granted, and none expired. For the nine-month period ended September
30, 2023, 40,116 prefunded warrants and 1,795 granted warrants to purchase shares of common stock were exercised for a total purchase
price of $1,622. See Note 13- Prefunded and Private Placement Warrants for further description.
The
Company uses the Black-Scholes pricing model to estimate the fair value of stock-based awards on the date of the grant.
There
was no compensation cost related to the warrants for the nine months ended September 30, 2023, and 2022, respectively.
The
Company’s outstanding and exercisable warrants As of September 30, 2023, are presented below:
SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS
| |
Number Outstanding | | |
Weighted Average Exercise Price | | |
Contractual Life In Years | | |
Intrinsic Value | |
Warrants outstanding as of December 31, 2022 | |
| 179,331 | | |
| 22.50 | | |
| 4.72 | | |
| 6,731 | |
Warrants granted | |
| | | |
| - | | |
| - | | |
| - | |
Warrants forfeited, expired, cancelled | |
| | | |
| - | | |
| - | | |
| - | |
Warrants exercised | |
| (1,795 | ) | |
| 22.50 | | |
| - | | |
| - | |
Warrants outstanding as of September 30, 2023 | |
| 177,536 | | |
| 22.50 | | |
| 4.02 | | |
| 0 | |
Warrants exercisable as of September 30, 2023 | |
| 177,536 | | |
| 22.50 | | |
| 4.02 | | |
| - | |
|
X |
- References
+ Details
Name: |
MEDS_DisclosureWarrantsAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
MEDS_WarrantsTextBlock |
Namespace Prefix: |
MEDS_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
OPTIONS
|
9 Months Ended |
Sep. 30, 2023 |
Share-Based Payment Arrangement [Abstract] |
|
OPTIONS |
NOTE
15 – OPTIONS
The
Company maintains stock option plans under which certain employees are awarded option grants based on a combination of performance and
tenure. The stock option plans provide for the grant of up to 155,556 shares, and the Company’s Second Amended and Restated 2019
Equity Incentive Plan provides for automatic increases in the number of shares available under such plan (currently 133,333 shares) on
April 1st of each calendar year, beginning in 2021 and ending in 2029 (each a “Date of Determination”), in each
case subject to the approval and determination of the administrator of the plan (the Board of Directors or Compensation Committee) on
or prior to the applicable Date of Determination, equal to the lesser of (A) ten percent (10%) of the total shares of common stock of
the Company outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares as determined
by the administrator. The administrator as a result of the annual meeting shareholder vote increased the number of shares available to
grant to employees under the 2019 incentive plan by 2 million. The administrator did not approve an increase in the number of shares
covered under the plan as of April 1, 2022.
For
the nine-month period ended September 30, 2023, 603 options to purchase shares were granted, 140 options to purchase shares were forfeited
and 2,319 options expired. For the nine-month period ended September 30, 2023, no options to purchase shares of common stock were exercised.
Total
compensation cost related to stock options granted was $25,978 and $67,439 for the nine-months ended September 30, 2023, and 2022, respectively.
The
following table represents stock option activity for the nine-month period ended September 30, 2023:
SCHEDULE OF STOCK OPTION ACTIVITY
| |
Number Outstanding | | |
Weighted- Average Exercise Price | | |
Weighted- Average Contractual Life in Years | | |
Intrinsic Value | |
Options outstanding as of December 31, 2022 | |
| 19,708 | | |
$ | 66.00 | | |
| 3.92 | | |
$ | - | |
Options exercisable as of December 31, 2022 | |
| 17,167 | | |
| 66.30 | | |
| 3.89 | | |
| - | |
Options granted | |
| 603 | | |
| 6.08 | | |
| 4.51 | | |
| 59,976 | |
Options forfeited | |
| (140 | ) | |
| 82.33 | | |
| 2.00 | | |
| - | |
Options expired | |
| (2,319 | ) | |
| 89.88 | | |
| 0.08 | | |
| - | |
Options exercised | |
| - | | |
| - | | |
| - | | |
| - | |
Options outstanding As of September 30, 2023 | |
| 17,852 | | |
| 66.10 | | |
| 3.95 | | |
| 112,073 | |
Options exercisable As of September 30, 2023 | |
| 17,252 | | |
| 62.43 | | |
| 2.99 | | |
| 52,097 | |
|
X |
- DefinitionThe entire disclosure for share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
CONTINGENCIES
|
9 Months Ended |
Sep. 30, 2023 |
Commitments and Contingencies Disclosure [Abstract] |
|
CONTINGENCIES |
NOTE
16 – CONTINGENCIES
Studebaker
Defense Group, LLC
In
July 2020, the Company’s wholly-owned subsidiary, IPS, entered into an agreement with Studebaker Defense Group, LLC
(“Studebaker”) wherein IPS would pay Studebaker a down payment of $550,000
and Studebaker would deliver 180,000
boxes of nitrile gloves by August 14, 2020. IPS wired the $550,000
to Studebaker, but to date, Studebaker has not delivered the gloves or provided a refund of the deposit. In December 2020, we filed
a complaint against Studebaker in Florida state court, Case No. 20-CA-010118 in the Circuit Court for the Thirteenth Judicial
Circuit in Hillsborough County, for among other things, breach of contract. Studebaker did not answer the complaint, nor did counsel
for Studebaker file an appearance. Accordingly, in February 2021, the Company filed for a default judgment; however, on March 22,
2021, counsel for Studebaker filed an appearance and shortly thereafter filed a motion totion vacate the default judgment and
dismiss the complaint on jurisdictional grounds. The court granted Studebaker’s motion to set aside the default judgment but
denied the motion to dismiss. The Company has filed several pretrial motions; the next step in the litigation after the pre-trial
motions are resolved will be a motion for summary judgment. The Company believes it will prevail on the merits but cannot determine
the timing of the judgment or the amount ultimately collected. At June 30, 2021, the $500,000
was recorded as Loss on Inventory Investment. The Company won this case but has not collected any settlement yet, another lawsuit
has been filed to collect.
On
April 13, 2023, a settlement was reached in the Studebaker Defense Group LLC. and IPS legal case. The court found in favor of IPS
and ordered Studebaker Defense Group, LLC. to pay $550,000 IPS. The payments were to commence on May 1, 2023 and continue monthly in 17 installments until the full
amount is paid in full but as of the filing date, no payment has been received by IPS.
Sandwave
Group Dsn Bhd and Crecom Burj Group SDN BHD
In
August 2020, IPS entered into an agreement with Sandwave Group Dsn Bhd (“Sandwave”), wherein IPS would pay Sandwave a
down payment of $581,250
and Sandwave’s supplier, Crecom Burj Group SDN BHD (“Crecom”), would deliver 150,000
boxes of nitrile gloves within 45 days. IPS wired the $581,250
to Sandwave, which in turn wired the purchase price to Crecom, which Crecom accepted; however, to date, Crecom has not delivered the
nitrile gloves. IPS demanded return of its $581,250
and Crecom acknowledged that IPS was entitled to a refund. As of February 2021, Crecom had not returned any funds and IPS filed a
complaint against Crecom in Malaysia: Case No. WA-22NCC-55-02/2021 in the High Court of Malaysia at Kuala Lumpur in the Federal
Territory, Malaysia for the Malaysian equivalent of breach of contract. On September 1, 2022 counsel for Crecom informed the court
that Crecom had been wound up on August 23, 2022; under Section 471 of the Malaysian Companies Act 2016, the suit filed by IPS was
stayed until leave of the court is obtained to proceed. Given this new information regarding Crecom the Company has decided at this
time to stop its pursuit of this lawsuit until or unless additional information is obtained by counsel for IPS. At June 30,
2021, the $581,250
was recorded as Loss on Inventory Investment.
GSG
PPE, LLC
On
November 19, 2021, IPS filed a complaint against GSG PPE, LLC (“GSG”) and Gary Waxman (“Waxman”), the owner,
alleging three counts of breach of contract for a purchase agreement, a promissory note, and a personal guaranty. Collectively, the
company alleges that GSG and Waxman have materially breached all three contracts. In late 2020, GSG and IPS executed a valid initial
contract setting the terms of a business transaction. GSG failed to pay IPS approximately 75% of the amount owed to IPS. GSG
acknowledged it owed the money and executed a promissory note in favor of IPS in the amount of $630,000
which matured on September 30, 2021. The note provides for attorney fees and interest in addition to the $630,000.
Waxman’s personal guaranty confirmed that GSG owed IPS $630,000.
On September 30, 2021, the $630,000
was recorded as Bad Debt Expense. A settlement was entered into between the parties in June 2022, whereby GSG and Waxman agreed to
pay $743,000 which included
attorney fees and interest, which is required to be paid to the Company in monthly installments over 17 months. The Company received
additional monthly installment payments as part of the agreement through January 2023. As of September 30, 2023, and through the
date of this filing, the Company has not received the monthly installment payments due to the Company from GSG since January
of 2023.
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//450-20/tableOfContent
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//450-30/tableOfContent
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483049/450-30-50-1
+ Details
Name: |
us-gaap_LossContingencyDisclosures |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
SEGMENT REPORTING
|
9 Months Ended |
Sep. 30, 2023 |
Segment Reporting [Abstract] |
|
SEGMENT REPORTING |
NOTE
17 – SEGMENT REPORTING
Operating
segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly
by the chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company’s chief
operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth
opportunities of each respective segment.
The
Company classifies its business interests into reportable segments which are:
|
● |
Trxade,
Inc. - Web based pharmaceutical marketplace platform – B2B sales |
|
● |
IPS
- Integra Pharma, LLC - Licensed wholesaler of brand, generic and non-drug products – B2B sales |
|
● |
Superlatus
– holds Sapientia’s intellectual property for advanced food extrusion technology and The Urgent Company – Manufacturer
of ice cream that is animal product-free, vegan, lactose-free, and made with plants – B2B sales |
|
● |
Unallocated - Other – corporate overhead expense, discontinued operations and Bonum Health, LLC. |
SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS
Nine
months ended September 30, 2023 | |
Trxade, Inc. | | |
IPS | | |
Superlatus | | |
Unallocated | | |
Total | |
Revenue | |
$ | 4,663,756 | | |
$ | 1,237,731 | | |
$ | - | | |
$ | 18,299 | | |
$ | 5,919,786 | |
Gross Profit | |
| 4,663,756 | | |
| 165,553 | | |
| (756 | ) | |
| 18,299 | | |
| 4,846,852 | |
Segment Assets | |
| - | | |
| - | | |
| 18,029,077 | | |
| 3,624,766 | | |
| 21,653,843 | |
Segment Profit (Loss) | |
| 1,570,796 | | |
| (388,900 | ) | |
| (440,268 | ) | |
| (6,869,237 | ) | |
| (6,127,609 | ) |
Cost of Sales | |
| - | | |
| 1,072,178 | | |
| 756 | | |
| - | | |
| 1,072,934 | |
Nine months ended September 30, 2022 | |
Trxade, Inc. | | |
IPS | | |
Superlatus | | |
Unallocated | | |
Total | |
Revenue | |
$ | 4,001,670 | | |
$ | 3,949,772 | | |
$ | - | | |
$ | 42,363 | | |
$ | 7,993,805 | |
Gross Profit | |
| 4,001,670 | | |
| (41,462 | ) | |
| - | | |
| 42,363 | | |
| 4,002,571 | |
Segment Assets | |
| 1,853,474 | | |
| 454,783 | | |
| - | | |
| 2,172,060 | | |
| 4,480,317 | |
Segment Profit (Loss) | |
| 1,320,138 | | |
| (493,203 | ) | |
| - | | |
| (3,433,774 | ) | |
| (2,606,839 | ) |
Cost of Sales | |
| - | | |
| 3,991,234 | | |
| - | | |
| - | | |
| 3,991,234 | |
|
X |
- References
+ Details
Name: |
us-gaap_SegmentReportingAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContent
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
+ Details
Name: |
us-gaap_SegmentReportingDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
SUBSEQUENT EVENTS
|
9 Months Ended |
Sep. 30, 2023 |
Subsequent Events [Abstract] |
|
SUBSEQUENT EVENTS |
NOTE
18 – SUBSEQUENT EVENTS
Stock
Swap Agreement
Upon
conclusion of the Stock Swap Transaction and Merger (see Note 1), the remaining operations within TRxADE will only consist of legacy
Superlatus operations. Management has determined that Superlatus will be the accounting acquirer in the merger based upon a detailed
analysis of the relevant U.S. GAAP guidance and the facts and circumstances outlined above. Consequently, Superlatus will apply acquisition
accounting to the assets and liabilities of TRxADE that are acquired or assumed upon the consummation of the merger. The historical financial
statements of Superlatus for periods ended prior to the consummation of the merger will reflect only the operations and financial condition
of Superlatus. Subsequent to the consummation of the merger, the financial statements of Superlatus will include the combined operations
and financial condition of Superlatus and remaining TRxADE operations.
As
a condition and inducement to Superlatus’s willingness to enter into the Merger Agreement, on June 28, 2023, Suren Ajjarapu and
Prashant Patel (the “Principal Stockholders”) entered into an agreement with the Company (the “Stock Swap Agreement”),
pursuant to which, the Company will transfer all of the shares or membership interest of a variety of operating subsidiaries currently
owned by the Company to Principal Stockholders, in exchange for Suren Ajjarapu to surrender 85,000 shares of the common stock of the
Company and Prashant Patel to surrender 81,666 shares of the common stock of the Company (the “Stock Swap Transaction”).
The closing of the Stock Swap Transaction shall take place simultaneously with the approval by the Company’s stockholders of the
conversion of the Series B preferred Stock into common stock. As of the date of this filing, the stockholders have not approved the conversion.
As discussed in Note 1 and Note
3, the closing conditions were not met and the Merger Agreement was amended on January 8, 2024.
Spero Asset
Purchase Agreement
On October
4, 2023, the Company entered into an all-cash asset purchase agreement to acquire the assets of Spero Foods, Inc. for $500,000. As of
the date of this filing, the Company is still working to complete the purchase.
Unregistered Sales of
Equity Securities Hudson Global Ventures, LLC
On October 4, 2023,
the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Hudson Global Ventures, LLC (the
“Purchaser”), pursuant to which the Company sold, in a private placement, (i) 290 shares of the Company’s Series C
Convertible Preferred Stock (the “Series C Preferred Stock”), stated value $1,000 per share (the “Stated Value”),
at a price of $1,000 per share, convertible into shares (the “Conversion Shares”) of the Company’s common stock, par
value $0.00001 per share (the “Common Stock”) and (ii) a warrant (the “Warrant”) to purchase up to 41,193 shares
of Common Stock. As additional consideration for entering into the Purchase Agreement, the Company issued to the Purchaser an additional
40,000 shares of Common Stock to be delivered to the Purchaser at the closing (the “Commitment Shares,” together with the
Series C Preferred Shares and the Warrant, the “Securities”). The offering resulted in gross proceeds to the company of $290,000.
Non-recourse funding agreement
On October 25, 2023,
the Company entered into a non-recourse funding agreement with a third-party for the purchase and sale of future receivables (the “Receivables
Agreement”). Pursuant to the Receivables Agreement, the third-party agreed to fund the Company $1,200,000 to purchase $1,728,000
of future receivables. Under the funding agreement, the third-party receives a priority interest in the receivables of Trxade Inc. The
Company also paid $60,000 as a one-time origination fee in connection with the Receivables Agreement. The Receivables Agreement also
allows for the third-party funder to file UCCs securing their interest in the receivables and includes customary events of default.
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//855/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
ORGANIZATION AND BASIS OF PRESENTATION (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Accounting Policies [Abstract] |
|
SCHEDULE OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE |
The
following table sets forth the computation of basic and diluted loss per share:
SCHEDULE
OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
For the Three Months Ended
September 30, | | |
For the Nine Months Ended
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Numerator: | |
| | | |
| | | |
| | | |
| | |
Net loss from continuing operations | |
$ | (171,607 | ) | |
$ | (314,735 | ) | |
$ | (2,004,581 | ) | |
$ | (1,923,817 | ) |
Net loss from discontinued operations | |
$ | (3,353,507 | ) | |
$ | (188,268 | ) | |
| (4,123,028 | ) | |
$ | (623,096 | ) |
Numerator for basic and diluted EPS - income available to common stockholders | |
| (3,525,114 | ) | |
$ | (503,003 | ) | |
| (6,127,609 | ) | |
$ | (2,546,913 | ) |
Denominator: | |
| | | |
| | | |
| | | |
| | |
Denominator for EPS – weighted average shares | |
| | | |
| | | |
| | | |
| | |
Basic | |
| 771,192 | | |
| 549,977 | | |
| 708,116 | | |
| 546,879 | |
Diluted | |
| 2,363,233 | | |
| 551,724 | | |
| 2,300,157 | | |
| 548,626 | |
Net loss per common share attributable to common stockholders | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (4.57 | ) | |
$ | (0.91 | ) | |
$ | (8.65 | ) | |
$ | (4.66 | ) |
Diluted | |
$ | (1.49 | ) | |
$ | (0.91 | ) | |
$ | (2.66 | ) | |
$ | (4.64 | ) |
Net loss per common share from continuing operations | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (0.22 | ) | |
$ | (0.57 | ) | |
$ | (2.83 | ) | |
$ | (3.52 | ) |
Diluted | |
$ | (0.07 | ) | |
$ | (0.57 | ) | |
$ | (0.87 | ) | |
$ | (3.51 | ) |
Net loss per common share from discontinued operations | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (4.35 | ) | |
$ | (0.34 | ) | |
$ | (5.82 | ) | |
$ | (1.14 | ) |
Diluted | |
$ | (1.42 | ) | |
$ | (0.34 | ) | |
$ | (1.79 | ) | |
$ | (1.14 | ) |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
ACQUISITIONS AND DISPOSITIONS (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Acquisitions And Dispositions |
|
SCHEDULE OF PURCHASE PRICE ALLOCATION |
The
provisional Amended Purchase Price allocation as of the acquisition date is presented as follows:
SCHEDULE
OF PURCHASE PRICE ALLOCATION
| |
July 31, 2023 | |
Purchase consideration: | |
| | |
Common Stock, at fair value | |
$ | 996,019 | |
Series B Preferred Stock, at fair value | |
| 11,504,070 | |
Total purchase consideration | |
$ | 12,500,089 | |
| |
| | |
Purchase price allocation: | |
| | |
Cash | |
$ | 5,546 | |
Prepaid expenses | |
| 3,705 | |
Inventory | |
| 122,792 | |
Intangible assets, net | |
| 9,777,478 | |
Goodwill | |
| 5,129,116 | |
Assets acquired | |
| 15,038,637 | |
Accounts payable and other current liabilities | |
| (633,548 | ) |
Notes payable | |
| (1,905,000 | ) |
Liabilities assumed | |
| (2,538,548 | ) |
Net assets acquired | |
$ | 12,500,089 | |
|
SCHEDULE OF FAIR VALUES OF ASSETS ACQUIRED |
The
following summarizes the provisional relative fair values of the assets acquired as of the acquisition date based on the allocation
of the cost of the asset acquisition:
SCHEDULE
OF FAIR VALUES OF ASSETS ACQUIRED
| |
September 27, 2023 | |
Purchase consideration: | |
| | |
Promissory note | |
$ | 3,150,000 | |
Total purchase consideration | |
$ | 3,150,000 | |
| |
| | |
Allocation of cost of assets acquired: | |
| | |
Inventory | |
$ | 2,960,235 | |
Property and equipment | |
| 231,170 | |
Operating right-of-use assets | |
| 383,218 | |
Assets acquired | |
| 3,574,623 | |
Liabilities assumed | |
| (424,623 | ) |
Net assets acquired | |
$ | 3,150,000 | |
|
SCHEDULE OF FINANCIAL STATEMENTS OF DISCONTINUED OPERATIONS |
SCHEDULE OF FINANCIAL STATEMENTS OF DISCONTINUED OPERATIONS
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Cash | |
$ | - | | |
$ | 22,474 | |
Accounts receivable | |
| - | | |
| 363 | |
Total assets of discontinued operations | |
$ | - | | |
$ | 22,837 | |
| |
| | | |
| | |
Accounts payable | |
$ | - | | |
$ | 46,500 | |
Total liabilities of discontinued operations | |
$ | - | | |
$ | 46,500 | |
|
SCHEDULE OF ASSETS AND LIABILITIES |
As a result of the transactions, the following assets and liabilities of APS and CSP were transferred to Wood Sage
as of August 22, 2023:
SCHEDULE
OF ASSETS AND LIABILITIES
| |
Alliance Pharma Solutions, LLC | | |
Community Specialty Pharmacy, LLC | |
Cash | |
$ | 1,050 | | |
$ | 61,988 | |
Accounts receivable, net | |
| - | | |
| 11,452 | |
Inventory | |
| - | | |
| 123,230 | |
Prepaid assets | |
| - | | |
| 525 | |
Intangible assets and capitalized software, net | |
| 739,337 | | |
| - | |
Accounts payable | |
| (23,982 | ) | |
| (231,876 | ) |
Accrued liabilities | |
| - | | |
| (10,182 | ) |
Net assets sold | |
$ | 716,405 | | |
$ | (44,863 | ) |
|
SCHEDULE OF DISCONTINUED OPERATIONS |
SCHEDULE
OF DISCONTINUED OPERATIONS
| |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
| |
| |
2023 | | |
2022 | |
| |
SOSRx | | |
APS | | |
CSP | | |
Total | |
| |
Three Months Ended September 30, | | |
Three Months Ended September 30, | | |
Three Months Ended September 30, | | |
Three Months Ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue | |
$ | - | | |
$ | 3,368 | | |
$ | - | | |
$ | - | | |
$ | 124,238 | | |
$ | 341,140 | | |
$ | 124,238 | | |
$ | 344,508 | |
Cost of sales | |
| - | | |
| - | | |
| - | | |
| - | | |
| 127,671 | | |
| 314,945 | | |
| 127,671 | | |
| 314,945 | |
Gross profit | |
| - | | |
| 3,368 | | |
| - | | |
| - | | |
| (3,433 | ) | |
| 26,195 | | |
| (3,433 | ) | |
| 29,563 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Operating expenses | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Wage and salary expense | |
| - | | |
| 17,689 | | |
| - | | |
| - | | |
| 108,772 | | |
| 70,002 | | |
| 108,772 | | |
| 87,691 | |
Professional fees | |
| - | | |
| - | | |
| - | | |
| 10,471 | | |
| 18,079 | | |
| 2,094 | | |
| 18,079 | | |
| 12,565 | |
Accounting and legal expense | |
| - | | |
| - | | |
| 1,948 | | |
| 104 | | |
| 700 | | |
| 500 | | |
| 2,648 | | |
| 604 | |
Technology expense | |
| - | | |
| 23,000 | | |
| 4,177 | | |
| 31,564 | | |
| 2,231 | | |
| 5,445 | | |
| 6,408 | | |
| 60,009 | |
General and administrative | |
| - | | |
| 29,907 | | |
| 134 | | |
| 3,527 | | |
| 4,257 | | |
| 25,428 | | |
| 4,391 | | |
| 58,862 | |
Total operating expense | |
| - | | |
| 70,596 | | |
| 6,259 | | |
| 45,666 | | |
| 134,039 | | |
| 103,469 | | |
| 140,298 | | |
| 219,731 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Operating loss from discontinued operations | |
| - | | |
| (67,228 | ) | |
| (6,259 | ) | |
| (45,666 | ) | |
| (137,472 | ) | |
| (77,274 | ) | |
| (143,731 | ) | |
| (190,168 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Other income (expense) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Gain (loss) on disposal of assets | |
| - | | |
| - | | |
| (1,783,209 | ) | |
| 1,900 | | |
| (1,426,567 | ) | |
| - | | |
| (3,209,776 | ) | |
| 1,900 | |
Total other income (expense) | |
| - | | |
| - | | |
| (1,783,209 | ) | |
| 1,900 | | |
| (1,426,567 | ) | |
| - | | |
| (3,209,776 | ) | |
| 1,900 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Loss from discontinued operations | |
$ | - | | |
$ | (67,228 | ) | |
$ | (1,789,468 | ) | |
$ | (43,766 | ) | |
$ | (1,564,039 | ) | |
$ | (77,274 | ) | |
$ | (3,353,507 | ) | |
$ | (188,268 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Loss per common share from discontinued operations | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | - | | |
$ | (0.12 | ) | |
$ | (2.32 | ) | |
$ | (0.08 | ) | |
$ | (2.03 | ) | |
$ | (0.14 | ) | |
$ | (4.35 | ) | |
$ | (0.34 | ) |
Diluted | |
$ | - | | |
$ | (0.12 | ) | |
$ | (0.76 | ) | |
$ | (0.08 | ) | |
$ | (0.66 | ) | |
$ | (0.14 | ) | |
$ | (1.42 | ) | |
$ | (0.34 | ) |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
| |
| |
2023 | | |
2022 | |
| |
SOSRx | | |
ASP | | |
CSP | | |
Total | |
| |
Nine months ended September 30, | | |
Nine months ended September 30, | | |
Nine months ended September 30, | | |
Nine months ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue | |
$ | - | | |
$ | 20,424 | | |
$ | - | | |
$ | - | | |
$ | 761,306 | | |
$ | 905,083 | | |
$ | 761,306 | | |
$ | 925,507 | |
Cost of sales | |
| - | | |
| - | | |
| - | | |
| - | | |
| 705,206 | | |
| 1,019,470 | | |
| 705,206 | | |
| 1,019,470 | |
Gross profit | |
| - | | |
| 20,424 | | |
| - | | |
| - | | |
| 56,100 | | |
| (114,387 | ) | |
| 56,100 | | |
| (93,963 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Operating expenses | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Wage and salary expense | |
| - | | |
| 54,939 | | |
| - | | |
| - | | |
| 456,297 | | |
| 180,819 | | |
| 456,297 | | |
| 235,758 | |
Professional fees | |
| - | | |
| - | | |
| 3,125 | | |
| 44,962 | | |
| 20,246 | | |
| 5,572 | | |
| 23,371 | | |
| 50,534 | |
Accounting and legal expense | |
| - | | |
| - | | |
| 7,773 | | |
| 104 | | |
| 63,000 | | |
| 500 | | |
| 70,773 | | |
| 604 | |
Technology expense | |
| - | | |
| 53,910 | | |
| 20,611 | | |
| 83,659 | | |
| 9,464 | | |
| 13,989 | | |
| 30,075 | | |
| 151,558 | |
General and administrative | |
| - | | |
| 33,873 | | |
| 3,762 | | |
| 10,761 | | |
| 32,830 | | |
| 47,945 | | |
| 36,592 | | |
| 92,579 | |
Total operating expense | |
| - | | |
| 142,722 | | |
| 35,271 | | |
| 139,486 | | |
| 581,837 | | |
| 248,825 | | |
| 617,108 | | |
| 531,033 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Operating loss from discontinued operations | |
| - | | |
| (122,298 | ) | |
| (35,271 | ) | |
| (139,486 | ) | |
| (525,737 | ) | |
| (363,212 | ) | |
| (561,008 | ) | |
| (624,996 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Other income (expense) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Gain (loss) on disposal of assets | |
| (352,244 | ) | |
| - | | |
| (1,783,209 | ) | |
| 1,900 | | |
| (1,426,567 | ) | |
| - | | |
| (3,562,020 | ) | |
| 1,900 | |
Total other income (expense) | |
| (352,244 | ) | |
| - | | |
| (1,783,209 | ) | |
| 1,900 | | |
| (1,426,567 | ) | |
| - | | |
| (3,562,020 | ) | |
| 1,900 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Loss from discontinued operations | |
$ | (352,244 | ) | |
$ | (122,298 | ) | |
$ | (1,818,480 | ) | |
$ | (137,586 | ) | |
$ | (1,952,304 | ) | |
$ | (363,212 | ) | |
$ | (4,123,028 | ) | |
$ | (623,096 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Loss per common share from discontinued operations | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (0.50 | ) | |
$ | (0.22 | ) | |
$ | (2.57 | ) | |
$ | (0.25 | ) | |
$ | (2.76 | ) | |
$ | (0.66 | ) | |
$ | (5.82 | ) | |
$ | (1.14 | ) |
Diluted | |
$ | (0.15 | ) | |
$ | (0.22 | ) | |
$ | (0.79 | ) | |
$ | (0.25 | ) | |
$ | (0.85 | ) | |
$ | (0.66 | ) | |
$ | (1.79 | ) | |
$ | (1.14 | ) |
|
X |
- References
+ Details
Name: |
MEDS_DisclosureAcquisitionsAndDispositionsAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSchedule of Assets and Liabilities [Table Text Block]
+ References
+ Details
Name: |
MEDS_ScheduleOfAssetsAndLiabilitiesTableTextBlock |
Namespace Prefix: |
MEDS_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSchedule Of Discontinued Operations [Table Text Block]
+ References
+ Details
Name: |
MEDS_ScheduleOfDiscontinuedOperationsTableTextBlock |
Namespace Prefix: |
MEDS_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5D -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3
+ Details
Name: |
us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Paragraph 1 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
REVENUE RECOGNITION (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Revenue Recognition |
|
SCHEDULE OF DISAGGREGATED REVENUE |
SCHEDULE
OF DISAGGREGATED REVENUE
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
Three months ended September 30, | | |
Nine months ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Product revenues | |
| | | |
| | | |
| | | |
| | |
Pharmaceutical product resale income | |
$ | 394,849 | | |
$ | 707,807 | | |
$ | 1,237,731 | | |
$ | 3,949,771 | |
Total product revenues | |
$ | 394,849 | | |
$ | 707,807 | | |
$ | 1,237,731 | | |
$ | 3,949,771 | |
| |
| | | |
| | | |
| | | |
| | |
Service revenues | |
| | | |
| | | |
| | | |
| | |
Transaction fee income | |
$ | 1,617,129 | | |
$ | 1,319,483 | | |
$ | 4,531,731 | | |
$ | 3,947,621 | |
Data service fee income | |
| 46,050 | | |
| 17,950 | | |
| 132,025 | | |
| 54,050 | |
SaaS fee income | |
| - | | |
| 10,563 | | |
| 18,299 | | |
| 42,363 | |
Total service revenues | |
$ | 1,663,179 | | |
$ | 1,347,996 | | |
$ | 4,682,055 | | |
$ | 4,044,034 | |
Total revenues | |
$ | 2,058,028 | | |
$ | 2,055,803 | | |
$ | 5,919,786 | | |
$ | 7,993,805 | |
|
X |
- References
+ Details
Name: |
MEDS_DisclosureRevenueRecognitionAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
+ Details
Name: |
us-gaap_DisaggregationOfRevenueTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
INVENTORY (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Inventory Disclosure [Abstract] |
|
SCHEDULE OF INVENTORY |
SCHEDULE
OF INVENTORY
As of | |
September 30, 2023 | | |
December 31, 2022 | |
Raw materials | |
$ | 1,895,406 | | |
$ | 68,448 | |
Finished goods | |
| 1,131,512 | | |
| - | |
Inventory | |
$ | 3,026,918 | | |
$ | 68,448 | |
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfInventoryCurrentTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
OTHER CURRENT LIABILITIES (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Other Liabilities Disclosure [Abstract] |
|
SCHEDULE OF OTHER CURRENT LIABILITIES |
As
of September 30, 2023 and December 31, 2022, other current liabilities consisted of the following:
SCHEDULE
OF OTHER CURRENT LIABILITIES
| |
September 30, 2023 | | |
December 31, 2022 | |
Purchase price payable | |
$ | 350,000 | | |
$ | - | |
Insurance refunds payable | |
| 62,390 | | |
| 62,390 | |
Deferred revenue | |
| - | | |
| 5,127 | |
Other current liabilities | |
$ | 412,390 | | |
$ | 67,517 | |
|
X |
- DefinitionTabular disclosure of other current liabilities.
+ References
+ Details
Name: |
us-gaap_OtherCurrentLiabilitiesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OtherLiabilitiesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
NOTES PAYABLE (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Debt Disclosure [Abstract] |
|
SCHEDULE OF NOTES PAYABLE BALANCES |
The
following table summarizes notes payable balances as of September 30, 2023:
SCHEDULE OF
NOTES PAYABLE BALANCES
| |
Current | | |
Noncurrent | | |
| | |
Accrued | |
| |
Portion | | |
Portion | | |
Total | | |
Interest | |
| |
Current Portion | | |
Non current Portion | | |
Note
Payable Total | | |
Accrued Interest | |
Perfect Day Note | |
$ | 3,150,000 | | |
$ | - | | |
$ | 3,150,000 | | |
$ | - | |
Danam Note | |
| 200,000 | | |
| - | | |
| 200,000 | | |
| - | |
Eat Well June 2023 Note | |
| 1,150,000 | | |
| - | | |
| 1,150,000 | | |
| - | |
Eat Well February 2023 Note | |
| - | | |
| 25,000 | | |
| 25,000 | | |
| 350 | |
Eat Well September 2022 Note | |
| 50,000 | | |
| - | | |
| 50,000 | | |
| 1,104 | |
Eat Well July 26, 2022 Note | |
| 35,000 | | |
| - | | |
| 35,000 | | |
| 798 | |
Eat Well July 12, 2022 Note | |
| 25,000 | | |
| - | | |
| 25,000 | | |
| 585 | |
Eat Well March 2022 Note | |
| 100,000 | | |
| - | | |
| 100,000 | | |
| 2,966 | |
Eat Well February 2022 Note | |
| 100,000 | | |
| - | | |
| 100,000 | | |
| 3,110 | |
Eat Well January 2022 Note | |
| 20,000 | | |
| - | | |
| 20,000 | | |
| 653 | |
Eat Well December 2021 Note | |
| 100,000 | | |
| - | | |
| 100,000 | | |
| 3,427 | |
Eat Well November 2021 Note | |
| 50,000 | | |
| - | | |
| 50,000 | | |
| 1,790 | |
Eat Well August 2021 Note | |
| 250,000 | | |
| - | | |
| 250,000 | | |
| 9,900 | |
| |
$ | 5,230,000 | | |
$ | 25,000 | | |
$ | 5,255,000 | | |
$ | 24,683 | |
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.
+ References
+ Details
Name: |
us-gaap_ScheduleOfDebtTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
WARRANTS (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Warrants |
|
SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS |
The
Company’s outstanding and exercisable warrants As of September 30, 2023, are presented below:
SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS
| |
Number Outstanding | | |
Weighted Average Exercise Price | | |
Contractual Life In Years | | |
Intrinsic Value | |
Warrants outstanding as of December 31, 2022 | |
| 179,331 | | |
| 22.50 | | |
| 4.72 | | |
| 6,731 | |
Warrants granted | |
| | | |
| - | | |
| - | | |
| - | |
Warrants forfeited, expired, cancelled | |
| | | |
| - | | |
| - | | |
| - | |
Warrants exercised | |
| (1,795 | ) | |
| 22.50 | | |
| - | | |
| - | |
Warrants outstanding as of September 30, 2023 | |
| 177,536 | | |
| 22.50 | | |
| 4.02 | | |
| 0 | |
Warrants exercisable as of September 30, 2023 | |
| 177,536 | | |
| 22.50 | | |
| 4.02 | | |
| - | |
|
X |
- References
+ Details
Name: |
MEDS_DisclosureWarrantsAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
OPTIONS (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Share-Based Payment Arrangement [Abstract] |
|
SCHEDULE OF STOCK OPTION ACTIVITY |
The
following table represents stock option activity for the nine-month period ended September 30, 2023:
SCHEDULE OF STOCK OPTION ACTIVITY
| |
Number Outstanding | | |
Weighted- Average Exercise Price | | |
Weighted- Average Contractual Life in Years | | |
Intrinsic Value | |
Options outstanding as of December 31, 2022 | |
| 19,708 | | |
$ | 66.00 | | |
| 3.92 | | |
$ | - | |
Options exercisable as of December 31, 2022 | |
| 17,167 | | |
| 66.30 | | |
| 3.89 | | |
| - | |
Options granted | |
| 603 | | |
| 6.08 | | |
| 4.51 | | |
| 59,976 | |
Options forfeited | |
| (140 | ) | |
| 82.33 | | |
| 2.00 | | |
| - | |
Options expired | |
| (2,319 | ) | |
| 89.88 | | |
| 0.08 | | |
| - | |
Options exercised | |
| - | | |
| - | | |
| - | | |
| - | |
Options outstanding As of September 30, 2023 | |
| 17,852 | | |
| 66.10 | | |
| 3.95 | | |
| 112,073 | |
Options exercisable As of September 30, 2023 | |
| 17,252 | | |
| 62.43 | | |
| 2.99 | | |
| 52,097 | |
|
X |
- DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
SEGMENT REPORTING (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
Segment Reporting [Abstract] |
|
SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS |
SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS
Nine
months ended September 30, 2023 | |
Trxade, Inc. | | |
IPS | | |
Superlatus | | |
Unallocated | | |
Total | |
Revenue | |
$ | 4,663,756 | | |
$ | 1,237,731 | | |
$ | - | | |
$ | 18,299 | | |
$ | 5,919,786 | |
Gross Profit | |
| 4,663,756 | | |
| 165,553 | | |
| (756 | ) | |
| 18,299 | | |
| 4,846,852 | |
Segment Assets | |
| - | | |
| - | | |
| 18,029,077 | | |
| 3,624,766 | | |
| 21,653,843 | |
Segment Profit (Loss) | |
| 1,570,796 | | |
| (388,900 | ) | |
| (440,268 | ) | |
| (6,869,237 | ) | |
| (6,127,609 | ) |
Cost of Sales | |
| - | | |
| 1,072,178 | | |
| 756 | | |
| - | | |
| 1,072,934 | |
Nine months ended September 30, 2022 | |
Trxade, Inc. | | |
IPS | | |
Superlatus | | |
Unallocated | | |
Total | |
Revenue | |
$ | 4,001,670 | | |
$ | 3,949,772 | | |
$ | - | | |
$ | 42,363 | | |
$ | 7,993,805 | |
Gross Profit | |
| 4,001,670 | | |
| (41,462 | ) | |
| - | | |
| 42,363 | | |
| 4,002,571 | |
Segment Assets | |
| 1,853,474 | | |
| 454,783 | | |
| - | | |
| 2,172,060 | | |
| 4,480,317 | |
Segment Profit (Loss) | |
| 1,320,138 | | |
| (493,203 | ) | |
| - | | |
| (3,433,774 | ) | |
| (2,606,839 | ) |
Cost of Sales | |
| - | | |
| 3,991,234 | | |
| - | | |
| - | | |
| 3,991,234 | |
|
X |
- DefinitionTabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
+ Details
Name: |
us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_SegmentReportingAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
SCHEDULE OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE (Details) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Product Information [Line Items] |
|
|
|
|
Net loss from continuing operations |
$ (171,607)
|
$ (340,474)
|
$ (2,004,581)
|
$ (1,983,743)
|
Net loss from discontinued operations |
$ (3,353,507)
|
$ (188,268)
|
$ (4,123,028)
|
$ (623,096)
|
Denominator for basic EPS - weighted average shares |
771,192
|
549,977
|
708,116
|
546,879
|
Denominator for diluted EPS - weighted average shares |
2,363,233
|
551,724
|
2,300,157
|
548,626
|
Net loss per common share attributable to common stockholders |
|
|
|
|
Basic |
$ (4.57)
|
$ (0.91)
|
$ (8.65)
|
$ (4.66)
|
Diluted |
(1.49)
|
(0.91)
|
(2.66)
|
(4.64)
|
Net loss per common share from continuing operations |
|
|
|
|
Basic |
(0.22)
|
(0.57)
|
(2.83)
|
(3.52)
|
Diluted |
(0.07)
|
(0.57)
|
(0.87)
|
(3.51)
|
Net loss per common share from discontinued operations |
|
|
|
|
Basic |
(4.35)
|
(0.34)
|
(5.82)
|
(1.14)
|
Diluted |
$ (1.42)
|
$ (0.34)
|
$ (1.79)
|
$ (1.14)
|
Numerator [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Net loss from continuing operations |
$ (171,607)
|
$ (314,735)
|
$ (2,004,581)
|
$ (1,923,817)
|
Net loss from discontinued operations |
(3,353,507)
|
(188,268)
|
(4,123,028)
|
(623,096)
|
Numerator for basic EPS - income available to common stockholders |
(3,525,114)
|
(503,003)
|
(6,127,609)
|
(2,546,913)
|
Numerator for diluted EPS - income available to common stockholders |
$ (3,525,114)
|
$ (503,003)
|
$ (6,127,609)
|
$ (2,546,913)
|
Denominator [Member] |
|
|
|
|
Product Information [Line Items] |
|
|
|
|
Denominator for basic EPS - weighted average shares |
771,192
|
549,977
|
708,116
|
546,879
|
Denominator for diluted EPS - weighted average shares |
2,363,233
|
551,724
|
2,300,157
|
548,626
|
X |
- DefinitionNetLossPerCommonShareFromContinuingOperationsAbstract
+ References
+ Details
Name: |
MEDS_NetLossPerCommonShareFromContinuingOperationsAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNetLossPerCommonShareFromDiscontinuedOperationsAbstract
+ References
+ Details
Name: |
MEDS_NetLossPerCommonShareFromDiscontinuedOperationsAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of income (loss) from continuing operations attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.13) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_IncomeLossFromContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_IncomeLossFromContinuingOperationsPerBasicShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1
+ Details
Name: |
us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3
+ Details
Name: |
us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionPer basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 5.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5
+ Details
Name: |
us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
+ Details
Name: |
us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40
+ Details
Name: |
us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=MEDS_NumeratorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=MEDS_DenominatorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) - USD ($)
|
|
|
|
|
|
|
9 Months Ended |
|
|
|
|
|
|
Jan. 08, 2024 |
Jan. 08, 2024 |
Jul. 31, 2023 |
Jun. 28, 2023 |
Jun. 21, 2023 |
Jan. 20, 2023 |
Sep. 30, 2021 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Jun. 26, 2023 |
Jan. 04, 2023 |
Dec. 31, 2022 |
May 23, 2022 |
May 20, 2022 |
Feb. 15, 2022 |
Shares issued price per share |
|
|
|
|
$ 1
|
|
|
$ 1
|
|
|
|
|
|
|
|
Reverse stock split |
|
|
|
|
Effective
June 21, 2023, the Company executed a 1:15 reverse stock split for stockholders of record on that date
|
|
|
Effective
June 21, 2023 the Company executed a 1:15 reverse stock split for stockholders of record on that date. This was executed to comply with
the Nasdaq Listing Rule 5550(a)(2) to have the price of the stock above $1.
|
|
|
|
|
|
|
|
Accounts Receivable, after Allowance for Credit Loss, Current |
|
|
|
|
|
|
|
$ 850,103
|
|
|
|
$ 649,263
|
|
|
|
Bad debt |
|
|
|
|
|
|
$ 630,000
|
|
|
|
|
|
|
|
|
Other receivables, net |
|
|
|
|
|
|
|
0
|
|
|
|
0
|
|
|
|
Other receivables, net |
|
|
|
|
|
|
|
$ 115,684
|
|
|
|
|
|
|
|
Warrants to purchase common stock |
|
|
|
|
|
|
|
177,536
|
|
|
|
|
|
|
|
Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares, issued |
|
|
|
|
|
|
|
50,000
|
|
|
|
|
|
|
|
Options to purchase common stock |
|
|
|
|
|
|
|
17,852
|
|
|
|
|
|
|
|
Warrants to purchase, shares |
|
|
|
|
|
|
|
|
|
|
601,740
|
|
|
|
|
Warrants, price per share |
|
|
|
|
|
|
|
|
|
|
$ 6.02
|
|
|
|
|
Series B Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock, Par or Stated Value Per Share |
|
|
|
|
|
|
|
$ 0.00001
|
|
$ 0.00001
|
|
$ 0.00001
|
|
|
|
SOSRx, LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disposal of assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 352,244
|
GSG PPE, LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bad debt |
|
|
|
|
|
|
|
$ 32,074
|
$ 98,841
|
|
|
|
|
|
|
GSG PPE, LLC [Member] | Single Customer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts Receivable, after Allowance for Credit Loss, Current |
|
|
|
|
|
|
|
$ 630,000
|
|
|
|
|
|
|
|
Community Specialty Pharmacy LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other receivables |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,200,000
|
|
Payment of other receivables |
|
|
|
|
|
|
|
|
|
|
|
|
$ 875,000
|
|
|
Membership Interest Purchase Agreements [Member] | Alliance Pharma Solutions LLC and Community Specialty Pharmacy LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sale of stock percentage |
|
|
|
|
|
100.00%
|
|
|
|
|
|
|
|
|
|
Membership Interest Purchase Agreements [Member] | Alliance Pharma Solutions LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sale of stock consideration value |
|
|
|
|
|
$ 125,000
|
|
|
|
|
|
|
|
|
|
Membership Interest Purchase Agreements [Member] | Community Specialty Pharmacy LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sale of stock consideration value |
|
|
|
|
|
100,000
|
|
|
|
|
|
|
|
|
|
Master Service Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional amount owed prior to agreement |
|
|
|
|
|
$ 1,075,000
|
|
|
|
|
|
|
|
|
|
Merger Agreement [Member] | Suran Aijarapu [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share conversion |
|
|
|
85,000
|
|
|
|
|
|
|
|
|
|
|
|
Merger Agreement [Member] | Prashant Patel [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share conversion |
|
|
|
81,666
|
|
|
|
|
|
|
|
|
|
|
|
Merger Agreement [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock per share |
|
|
$ 7.30
|
|
|
|
|
|
|
|
|
|
|
|
|
Merger Agreement [Member] | Series B Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares, issued |
|
136,441
|
136,441
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock issued and outstanding percentage |
|
|
19.99%
|
|
|
|
|
|
|
|
|
|
|
|
|
Share conversion |
|
15,759
|
306,855
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock, Par or Stated Value Per Share |
|
|
$ 0.00001
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion ratio, shares |
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares, issued value |
|
|
$ 225,000,169
|
|
|
|
|
|
|
|
|
|
|
|
|
Amended Meger Agreement [Member] | Common Stock [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares during period |
136,441
|
136,441
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of total issued and outstanding common stock |
19.99%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued price per share |
$ 7.30
|
$ 7.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares during period, value |
$ 12,500,089
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amended Meger Agreement [Member] | Series B Preferred Stock [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion ratio, shares |
100
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares during period |
15,759
|
15,759
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued price per share |
$ 0.00001
|
$ 0.00001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares surrendered |
289,731
|
289,731
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trxade, Inc.[Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity Method Investment, Ownership Percentage |
|
|
|
|
|
|
|
100.00%
|
|
|
|
|
|
|
|
SOSRx, LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity Method Investment, Ownership Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
51.00%
|
Exchange Health LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity Method Investment, Ownership Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
49.00%
|
X |
- DefinitionAdditional amounts owed prior to business agreement.
+ References
+ Details
Name: |
MEDS_AdditionalAmountsOwedPriorToBusinessAgreement |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPayment of other receivables
+ References
+ Details
Name: |
MEDS_PaymentOfOtherReceivables |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPercentage of total issued and Outstanding commonstock
+ References
+ Details
Name: |
MEDS_PercentageOfTotalIssuedAndOutstandingCommonStock |
Namespace Prefix: |
MEDS_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
MEDS_SharesSurrendered |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionStock issued and outstanding percentage.
+ References
+ Details
Name: |
MEDS_StockIssuedAndOutstandingPercentage |
Namespace Prefix: |
MEDS_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.
+ References
+ Details
Name: |
us-gaap_AccountsAndOtherReceivablesNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9
+ Details
Name: |
us-gaap_AccountsReceivableNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of warrants or rights outstanding.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued for each share of convertible preferred stock that is converted.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16
+ Details
Name: |
us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
+ Details
Name: |
us-gaap_EquityMethodInvestmentOwnershipPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount due from parties in nontrade transactions, classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherReceivables |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.
+ References
+ Details
Name: |
us-gaap_OtherReceivablesNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_ProvisionForDoubtfulAccounts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCash received on stock transaction after deduction of issuance costs.
+ References
+ Details
Name: |
us-gaap_SaleOfStockConsiderationReceivedOnTransaction |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPercentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.
+ References
+ Details
Name: |
us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNet number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
+ Details
Name: |
us-gaap_SharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPer share or per unit amount of equity securities issued.
+ References
+ Details
Name: |
us-gaap_SharesIssuedPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4
+ Details
Name: |
us-gaap_StockholdersEquityReverseStockSplit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=MEDS_SosRxLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=MEDS_GSGPPELLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_MajorCustomersAxis=MEDS_SingleCustomerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=MEDS_MembershipInterestPurchaseAgreementsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ConsolidatedEntitiesAxis=MEDS_AlliancePharmaSolutionsLLCAndCommunitySpecialtyPharmacyLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ConsolidatedEntitiesAxis=MEDS_AlliancePharmaSolutionsLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=MEDS_MasterServiceAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=MEDS_MergerAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=MEDS_SuranAijarapuMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=MEDS_PrashantPatelMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=MEDS_AmendedMegerAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MEDS_TrxadeIncMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MEDS_SosRxLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MEDS_ExchangeHealthLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
GOING CONCERN (Details Narrative) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
|
Retained deficit |
$ 21,529,975
|
$ 19,719,536
|
Working capital deficit |
3,544,460
|
|
Cash |
$ 34,031
|
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20
+ Details
Name: |
us-gaap_Cash |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.4
SCHEDULE OF PURCHASE PRICE ALLOCATION (Details) - USD ($)
|
Jul. 31, 2023 |
Sep. 30, 2023 |
Dec. 31, 2022 |
Restructuring Cost and Reserve [Line Items] |
|
|
|
Goodwill |
|
$ 5,129,116
|
|
Superlatus, Inc. [Member] |
|
|
|
Restructuring Cost and Reserve [Line Items] |
|
|
|
Common stock, at fair value |
$ 996,019
|
|
|
Series B Preferred Stock, at fair value |
11,504,070
|
|
|
Total purchase consideration |
12,500,089
|
|
|
Cash |
5,546
|
|
|
Prepaid expenses |
3,705
|
|
|
Inventory |
122,792
|
|
|
Intangible assets, net |
9,777,478
|
|
|
Goodwill |
5,129,116
|
|
|
Assets acquired |
15,038,637
|
|
|
Accounts payable and other current liabilities |
(633,548)
|
|
|
Notes payable |
(1,905,000)
|
|
|
Liabilities assumed |
(2,538,548)
|
|
|
Net assets acquired |
$ 12,500,089
|
|
|
X |
- DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7
+ Details
Name: |
us-gaap_BusinessCombinationConsiderationTransferred1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7
+ Details
Name: |
us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1
+ Details
Name: |
us-gaap_BusinessCombinationConsiderationTransferredOther1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of assets acquired at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of intangible assets, excluding goodwill, acquired at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe amount of inventory recognized as of the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities assumed at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Goodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1
+ Details
Name: |
us-gaap_RestructuringCostAndReserveLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=MEDS_SuperlatusIncMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
SCHEDULE OF FAIR VALUES OF ASSETS ACQUIRED (Details) - The Urgent Company, Inc. [Member]
|
9 Months Ended |
Sep. 30, 2023
USD ($)
|
Asset Acquisition [Line Items] |
|
Promissory note |
$ 3,150,000
|
Total purchase consideration |
3,150,000
|
Inventory |
2,960,235
|
Property and equipment |
231,170
|
Goodwill |
383,218
|
Assets acquired |
3,574,623
|
Liabilities assumed |
(424,623)
|
Net assets acquired |
$ 3,150,000
|
X |
- DefinitionAsset acquisition consideration transferred liabilities assumed.
+ References
+ Details
Name: |
MEDS_AssetAcquisitionConsiderationTransferredLiabilitiesAssumed |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAsset acquisition recognized identifiable assets acquired.
+ References
+ Details
Name: |
MEDS_AssetAcquisitionRecognizedIdentifiableAssetsAcquired |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAsset acquisition recognized identifiable goodwill.
+ References
+ Details
Name: |
MEDS_AssetAcquisitionRecognizedIdentifiableGoodwill |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAsset acquisition recognized identifiable inventory.
+ References
+ Details
Name: |
MEDS_AssetAcquisitionRecognizedIdentifiableInventory |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAsset acquisition recognized identifiable liabilities assumed.
+ References
+ Details
Name: |
MEDS_AssetAcquisitionRecognizedIdentifiableLiabilitiesAssumed |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAsset acquisition recognized identifiable net assets acquired.
+ References
+ Details
Name: |
MEDS_AssetAcquisitionRecognizedIdentifiableNetAssetsAcquired |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAsset acquisition recognized identifiable property and equipment.
+ References
+ Details
Name: |
MEDS_AssetAcquisitionRecognizedIdentifiablePropertyandEquipment |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2
+ Details
Name: |
us-gaap_AssetAcquisitionConsiderationTransferred |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3
+ Details
Name: |
us-gaap_AssetAcquisitionLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AssetAcquisitionAxis=MEDS_TheUrgentCompanyMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
X |
- DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount classified as accounts payable attributable to disposal group held for sale or disposed of.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480547/715-80-55-8
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-6
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-6
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-11
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-11
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480606/715-80-35-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-9
Reference 19: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-6
+ Details
Name: |
us-gaap_MultiemployerPlansLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=MEDS_SosRxLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
SCHEDULE OF ASSETS AND LIABILITIES (Details)
|
Aug. 22, 2023
USD ($)
|
Alliance Pharma Solutions LLC [Member] |
|
Multiemployer Plan [Line Items] |
|
Cash |
$ 1,050
|
Accounts receivable, net |
|
Inventory |
|
Prepaid assets |
|
Intangible assets and capitalized software, net |
739,337
|
Accounts payable |
(23,982)
|
Accrued liabilities |
|
Net assets sold |
716,405
|
Community Speciality Pharmacy LLC [Member] |
|
Multiemployer Plan [Line Items] |
|
Cash |
61,988
|
Accounts receivable, net |
11,452
|
Inventory |
123,230
|
Prepaid assets |
525
|
Intangible assets and capitalized software, net |
|
Accounts payable |
(231,876)
|
Accrued liabilities |
(10,182)
|
Net assets sold |
$ (44,863)
|
X |
- DefinitionDisposal group including discontinued operation net assets.
+ References
+ Details
Name: |
MEDS_DisposalGroupIncludingDiscontinuedOperationNetAssets |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480547/715-80-55-8
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-6
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-6
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-11
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-11
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480606/715-80-35-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-5
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-9
Reference 19: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480576/715-80-50-6
+ Details
Name: |
us-gaap_MultiemployerPlansLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=MEDS_AlliancePharmaSolutionsLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=MEDS_CommunitySpecialityPharmacyLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
SCHEDULE OF DISCONTINUED OPERATIONS (Details) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Revenue |
$ 124,238
|
$ 344,508
|
$ 761,306
|
$ 925,507
|
Cost of sales |
127,671
|
314,945
|
705,206
|
1,019,470
|
Gross profit |
(3,433)
|
29,563
|
56,100
|
(93,963)
|
Operating expenses |
|
|
|
|
Wage and salary expense |
108,772
|
87,691
|
456,297
|
235,758
|
Professional fees |
18,079
|
12,565
|
23,371
|
50,534
|
Accounting and legal expense |
2,648
|
604
|
70,773
|
604
|
Technology expense |
6,408
|
60,009
|
30,075
|
151,558
|
General and administrative |
4,391
|
58,862
|
36,592
|
92,579
|
Total operating expense |
140,298
|
219,731
|
617,108
|
531,033
|
Operating loss from discontinued operations |
(143,731)
|
(190,168)
|
(561,008)
|
(624,996)
|
Other income (expense) |
|
|
|
|
Gain (loss) on disposal of assets |
(3,209,776)
|
1,900
|
(3,562,020)
|
1,900
|
Total other income (expense) |
(3,209,776)
|
1,900
|
(3,562,020)
|
1,900
|
Loss from discontinued operations |
$ (3,353,507)
|
$ (188,268)
|
$ (4,123,028)
|
$ (623,096)
|
Loss per common share from discontinued operations |
|
|
|
|
Basic |
$ (4.35)
|
$ (0.34)
|
$ (5.82)
|
$ (1.14)
|
Diluted |
$ (1.42)
|
$ (0.34)
|
$ (1.79)
|
$ (1.14)
|
SOSRx [Member] |
|
|
|
|
Revenue |
|
$ 3,368
|
|
$ 20,424
|
Cost of sales |
|
|
|
|
Gross profit |
|
3,368
|
|
20,424
|
Operating expenses |
|
|
|
|
Wage and salary expense |
|
17,689
|
|
54,939
|
Professional fees |
|
|
|
|
Accounting and legal expense |
|
|
|
|
Technology expense |
|
23,000
|
|
53,910
|
General and administrative |
|
29,907
|
|
33,873
|
Total operating expense |
|
70,596
|
|
142,722
|
Operating loss from discontinued operations |
|
(67,228)
|
|
(122,298)
|
Other income (expense) |
|
|
|
|
Gain (loss) on disposal of assets |
|
|
(352,244)
|
|
Total other income (expense) |
|
|
(352,244)
|
|
Loss from discontinued operations |
|
$ (67,228)
|
$ (352,244)
|
$ (122,298)
|
Loss per common share from discontinued operations |
|
|
|
|
Basic |
|
$ (0.12)
|
$ (0.50)
|
$ (0.22)
|
Diluted |
|
$ (0.12)
|
$ (0.15)
|
$ (0.22)
|
Alliance Pharma Solution [Member] |
|
|
|
|
Revenue |
|
|
|
|
Cost of sales |
|
|
|
|
Gross profit |
|
|
|
|
Operating expenses |
|
|
|
|
Wage and salary expense |
|
|
|
|
Professional fees |
|
10,471
|
3,125
|
44,962
|
Accounting and legal expense |
1,948
|
104
|
7,773
|
104
|
Technology expense |
4,177
|
31,564
|
20,611
|
83,659
|
General and administrative |
134
|
3,527
|
3,762
|
10,761
|
Total operating expense |
6,259
|
45,666
|
35,271
|
139,486
|
Operating loss from discontinued operations |
(6,259)
|
(45,666)
|
(35,271)
|
(139,486)
|
Other income (expense) |
|
|
|
|
Gain (loss) on disposal of assets |
(1,783,209)
|
1,900
|
(1,783,209)
|
1,900
|
Total other income (expense) |
(1,783,209)
|
1,900
|
(1,783,209)
|
1,900
|
Loss from discontinued operations |
$ (1,789,468)
|
$ (43,766)
|
$ (1,818,480)
|
$ (137,586)
|
Loss per common share from discontinued operations |
|
|
|
|
Basic |
$ (2.32)
|
$ (0.08)
|
$ (2.57)
|
$ (0.25)
|
Diluted |
$ (0.76)
|
$ (0.08)
|
$ (0.79)
|
$ (0.25)
|
Community Speciality Pharmacy [Member] |
|
|
|
|
Revenue |
$ 124,238
|
$ 341,140
|
$ 761,306
|
$ 905,083
|
Cost of sales |
127,671
|
314,945
|
705,206
|
1,019,470
|
Gross profit |
(3,433)
|
26,195
|
56,100
|
(114,387)
|
Operating expenses |
|
|
|
|
Wage and salary expense |
108,772
|
70,002
|
456,297
|
180,819
|
Professional fees |
18,079
|
2,094
|
20,246
|
5,572
|
Accounting and legal expense |
700
|
500
|
63,000
|
500
|
Technology expense |
2,231
|
5,445
|
9,464
|
13,989
|
General and administrative |
4,257
|
25,428
|
32,830
|
47,945
|
Total operating expense |
134,039
|
103,469
|
581,837
|
248,825
|
Operating loss from discontinued operations |
(137,472)
|
(77,274)
|
(525,737)
|
(363,212)
|
Other income (expense) |
|
|
|
|
Gain (loss) on disposal of assets |
(1,426,567)
|
|
(1,426,567)
|
|
Total other income (expense) |
(1,426,567)
|
|
(1,426,567)
|
|
Loss from discontinued operations |
$ (1,564,039)
|
$ (77,274)
|
$ (1,952,304)
|
$ (363,212)
|
Loss per common share from discontinued operations |
|
|
|
|
Basic |
$ (2.03)
|
$ (0.14)
|
$ (2.76)
|
$ (0.66)
|
Diluted |
$ (0.66)
|
$ (0.14)
|
$ (0.85)
|
$ (0.66)
|
X |
- DefinitionDisposal group including discontinued operation accounting and legal expense.
+ References
+ Details
Name: |
MEDS_DisposalGroupIncludingDiscontinuedOperationAccountingAndLegalExpense |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDisposal group including discontinued operation gain loss on disposal of asset.
+ References
+ Details
Name: |
MEDS_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposalOfAsset |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
MEDS_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
MEDS_DisposalGroupIncludingDiscontinuedOperationOtherIncomeAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisposal group including discontinued operation other income expenses.
+ References
+ Details
Name: |
MEDS_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDisposal group including discontinued operation other income loss from discontinued opeations.
+ References
+ Details
Name: |
MEDS_DisposalGroupIncludingDiscontinuedOperationOtherIncomeLossFromDiscontinuedOpeations |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDisposal group including discontinued operation professional expense.
+ References
+ Details
Name: |
MEDS_DisposalGroupIncludingDiscontinuedOperationProfessionalExpense |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDisposal group including discontinued operation technology expense.
+ References
+ Details
Name: |
MEDS_DisposalGroupIncludingDiscontinuedOperationTechnologyExpense |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDisposal group including discontinued operation wages and salary expense.
+ References
+ Details
Name: |
MEDS_DisposalGroupIncludingDiscontinuedOperationWagesAndSalaryExpense |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
MEDS_LossPerCommonShareFromDiscontinuedOperationsAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of revenue attributable to disposal group, including, but not limited to, discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionPer basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 5.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5
+ Details
Name: |
us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
dei_LegalEntityAxis=MEDS_SOSRxMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=MEDS_AlliancePharmaSolutionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
ACQUISITIONS AND DISPOSITIONS (Details Narrative) - USD ($)
|
|
|
|
9 Months Ended |
|
|
|
Jan. 08, 2024 |
Sep. 27, 2023 |
Jul. 31, 2023 |
Jul. 31, 2023 |
Sep. 30, 2023 |
Aug. 22, 2023 |
Feb. 04, 2023 |
Sep. 30, 2021 |
Notes payable |
|
|
|
|
$ 5,255,000
|
|
|
|
Debt Instrument, Face Amount |
|
|
|
|
|
|
|
$ 630,000
|
Gain loss on disposal of assets |
|
|
|
|
$ 3,209,776
|
|
|
|
Promissory Note [Member] |
|
|
|
|
|
|
|
|
Debt Instrument, Face Amount |
|
|
|
|
|
$ 125,000
|
|
|
Promissory Note [Member] | Community Speciality Pharmacy LLC [Member] |
|
|
|
|
|
|
|
|
Debt Instrument, Face Amount |
|
|
|
|
|
$ 100,000
|
|
|
Alliance Pharma Solutions LLC [Member] |
|
|
|
|
|
|
|
|
Ownership percentage |
|
|
|
|
|
100.00%
|
|
|
SOSRx, LLC [Member] |
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
$ 500,000
|
|
Accounts payable |
|
|
|
|
|
|
$ 15,000
|
|
Asset Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
Asset acquisition consideration transferred |
|
$ 3,150,000
|
|
|
|
|
|
|
Series B Preferred Stock [Member] |
|
|
|
|
|
|
|
|
Stock issued |
|
|
100
|
|
|
|
|
|
Series B Preferred Stock [Member] | Merger Agreement [Member] |
|
|
|
|
|
|
|
|
Stock issued during period shares other |
136,441
|
|
|
136,441
|
|
|
|
|
Stock issued and outstanding percentage |
|
|
|
19.99%
|
|
|
|
|
Stock issued during period shares conversion of units |
15,759
|
|
|
306,855
|
|
|
|
|
Stock issued during period shares conversion of units |
0.00001
|
|
|
|
|
|
|
|
Series B Preferred Stock [Member] | Merger Agreement [Member] | Superlatus, Inc. [Member] |
|
|
|
|
|
|
|
|
Business acquisition percentage of voting interests acquired |
|
|
100.00%
|
100.00%
|
|
|
|
|
Business acquisition share price |
|
|
$ 7.30
|
$ 7.30
|
|
|
|
|
Stock issued and outstanding percentage |
19.99%
|
|
|
19.99%
|
|
|
|
|
Business combination step acquisition equity interest in acquiree fair value |
$ 12,500,089
|
|
|
$ 225,000,169
|
|
|
|
|
Series B Preferred Stock [Member] | Amended Meger Agreement [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
Shares surrendered |
289,731
|
|
|
|
|
|
|
|
X |
- DefinitionGain loss on disposal of assets.
+ References
+ Details
Name: |
MEDS_GainLossOnDisposalOfAssets |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
MEDS_SharesSurrendered |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionStock issued and outstanding percentage.
+ References
+ Details
Name: |
MEDS_StockIssuedAndOutstandingPercentage |
Namespace Prefix: |
MEDS_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period shares conversion par value.
+ References
+ Details
Name: |
MEDS_StockIssuedDuringPeriodSharesConversionParValue |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_AccountsPayableCurrentAndNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2
+ Details
Name: |
us-gaap_AssetAcquisitionConsiderationTransferred |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionPercentage of voting equity interests acquired at the acquisition date in the business combination.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2
+ Details
Name: |
us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks paid or offered to be paid in a business combination.
+ References
+ Details
Name: |
us-gaap_BusinessAcquisitionSharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g)(1) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2
+ Details
Name: |
us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
+ Details
Name: |
us-gaap_EquityMethodInvestmentOwnershipPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_NotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_PromissoryNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MEDS_AlliancePharmaSolutionsLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=MEDS_SosRxLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=MEDS_AssetPurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=MEDS_MergerAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=MEDS_SuperlatusIncMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=MEDS_AmendedMegerAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
|
|
9 Months Ended |
Feb. 15, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Related Party Transaction [Line Items] |
|
|
|
Annual base salary |
|
$ 400,000
|
|
Promissory note issued |
|
|
$ 500,000
|
Related party debt |
|
5,255,000
|
|
Related Party [Member] |
|
|
|
Related Party Transaction [Line Items] |
|
|
|
Related party debt |
|
$ 0
|
|
Related party transaction, description of transaction |
|
(i)
provides that all accumulated losses of SOSRx through December 20, 2022, will be allocated 51% to the Company and 49% to Exchange Health;
(ii) provides for a total of approximately $15,000 in outstanding invoices owed by the Company to SOSRx to be waived; (iii) includes
certain indemnification obligations of SOSRx and Exchange Health; (iv) requires SOSRx to pay certain pre-agreed outstanding invoices
of SOSRx; (v) includes mutual releases of the Company and SOSRx and Exchange Health; and (vi) includes customary representations and
warranties of the parties.
|
|
SOSRx, LLC [Member] |
|
|
|
Related Party Transaction [Line Items] |
|
|
|
Related party transaction amount |
$ 325,000
|
|
|
Other commitment |
400,000
|
|
|
SOSRx [Member] |
|
|
|
Related Party Transaction [Line Items] |
|
|
|
Promissory note issued |
500,000
|
|
|
Exchange Health LLC [Member] | Software and contracts [Member] |
|
|
|
Related Party Transaction [Line Items] |
|
|
|
Proceeds from intangible assets. |
$ 792,000
|
|
|
Scietech LLC [Member] |
|
|
|
Related Party Transaction [Line Items] |
|
|
|
Equity method investment, ownership percentage |
|
31.00%
|
|
SOSRx [Member] |
|
|
|
Related Party Transaction [Line Items] |
|
|
|
Equity method investment, ownership percentage |
51.00%
|
|
|
Exchange Health LLC [Member] |
|
|
|
Related Party Transaction [Line Items] |
|
|
|
Equity method investment, ownership percentage |
49.00%
|
|
|
X |
- DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
+ Details
Name: |
us-gaap_EquityMethodInvestmentOwnershipPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe fair value of notes issued in noncash investing and financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_NotesIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_NotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionMinimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.
+ References
+ Details
Name: |
us-gaap_OtherCommitment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12
+ Details
Name: |
us-gaap_ProceedsFromSaleOfIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
dei_LegalEntityAxis=MEDS_SosRxLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=MEDS_SOSRxMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=MEDS_ExchangeHealthLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=MEDS_SoftwareAndContractsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MEDS_ScietechLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MEDS_SOSRxMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MEDS_ExchangeHealthLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
SCHEDULE OF DISAGGREGATED REVENUE (Details) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Product revenues |
|
|
|
|
Total revenues |
$ 2,058,028
|
$ 2,055,803
|
$ 5,919,786
|
$ 7,993,805
|
Product Revenue [Member] |
|
|
|
|
Product revenues |
|
|
|
|
Pharmaceutical product resale income |
394,849
|
707,807
|
1,237,731
|
3,949,771
|
Total revenues |
394,849
|
707,807
|
1,237,731
|
3,949,771
|
Service revenue member |
|
|
|
|
Product revenues |
|
|
|
|
Total revenues |
1,663,179
|
1,347,996
|
4,682,055
|
4,044,034
|
Service revenues |
|
|
|
|
Transaction fee income |
1,617,129
|
1,319,483
|
4,531,731
|
3,947,621
|
Data service fee income |
46,050
|
17,950
|
132,025
|
54,050
|
SaaS fee income |
|
$ 10,563
|
$ 18,299
|
$ 42,363
|
X |
- Definition
+ References
+ Details
Name: |
MEDS_DataServiceFeeIncome |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionPharmaceutical product resale income
+ References
+ Details
Name: |
MEDS_PharmaceuticalProductResaleIncome |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
MEDS_TransactionFeeIncome |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=MEDS_ProductRevenueMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=MEDS_ServiceRevenueMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
SCHEDULE OF INVENTORY (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Inventory Disclosure [Abstract] |
|
|
Raw materials |
$ 1,895,406
|
$ 68,448
|
Finished goods |
1,131,512
|
|
Inventory |
$ 3,026,918
|
$ 68,448
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryFinishedGoods |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryRawMaterials |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.4
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
+ Details
Name: |
us-gaap_ReceivablesNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=MEDS_PromissoryNoteAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
SCHEDULE OF INTANGIBLE ASSETS NET (Details) - USD ($)
|
9 Months Ended |
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Finite-Lived Intangible Assets [Line Items] |
|
|
Intangible assets, Net |
$ 9,451,562
|
|
Developed Technology Rights [Member] |
|
|
Finite-Lived Intangible Assets [Line Items] |
|
|
Weighted Average Useful Life (years) |
5 years
|
|
Cost |
$ 9,777,478
|
|
Accumulated Amortization |
(325,916)
|
|
Intangible assets, Net |
$ 9,451,562
|
|
X |
- DefinitionWeighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1
+ Details
Name: |
us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1
+ Details
Name: |
us-gaap_IntangibleAssetsNetExcludingGoodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
X |
- DefinitionInsurance refunds payable.
+ References
+ Details
Name: |
MEDS_InsuranceRefundsPayable |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DeferredRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_OtherLiabilitiesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
CONTINGENT FUNDING LIABILITIES (Details Narrative) - USD ($)
|
Sep. 30, 2023 |
Jun. 27, 2023 |
Mar. 14, 2023 |
Dec. 31, 2022 |
Sep. 14, 2022 |
Jun. 27, 2022 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
Contingent funding liabilities |
$ 452,348
|
|
|
$ 108,036
|
|
|
Receivables Agreement [Member] |
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
Contingent funding liabilities |
$ 452,348
|
$ 1,250,000
|
$ 875,000
|
$ 108,036
|
$ 275,000
|
$ 550,000
|
Receivables net current |
|
1,800,000
|
1,224,000
|
|
396,000
|
792,000
|
One-time origination fee |
|
$ 62,500
|
$ 42,500
|
|
$ 15,000
|
$ 27,500
|
Interest rate |
31.00%
|
|
|
31.00%
|
|
|
X |
- DefinitionContingent funding liabilities.
+ References
+ Details
Name: |
MEDS_ContingentFundingLiabilities |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of the fee that accompanies borrowing money under the debt instrument.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentFeeAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateEffectivePercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
+ Details
Name: |
us-gaap_ReceivablesNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=MEDS_ReceivablesAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
SCHEDULE OF NOTES PAYABLE BALANCES (Details) - USD ($)
|
Sep. 30, 2023 |
Sep. 27, 2023 |
Sep. 14, 2023 |
Short-Term Debt [Line Items] |
|
|
|
Current Portion |
$ 5,230,000
|
|
|
Non current Portion |
25,000
|
|
|
Note Payable Total |
5,255,000
|
|
|
Accrued Interest |
24,683
|
|
|
Perfect Day Note [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Current Portion |
3,150,000
|
|
|
Non current Portion |
|
|
|
Note Payable Total |
3,150,000
|
$ 3,150,000
|
|
Accrued Interest |
|
|
|
Danam Note [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Current Portion |
200,000
|
|
|
Non current Portion |
|
|
|
Note Payable Total |
200,000
|
|
$ 300,000
|
Accrued Interest |
|
|
|
Eat Well June 2023 Note [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Current Portion |
1,150,000
|
|
|
Non current Portion |
|
|
|
Note Payable Total |
1,150,000
|
|
|
Accrued Interest |
|
|
|
EatWell February 2023 Note [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Current Portion |
|
|
|
Non current Portion |
25,000
|
|
|
Note Payable Total |
25,000
|
|
|
Accrued Interest |
350
|
|
|
Eat Well September 2022 Note [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Current Portion |
50,000
|
|
|
Non current Portion |
|
|
|
Note Payable Total |
50,000
|
|
|
Accrued Interest |
1,104
|
|
|
Eat Well July 26, 2022 Note [Member |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Current Portion |
35,000
|
|
|
Non current Portion |
|
|
|
Note Payable Total |
35,000
|
|
|
Accrued Interest |
798
|
|
|
Eat Well July 12, 2022 Note [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Current Portion |
25,000
|
|
|
Non current Portion |
|
|
|
Note Payable Total |
25,000
|
|
|
Accrued Interest |
585
|
|
|
Eat Well March 2022 Note [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Current Portion |
100,000
|
|
|
Non current Portion |
|
|
|
Note Payable Total |
100,000
|
|
|
Accrued Interest |
2,966
|
|
|
Eat Well February 2022 Note [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Current Portion |
100,000
|
|
|
Non current Portion |
|
|
|
Note Payable Total |
100,000
|
|
|
Accrued Interest |
3,110
|
|
|
Eat Well January 2022 Note [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Current Portion |
20,000
|
|
|
Non current Portion |
|
|
|
Note Payable Total |
20,000
|
|
|
Accrued Interest |
653
|
|
|
Eat Well December 2021 Note [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Current Portion |
100,000
|
|
|
Non current Portion |
|
|
|
Note Payable Total |
100,000
|
|
|
Accrued Interest |
3,427
|
|
|
Eat Well November 2021 Note [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Current Portion |
50,000
|
|
|
Non current Portion |
|
|
|
Note Payable Total |
50,000
|
|
|
Accrued Interest |
1,790
|
|
|
Eat Well August 2021 Note [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Current Portion |
250,000
|
|
|
Non current Portion |
|
|
|
Note Payable Total |
250,000
|
|
|
Accrued Interest |
$ 9,900
|
|
|
X |
- DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InterestPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LongTermNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_NotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_NotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_PerfectDayNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_DanamNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellJuneTwentyTwentyTwentyThreeNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellFebruaryTwentyTwentyThreeNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellSeptemberTwentyTwentyTwoNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellJulyTwentySixTwentyTwentyTwoNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellJulyTwelveTwentyTwentyTwoNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellMarchTwentyTwentyTwoNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellFebruaryTwentyTwentyTwoNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellJanuaryTwentyTwentyTwoNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellDecemberTwentyTwentyOneNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellNovemberTwentyTwentyOneNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellAugustTwentyTwentyOneNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
NOTES PAYABLE (Details Narrative) - USD ($)
|
|
|
|
|
|
|
|
|
|
|
|
1 Months Ended |
|
|
|
|
|
Jun. 16, 2023 |
Feb. 08, 2023 |
Sep. 14, 2022 |
Jul. 26, 2022 |
Jul. 12, 2022 |
Mar. 15, 2022 |
Feb. 01, 2022 |
Jan. 20, 2022 |
Dec. 24, 2021 |
Nov. 10, 2021 |
Aug. 18, 2021 |
Oct. 31, 2023 |
Jan. 16, 2024 |
Oct. 13, 2023 |
Sep. 30, 2023 |
Sep. 27, 2023 |
Sep. 14, 2023 |
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,255,000
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24,683
|
|
|
Perfect Day Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,150,000
|
$ 3,150,000
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Danam Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 200,000
|
|
$ 300,000
|
Additional deposits |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
$ 200,000
|
Debt instrument interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Danam Note [Member] | Forecast [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
$ 50,000
|
|
|
|
|
Danam Note [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Repayments of debt |
|
|
|
|
|
|
|
|
|
|
|
$ 250,000
|
|
|
|
|
|
Eat Well June 2023 Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of secured debt |
$ 1,150,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Membership interests |
100.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument interest rate |
12.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity date |
Dec. 31, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Secured debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,150,000
|
|
|
EatWell February 2023 Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
350
|
|
|
EatWell February 2023 Note [Member] | Loan Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
$ 25,000
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
|
|
Debt instrument interest rate |
|
1.87%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity date |
|
Feb. 07, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
350
|
|
|
Eat Well September 2022 Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,104
|
|
|
Eat Well September 2022 Note [Member] | Loan Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
$ 50,000
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
|
Debt instrument interest rate |
|
|
1.87%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity date |
|
|
Sep. 13, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,140
|
|
|
Eat Well July 26, 2022 Note [Member |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
35,000
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
798
|
|
|
Eat Well July 26, 2022 Note [Member | Loan Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
$ 35,000
|
|
|
|
|
|
|
|
|
|
|
35,000
|
|
|
Debt instrument interest rate |
|
|
|
1.87%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity date |
|
|
|
Jul. 25, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
798
|
|
|
Eat Well July 12, 2022 Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,000
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
585
|
|
|
Eat Well July 12, 2022 Note [Member] | Loan Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
$ 25,000
|
|
|
|
|
|
|
|
|
|
25,000
|
|
|
Debt instrument interest rate |
|
|
|
|
1.87%
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity date |
|
|
|
|
Jul. 11, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
585
|
|
|
Eat Well March 2022 Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,966
|
|
|
Eat Well March 2022 Note [Member] | Loan Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
100,000
|
|
|
Debt instrument interest rate |
|
|
|
|
|
1.87%
|
|
|
|
|
|
|
|
|
|
|
|
Maturity date |
|
|
|
|
|
Mar. 14, 2024
|
|
|
|
|
|
|
|
|
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,966
|
|
|
Eat Well February 2022 Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,110
|
|
|
Eat Well February 2022 Note [Member] | Loan Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
100,000
|
|
|
Debt instrument interest rate |
|
|
|
|
|
|
1.87%
|
|
|
|
|
|
|
|
|
|
|
Maturity date |
|
|
|
|
|
|
Feb. 01, 2024
|
|
|
|
|
|
|
|
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,110
|
|
|
Eat Well January 2022 Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,000
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
653
|
|
|
Eat Well January 2022 Note [Member] | Loan Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
$ 20,000
|
|
|
|
|
|
|
20,000
|
|
|
Debt instrument interest rate |
|
|
|
|
|
|
|
1.87%
|
|
|
|
|
|
|
|
|
|
Maturity date |
|
|
|
|
|
|
|
Jan. 20, 2024
|
|
|
|
|
|
|
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
653
|
|
|
Eat Well December 2021 Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,427
|
|
|
Eat Well December 2021 Note [Member] | Loan Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
100,000
|
|
|
Debt instrument interest rate |
|
|
|
|
|
|
|
|
1.87%
|
|
|
|
|
|
|
|
|
Maturity date |
|
|
|
|
|
|
|
|
Dec. 24, 2023
|
|
|
|
|
|
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,427
|
|
|
Eat Well November 2021 Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,790
|
|
|
Eat Well November 2021 Note [Member] | Loan Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
$ 50,000
|
|
|
|
|
50,000
|
|
|
Debt instrument interest rate |
|
|
|
|
|
|
|
|
|
1.87%
|
|
|
|
|
|
|
|
Maturity date |
|
|
|
|
|
|
|
|
|
Nov. 10, 2023
|
|
|
|
|
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,790
|
|
|
Eat Well August 2021 Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
250,000
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,900
|
|
|
Eat Well August 2021 Note [Member] | Loan Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable |
|
|
|
|
|
|
|
|
|
|
$ 250,000
|
|
|
|
250,000
|
|
|
Debt instrument interest rate |
|
|
|
|
|
|
|
|
|
|
1.87%
|
|
|
|
|
|
|
Maturity date |
|
|
|
|
|
|
|
|
|
|
Aug. 18, 2023
|
|
|
|
|
|
|
Interest payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 9,900
|
|
|
X |
- DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateEffectivePercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.12) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Deposits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InterestPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_NotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfSecuredDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_RepaymentsOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_SecuredDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_PerfectDayNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_DanamNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementScenarioAxis=srt_ScenarioForecastMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellJuneTwentyTwentyThreeNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellFebruaryTwentyTwentyThreeNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=MEDS_LoanAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellSeptemberTwentyTwentyTwoNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellJulyTwentySixTwentyTwentyTwoNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellJulyTwelveTwentyTwentyTwoNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellMarchTwentyTwentyTwoNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellFebruaryTwentyTwentyTwoNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellJanuaryTwentyTwentyTwoNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellDecemberTwentyTwentyOneNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellNovemberTwentyTwentyOneNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=MEDS_EatWellAugustTwentyTwentyOneNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
|
|
|
|
3 Months Ended |
9 Months Ended |
|
|
Jul. 31, 2023 |
Jun. 21, 2023 |
Aug. 31, 2022 |
Jun. 30, 2023 |
Mar. 31, 2023 |
Sep. 30, 2022 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Sep. 30, 2023 |
Jun. 26, 2023 |
Dec. 31, 2022 |
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Stockholders' equity, reverse stock split |
|
Effective
June 21, 2023, the Company executed a 1:15 reverse stock split for stockholders of record on that date
|
|
|
|
|
|
|
Effective
June 21, 2023 the Company executed a 1:15 reverse stock split for stockholders of record on that date. This was executed to comply with
the Nasdaq Listing Rule 5550(a)(2) to have the price of the stock above $1.
|
|
|
Shares issued price per share |
|
$ 1
|
|
|
|
|
|
|
$ 1
|
|
|
Stock issued during period value issued for services |
|
|
|
$ 15,813
|
$ 63,486
|
$ 63,126
|
$ 12,222
|
$ 32,083
|
|
|
|
Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Stock issued during period shares issued for services |
|
|
|
|
14,362
|
14,511
|
|
|
|
|
|
Stock issued during period value issued for services |
|
|
|
|
|
$ 1
|
|
|
|
|
|
Officers [Member] |
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Stock issued during period, shares |
|
|
5,460
|
|
|
|
|
|
|
|
|
Employees [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Decrease in salaries |
|
|
|
|
|
|
|
|
$ 37,000
|
|
|
Share based compensation, shares |
|
|
|
|
|
|
|
|
2,126
|
|
|
Board of Directors Chairman [Member] |
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Stock issued during period shares issued for services |
|
|
3,635
|
|
|
|
|
|
|
|
|
Stock issued during period value issued for services |
|
|
$ 63,250
|
|
|
|
|
|
|
|
|
Series B Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, shares authorized |
|
|
|
|
|
|
|
|
787,754
|
787,754
|
787,754
|
Preferred stock, par value |
|
|
|
|
|
|
|
|
$ 0.00001
|
$ 0.00001
|
$ 0.00001
|
Stock issued during period, shares |
100
|
|
|
|
|
|
|
|
|
|
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ClassOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPer share or per unit amount of equity securities issued.
+ References
+ Details
Name: |
us-gaap_SharesIssuedPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4
+ Details
Name: |
us-gaap_StockholdersEquityReverseStockSplit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=MEDS_OfficersMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=MEDS_EmployeesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPer share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_StockOptionExercisePriceDecrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_WarrantExercisePriceDecrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer share increase in exercise price of warrant. Excludes change due to standard antidilution provision.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_WarrantExercisePriceIncrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=MEDS_PreFundedWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details)
|
9 Months Ended |
Sep. 30, 2023
USD ($)
$ / shares
shares
|
Warrants |
|
Number Outstanding, Warrants Outstanding Beginning Balance | shares |
179,331
|
Weighted Average Exercise Price, Warrants Outstanding Beginning Balance |
$ 22.50
|
Contractual Life in Years, Warrants Outstanding Beginning Balance |
4 years 8 months 19 days
|
Intrinsic Value Outstanding Beginning Balance | $ |
$ 6,731
|
Weighted Average Exercise Price, Warrants Granted |
|
Weighted Average Exercise Price, Warrants Forfeited, Expired, Cancelled |
|
Number Outstanding, Warrants Exercised | shares |
(1,795)
|
Weighted Average Exercise Price, Warrants Outstanding Exercised |
$ 22.50
|
Number Outstanding, Warrants Outstanding Ending Balance | shares |
177,536
|
Weighted Average Exercise Price, Warrants Outstanding Ending Balance |
$ 22.50
|
Contractual Life in Years, Warrants Outstanding Ending Balance |
4 years 7 days
|
Intrinsic Value Outstanding Ending Balance | $ |
$ 0
|
Number Outstanding, Warrants Exercisable Ending Balance | shares |
177,536
|
Weighted Average Exercise Price, Exercisable Ending Balance |
$ 22.50
|
Contractual Life in Years, Warrants Exercisable Ending Balance |
4 years 7 days
|
X |
- References
+ Details
Name: |
MEDS_DisclosureWarrantsAbstract |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity exercisable number split adjusted.
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableNumberSplitAdjusted |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity exercisable weighted average exercise price.
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
MEDS_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionShare Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Split Adjusted.
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedSplitAdjusted |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by sharebasedpayment award non option equity instruments exercises in period weighted average exercise price
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
MEDS_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted Average Exercise Price, Warrants Forfeited.
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
MEDS_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments grants in period weighted average exercise price.
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
MEDS_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments outstanding number split adjusted.
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumberSplitAdjusted |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
MEDS_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term beginning.
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionContractual life in years warrants outstanding, ending.
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non options equity instrument outstanding intrinsic value.
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionContractual Life Warrants, Warrants Exercisable Ending.
+ References
+ Details
Name: |
MEDS_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
WARRANTS (Details Narrative) - USD ($)
|
9 Months Ended |
|
|
Sep. 30, 2023 |
Sep. 30, 2022 |
Jan. 04, 2023 |
Oct. 04, 2022 |
Number of warrants granted |
0
|
|
|
|
Warrants, expired |
0
|
|
|
|
Share-based payment arrangement, noncash expense |
$ 25,978
|
$ 67,439
|
|
|
Private Placement Warrants [Member] |
|
|
|
|
Warrants, exercised |
40,116
|
|
|
|
Warrant [Member] |
|
|
|
|
Number of warrants granted |
1,795
|
|
|
|
Warrants price per share |
|
|
$ 6.02
|
|
Share-based payment arrangement, noncash expense |
$ 0
|
$ 0
|
|
|
Pre Funded Warrants [Member] |
|
|
|
|
Warrants price per share |
$ 1,622
|
|
$ 6.02
|
$ 17.25
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of non-option equity instruments exercised by participants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares under non-option equity instrument agreements that were either cancelled or expired.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(3)-(4) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNet number of non-option equity instruments granted to participants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(1) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=MEDS_PrivatePlacementWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=MEDS_PreFundedWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
SCHEDULE OF STOCK OPTION ACTIVITY (Details) - Stock Options [Member]
|
9 Months Ended |
Sep. 30, 2023
USD ($)
$ / shares
shares
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
Number Outstanding, Options outstanding, Beginning Balance | shares |
19,708
|
Weighted average exercise price outstanding, Beginning Balance | $ / shares |
$ 66.00
|
Weighted - Average Contractual Life in Years, Beginning Balance |
3 years 11 months 1 day
|
Intrinsic Value Options Outstanding, Beginning Balance | $ |
|
Number Outstanding, Options Exercisable | shares |
17,167
|
Weighted average Exercise Price Outstanding, Options Exercisable | $ / shares |
$ 66.30
|
Weighted - Average Contractual Life in Years, Options Exercisable |
3 years 10 months 20 days
|
Intrinsic Value, Options Exercisable | $ |
|
Number Outstanding, Granted | shares |
603
|
Weighted average Exercise Price Outstanding, Options Granted | $ / shares |
$ 6.08
|
Weighted - Average Contractual Life in Years, Options Granted |
4 years 6 months 3 days
|
Intrinsic Value, Options Granted | $ |
$ 59,976
|
Number Outstanding, Forfeited | shares |
(140)
|
Weighted average Exercise Price Outstanding, Options Forfeited | $ / shares |
$ 82.33
|
Weighted - Average Contractual Life in Years, Options Forfeited |
2 years
|
Number Outstanding, Expired | shares |
(2,319)
|
Weighted average Exercise Price Outstanding, Options Expired | $ / shares |
$ 89.88
|
Weighted - Average Contractual Life in Years, Options Expired |
29 days
|
Number Outstanding, Exercised | shares |
|
Weighted average Exercise Price Outstanding, Options Exercised | $ / shares |
|
Number Outstanding, Options Outstanding Ending Balance | shares |
17,852
|
Weighted average Exercise Price Outstanding, Options Outstanding Ending Balance | $ / shares |
$ 66.10
|
Weighted - Average Contractual Life in Years, Options Outstanding Ending Balance |
3 years 11 months 12 days
|
Intrinsic Value, Options Outstanding Ending Balance | $ |
$ 112,073
|
Number Outstanding, Options Exercisable Ending Balance | shares |
17,252
|
Weighted average Exercise Price Outstanding, Options Exercisable Ending Balance | $ / shares |
$ 62.43
|
Weighted - Average Contractual Life in Years, Options Exercisable Ending Balance |
2 years 11 months 26 days
|
Intrinsic Value, Options Exercisable Ending Balance | $ |
$ 52,097
|
X |
- DefinitionShare based compensation arrangement by share based payment award options exercisable split adjusted number.
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableSplitAdjustedNumber |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionShare based compensation arrangement by share based payment award options expirations split adjusted in period.
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsSplitAdjustedInPeriod |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award options forfeitures split adjusted in period.
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresSplitAdjustedInPeriod |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award options grants split adjusted in period gross.
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsSplitAdjustedInPeriodGross |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award options outstanding split adjusted number.
+ References
+ Details
Name: |
MEDS_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingSplitAdjustedNumber |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionShare based compensation arrangement by share based payment award options exercisable intrinsic value granted.
+ References
+ Details
Name: |
MEDS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValueGranted |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award options exercisable weighted average remaining contractual term.
+ References
+ Details
Name: |
MEDS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by sharebased payment award options exercisable weighted average remaining contractual term expired.
+ References
+ Details
Name: |
MEDS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermExpired |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by sharebased payment award options exercisable weighted average remaining contractual term forfeited.
+ References
+ Details
Name: |
MEDS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermForfeited |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSharebased payment award options exercisable weighted average remaining contractual term granted.
+ References
+ Details
Name: |
MEDS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.
+ References
+ Details
Name: |
MEDS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSharebased compensation arrangement by share based payment award options outstanding weighted average remaining contractual term beginning.
+ References
+ Details
Name: |
MEDS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermBeginning |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award options exercised split adjusted.
+ References
+ Details
Name: |
MEDS_StockIssuedDuringPeriodSharesStockOptionsExercisedSplitAdjusted |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=MEDS_StockOptionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
OPTIONS (Details Narrative) - USD ($)
|
9 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
|
Options expense |
$ 25,978
|
$ 67,439
|
Share-Based Payment Arrangement [Member] |
|
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
|
Options to purchase common stock granted |
603
|
|
Options to purchase common stock forfeited |
140
|
|
Options to purchase common stock expired |
2,319
|
|
Options to purchase common stock exercised |
0
|
|
Stock Option Plan [Member] |
|
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
|
Options to purchase common stock granted |
155,556
|
|
Second Amended and Restated 2019 Equity Incentive Plan [Member] |
|
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
|
Stock issued during period, shares |
133,333
|
|
Share-based payment award, description |
beginning in 2021 and ending in 2029 (each a “Date of Determination”), in each
case subject to the approval and determination of the administrator of the plan (the Board of Directors or Compensation Committee) on
or prior to the applicable Date of Determination, equal to the lesser of (A) ten percent (10%) of the total shares of common stock of
the Company outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares as determined
by the administrator. The administrator as a result of the annual meeting shareholder vote increased the number of shares available to
grant to employees under the 2019 incentive plan by 2 million. The administrator did not approve an increase in the number of shares
covered under the plan as of April 1, 2022.
|
|
Number of shares available for grant |
2,000,000
|
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDescription of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=MEDS_StockOptionPlanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=MEDS_SecondAmendedAndRestatedTwoThousandAndNineteenEquityIncentivePlanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
CONTINGENCIES (Details Narrative)
|
|
|
|
1 Months Ended |
6 Months Ended |
9 Months Ended |
Apr. 13, 2023
USD ($)
|
Sep. 30, 2021
USD ($)
|
Aug. 14, 2020
Integer
|
Jun. 30, 2022
USD ($)
|
Aug. 31, 2020
USD ($)
Integer
|
Jul. 31, 2020
USD ($)
|
Jun. 30, 2021
USD ($)
|
Sep. 30, 2023
USD ($)
|
Repayments of related party debt |
$ 550,000
|
|
|
|
|
|
|
|
Principal amount |
|
$ 630,000
|
|
|
|
|
|
|
Attorney fees |
|
|
|
|
|
|
|
$ 630,000
|
Bad debt expenses |
|
$ 630,000
|
|
|
|
|
|
|
Attorney fees |
|
|
|
$ 743,000
|
|
|
|
|
Waxman [Member] |
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
|
|
$ 630,000
|
IPS [Member] | Studebaker Defense Group, LLC [Member] |
|
|
|
|
|
|
|
|
Down payment |
|
|
|
|
|
$ 550,000
|
|
|
Loss contingency damages sought value |
|
|
|
|
|
$ 550,000
|
|
|
Loss on inventory investment |
|
|
|
|
|
|
$ 500,000
|
|
IPS [Member] | Sandwave Group Dsn Bhd [Member] |
|
|
|
|
|
|
|
|
Down payment |
|
|
|
|
$ 581,250
|
|
|
|
Number of nitrile gloves delivered | Integer |
|
|
|
|
150,000
|
|
|
|
Loss contingency damages sought value |
|
|
|
|
$ 581,250
|
|
|
|
Loss on inventory investment |
|
|
|
|
|
|
$ 581,250
|
|
IPS [Member] | Crecom Burj Group Sdn Bhd [Member] |
|
|
|
|
|
|
|
|
Loss contingency damages sought value |
|
|
|
|
$ 581,250
|
|
|
|
Integra [Member] | Studebaker Defense Group, LLC [Member] |
|
|
|
|
|
|
|
|
Number of nitrile gloves delivered | Integer |
|
|
180,000
|
|
|
|
|
|
X |
- DefinitionLoss on inventory investment.
+ References
+ Details
Name: |
MEDS_LossOnInventoryInvestment |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of nitrile gloves delivered.
+ References
+ Details
Name: |
MEDS_NumberOfNitrileGlovesDelivered |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:integerItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_LegalFees |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe value (monetary amount) of the award the plaintiff seeks in the legal matter.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9
+ Details
Name: |
us-gaap_LossContingencyDamagesSoughtValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_ProvisionForDoubtfulAccounts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=MEDS_WaxmanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=MEDS_IPSMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=MEDS_IntegraMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS (Details) - USD ($)
|
3 Months Ended |
9 Months Ended |
|
Sep. 30, 2023 |
Jun. 30, 2023 |
Mar. 31, 2023 |
Sep. 30, 2022 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
Revenue |
$ 2,058,028
|
|
|
$ 2,055,803
|
|
|
$ 5,919,786
|
$ 7,993,805
|
|
Gross Profit |
1,704,578
|
|
|
1,372,428
|
|
|
4,846,852
|
4,002,571
|
|
Segment Assets |
21,653,843
|
|
|
4,480,317
|
|
|
21,653,843
|
4,480,317
|
$ 3,710,026
|
Segment Profit (Loss) |
(3,525,114)
|
$ (1,974,878)
|
$ (677,953)
|
(528,742)
|
$ (1,112,261)
|
$ (965,836)
|
(6,127,609)
|
(2,606,839)
|
|
Cost of Sales |
|
|
|
|
|
|
1,072,934
|
3,991,234
|
|
Trxade, Inc.[Member] |
|
|
|
|
|
|
|
|
|
Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
Revenue |
|
|
|
|
|
|
4,663,756
|
4,001,670
|
|
Gross Profit |
|
|
|
|
|
|
4,663,756
|
4,001,670
|
|
Segment Assets |
|
|
|
1,853,474
|
|
|
|
1,853,474
|
|
Segment Profit (Loss) |
|
|
|
|
|
|
1,570,796
|
1,320,138
|
|
Cost of Sales |
|
|
|
|
|
|
|
|
|
IPS [Member] |
|
|
|
|
|
|
|
|
|
Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
Revenue |
|
|
|
|
|
|
1,237,731
|
3,949,772
|
|
Gross Profit |
|
|
|
|
|
|
165,553
|
(41,462)
|
|
Segment Assets |
|
|
|
454,783
|
|
|
|
454,783
|
|
Segment Profit (Loss) |
|
|
|
|
|
|
(388,900)
|
(493,203)
|
|
Cost of Sales |
|
|
|
|
|
|
1,072,178
|
3,991,234
|
|
Superlatus [Member] |
|
|
|
|
|
|
|
|
|
Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
Revenue |
|
|
|
|
|
|
|
|
|
Gross Profit |
|
|
|
|
|
|
(756)
|
|
|
Segment Assets |
18,029,077
|
|
|
|
|
|
18,029,077
|
|
|
Segment Profit (Loss) |
|
|
|
|
|
|
(440,268)
|
|
|
Cost of Sales |
|
|
|
|
|
|
756
|
|
|
Other Segments [Member] |
|
|
|
|
|
|
|
|
|
Segment Reporting Information [Line Items] |
|
|
|
|
|
|
|
|
|
Revenue |
|
|
|
|
|
|
18,299
|
42,363
|
|
Gross Profit |
|
|
|
|
|
|
18,299
|
42,363
|
|
Segment Assets |
$ 3,624,766
|
|
|
$ 2,172,060
|
|
|
3,624,766
|
2,172,060
|
|
Segment Profit (Loss) |
|
|
|
|
|
|
(6,869,237)
|
(3,433,774)
|
|
Cost of Sales |
|
|
|
|
|
|
|
|
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_CostOfRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GrossProfit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2
Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementBusinessSegmentsAxis=MEDS_TrxadeIncMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementBusinessSegmentsAxis=MEDS_IPSMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementBusinessSegmentsAxis=MEDS_SuperlatusMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
|
Oct. 04, 2023 |
Jun. 28, 2023 |
Oct. 25, 2023 |
Sep. 30, 2023 |
Jun. 27, 2023 |
Jun. 21, 2023 |
Mar. 14, 2023 |
Jan. 04, 2023 |
Dec. 31, 2022 |
Sep. 14, 2022 |
Jun. 27, 2022 |
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Shares issued price per share |
|
|
|
$ 1
|
|
$ 1
|
|
|
|
|
|
Common stock par value per share |
|
|
|
$ 0.00001
|
|
|
|
|
$ 0.00001
|
|
|
Contingent funding liabilities |
|
|
|
$ 452,348
|
|
|
|
|
$ 108,036
|
|
|
Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Warrants to purchase shares |
|
|
|
|
|
|
|
601,740
|
|
|
|
Merger Agreement [Member] | Suran Aijarapu [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Stock issued during period shares conversion of units |
|
85,000
|
|
|
|
|
|
|
|
|
|
Merger Agreement [Member] | Prashant Patel [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Stock issued during period shares conversion of units |
|
81,666
|
|
|
|
|
|
|
|
|
|
Purchase Agreement [Member] | Spero Foods Inc [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Asset acquisition consideration transferred |
$ 500,000
|
|
|
|
|
|
|
|
|
|
|
Purchase Agreement [Member] | Hudson Global Ventures LLC [Member] | Subsequent Event [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
New isssues |
40,000
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of private placement |
$ 290,000
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement [Member] | Hudson Global Ventures LLC [Member] | Subsequent Event [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Common stock par value per share |
$ 0.00001
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement [Member] | Hudson Global Ventures LLC [Member] | Subsequent Event [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Warrants to purchase shares |
41,193
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement [Member] | Hudson Global Ventures LLC [Member] | Subsequent Event [Member] | Series C Convertible Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
New isssues |
290
|
|
|
|
|
|
|
|
|
|
|
Stated value per share |
$ 1,000
|
|
|
|
|
|
|
|
|
|
|
Shares issued price per share |
$ 1,000
|
|
|
|
|
|
|
|
|
|
|
Receivables Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Contingent funding liabilities |
|
|
|
$ 452,348
|
$ 1,250,000
|
|
$ 875,000
|
|
$ 108,036
|
$ 275,000
|
$ 550,000
|
Receivables net current |
|
|
|
|
1,800,000
|
|
1,224,000
|
|
|
396,000
|
792,000
|
One-time origination fee |
|
|
|
|
$ 62,500
|
|
$ 42,500
|
|
|
$ 15,000
|
$ 27,500
|
Receivables Agreement [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Contingent funding liabilities |
|
|
$ 1,200,000
|
|
|
|
|
|
|
|
|
Receivables net current |
|
|
1,728,000
|
|
|
|
|
|
|
|
|
One-time origination fee |
|
|
$ 60,000
|
|
|
|
|
|
|
|
|
X |
- DefinitionContingent funding liabilities.
+ References
+ Details
Name: |
MEDS_ContingentFundingLiabilities |
Namespace Prefix: |
MEDS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2
+ Details
Name: |
us-gaap_AssetAcquisitionConsiderationTransferred |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of the fee that accompanies borrowing money under the debt instrument.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentFeeAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfPrivatePlacement |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
+ Details
Name: |
us-gaap_ReceivablesNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionPer share or per unit amount of equity securities issued.
+ References
+ Details
Name: |
us-gaap_SharesIssuedPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=MEDS_MergerAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=MEDS_SuranAijarapuMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=MEDS_PrashantPatelMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=MEDS_PurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=MEDS_SperoFoodsIncMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=MEDS_HudsonGlobalVenturesLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=MEDS_SecuritiesPurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=MEDS_SeriesCConvertiblePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=MEDS_ReceivablesAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
TRxADE Health (NASDAQ:MEDS)
Historical Stock Chart
From Jul 2024 to Aug 2024
TRxADE Health (NASDAQ:MEDS)
Historical Stock Chart
From Aug 2023 to Aug 2024